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Sym bols and  abbreviations
ADA adenosine deaminase
AIDS acquired immune deficiency syndrome
AIRE autoimmune regulator
ALL acute lymphoblastic leukaemia
ALPS autoimmune lympboprolifcrative
syndrome
AML acute myeloid leukaemia
ANA anti-nuclear antibody
ANCA anti-neutrophil cytoplasmic antibody
A PC antigen-presenting cell
APECED autoimmune polyendocrinopathy-
candidiasis-ectodcnnal
dysplasia
APGS autoimmune polyglandular syndrome
APS anti-phospholipid syndrome
APP amyloid-precursor protein
APTT activated partial thromboplastin time
ARA American Rheumatism Association
ARDS adult respiratory distress syndrome
AS ankylosing spondylitis
ASCA aati-Sacchmomyces cerevisiae antibod­
ies
ASOT antistreptolysin О ttore
AT ataxia telangiectasia
ATG anti-thymocyte globulin
ATM ataxia telangiectasia mutated protein
AZT azidothymidine (zidovudine)
В ACNS benign angiitis of the CNS
BAL bronchoalveolar lavage
BCG bacille Calmette-Guerin
BCOADC branch-chain 2-oxo-acid dehydrogenase
complex
bd twice a day
BIS bias index score
BM bone marrow
BMS biomedical scientist
BMT bone marrow transplantation
BSACI British Society for Allergy and Clinical
Immunology
BSI British Society for Immunology
CAH chronic active hepatitis
CALLA common acute lymphoblastic leukae­
mia antigen
cAMP cyclic adenosine monophosphate
C-ANCA cytoplasmic ANCA 
CAR cancer-associated retinopathy
CATCH-22 cardiac abnormalities, abnormal facies, 
thymic hypoplasia,
cleft palate, and hypocaicaemia, associated with
22qll
deletions
C4BP G4 binding protein
CCP cyclic citrullinated peptide
CCV chosen coefficient of variance
2CDA 2-chloro-deoxyadenosine
CE Conformite Europeame
CF cystic fibrosis
CFS chronic fatigue syndrome
ICGD chronic granulomatous disease
CHAD cold haemolytic disease
CHARGE colobomata, heart disease, atresia of 
cfaoanar, retarded growth, genital hypoplasia, ear 
anomalies
CHH cartilage-hair hypoplasia
CHS Chediak-Higashi syndrome
СТО combined immtmodeficiency
СГОР chronic inflammatory demyelioating
polyneuropathy
СТО Crcutzfeldt-Jakob disease
QC creatine lrinase
CLL chronic lymphocytic leukaemia
CMC chronic mucocutaneous candidiasis
CME continuing medical education
CM1 cell-mediated immunity
CML chronic myeloid leukaemia
CMV cytomegalovirus
CNS central nervous system
ConA concanavalin A
COPD chronic obstructive pulmonary disease
COSHH control of substances hazardous to
health
CPA Clinical Pathology Accreditation
CPD continuing professional development
1CPSM Council for Professions Supplementary
to Medicine
Сг& E creatinine and electolytes
CREST calcinosis-Raynaud's-oesophageal dys-
motility-sclerodactyly-telangiectasia
CRF chronic renal failure
CRP C-retctive protein
CSF cerebrospinal fluid
CSF-1 colony-stimulating factor-1
CSS Churg-Strauss syndrome
CT computed tomography
CTD connective tissue disease
CTL cytotoxic T lymphocyte
CTLp cytotoxic T-lymphocyte precursor
CV coefficient of variation
CVA cerebrovascular accident
CV1D common variable immunodeficiency
CyA cyclosporin A
DAF decay accelerating factor
dATP deoxyadenosine triphosphate
DBPC double-blind, placebo-controlled
DOT direct Coombs test
dGTP deoxyguanosine triphosphate
DH dermatitis herpetiformis or Department
of Health
DIC disseminated intravascular coagulation
DIF direct immunofluorescence
DM deimatomyositis
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DMARDs disease-modifying drugs anti-rheumatic GFR glomerular filtration rate
drugs GGT gammaglutamyt transferase
G1 gastrointestinal
GLP good laboratory practice
GM-CSF 
lating factor
granulocyte-macrophage colony stimu-
DNA deoxyribonucleic acid GN glomerulonephritis
DNA-PKcs DNA protein kinase catalytic subunit GP glycoprotein
DPT diphtheria-pertussis-tetanus GPC gastric parietal cell
DRL drug-related lupus G6PD glucose 6-phosphate dehydrogenase
dRWT dilute Russell's viper venom test GPI glucosylphosphatidylinositol
dsDNA double-stranded DNA GS-ANA granulocyte anti-nuclear antibody
DTH delayed-type hypersensitivity GTN glyceryl trinitrate
DV designated value GvHD graft-versus-host disease
DVT deep vein thrombosis GvL graft-versus-leukaemia
EA early antigen GvT graft-versus-tumour
EAA extrinsic allergic alveolitis HAART highly active antiretroviral therapy
EBNA EBV nuclear antigen HAE hereditary angioedema
EBV Epstein-Barr virus H & E haematoxylin and eosin
ECG electrocardiogram HAMA human anti-mouse antibodies
ECP eosinophil cationic protein HANE hereditary angioneurotic oedema
EDTA ethylenediaminetetraacetic acid Hb haemoglobin
EGF epidermal growth factor HBsAg hepatitis В surface antigen
EIA enzyme-linked immunoassay HCC Healthcare Commission
ELISA enzyme-linked immunosorbent assay HCL hairy cell leukaemia
EM electron microscopy HCV hepatitis C virus
EMA endomysial antibodies HD Hodgkin's disease
EMG electromyogram hdlVIg high-dose intravenous immunoglobulin
ENA extractable nuclear antigen HELLP haemolysis-elevated liver enzymes-low
ENT ear, nose, and throat platelets
EPD enzyme-potentiated desensitization HEP histamine equivalent potency
EPO erythropoietin HEp-2 human epithelial cell line
EQA external quality assessment HGV hepatitis G virus
ESR erythrocyte sedimentation rate HHV human herpesvirus
FAST fluorescent allergosorbent test Hib Haemophilus influenzae type b
FBC full blood count HIGE hyper-lgE syndrome
FCAS familial cold autoinflammatory syn- H1GM hyper-IgM
drome HIT heparin-induced thrombocytopenia
FcR Fc receptor HIV human immunodeficiency virus
FCS fetal calf serum HLA human leucocyte antigen
FEV1 forced expired volume (one second) HR-CT high-resolution CT
FFA free fatty acid HRF homologous restriction factor
FFP fresh frozen plasma HRT hormone replacement therapy
FIA fluorescent immunoassay HSCT haematopoietic stem cell transplantation
FISH fluorescent in situ hybridization HSE Health and Safety Executive
FITC fluorescein isothiocyanate Hsp heat-shock protein
FLH familial lymphohistiocytosis HSP Henoch-Schonlein purpura
FMF familial Mediterranean fever HSV herpes simplex virus
fMLP N-formyl-methionyl-leucyl- 5-HT 5-hydroxytryptamine (serotonin)
phenylalanine HTLp helper-T lymphocyte precursor
FSH follicle-stimulating hormone HTLV-1 human T-cell leukaemia virus-1
FT3 free triiodothyronine HUS haemolytic-uraemic syndrome
FT4 free thyroxine HUV hypocomplementaemic urticarial vascu-
FVC forced vital capacity litis
GABA y-aminobutyric acid ICA islet cell antibodies
GACNS granulomatous angiitis of the CNS ICAM intercellular adhesion molecule
GAD glutamic acid carboxylase 1CF immunodeficiency-centromeric insta-
GBM glomerular basement membrane bility-abnormal fades
GBS Guillain-Barre syndrome ICOS inducible co-stimulator
GCA giant-cell arteritis Ю intradermal
G-CSF granulocyte colony stimulating factor IDDM insulin-dependent diabetes mellitus
GDP guanosine diphosphate ШТ intradermal test
GFD gluten-free diet IEF Immunoelectrophoresis
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IF intrinsic factor MLR mixed lymphocyte reaction
IFN interferon MMF mycophenolate mofettl
Ig immunoglobulin MMR measles, mumps, and rubella virus
1GF1-R insulin-like growth factor-1 receptor MND multiple nuclear dots
I1F indirect immunofluorescence MOG myelin oligodendrocyte glycoprotein
IL interleukin MPA microscopic polyarteritis
IM intramuscularly) MPGN membranoproliferative giomeru-
IMIg intramuscular immunoglobulin lonephritis
INR international normalized ratio MPO myeloperoxidase
1PEX X-linked immune dysregulation with MRA magnetic resonance angiography
polyendocrinopathy MRBIS mean running bias index score
1PF idiopathic pulmonary fibrosis MRI magnetic resonance imaging
IRAK-4 interleukin-1 receptor-associated MR VIS mean running variance index score
kinase 4 MS multiple sclerosis
ISCOMS immunostimulatory complexes MSA mitotic spindle antigens
ITP immune thrombocytopenia mTOR mammalian target of rapamycin
ITU intensive care unit MTX methotrexate
IU international units MUD matched unrelated donor
IV intravenously) MuSK muscle-specific tyrosine kinase
IVIg intravenous immunoglobulin NADPH reduced nicotinamide adenine dinucleo-
JCA juvenile chronic arthritis tide phosphate
JDF Juvenile Diabetes Foundation NAP neutrophil alkaline phosphatase
KIR killer-cell lg-like receptors NARES non-allergic rhinitis with eosinophilia
LAC lupus anticoagulant NB notabene
LAD leucocyte adhesion defect NBT nitroblue tetrazolium test
LAK lymphokine-activated killer cell NCAM neuronal cell adhesion molecule
LC liver cytosol NF-AT nuclear factor of activated T cells
LDH lactate dehydrogenase NHL non-Hodgkin's lymphoma
LE lupus erythematosus NIDDM nou-insulin-depcndeut diabetes mcflitus
LEMS Lambert-Eaton myasthenic syndrome NK natural killer
LFA lymphocyte function antigen NMR nuclear magnetic resonance
LFT liver function test NOM1D neonatal-onset multisystem inflamma-
LG lymphomatoid granulomatosis tory disease
LGL large granular lymphocyte NRL natural rubber latex
LIF leukaemia inhibitory factor NSAlDs nonsteroidal anti-inflammatory drugs
LKM liver-kidney microsomal antibodies NuMA nuclear mitotic apparatus protein
LM liver microsome OCP oral contraceptive pill
LP lumbar puncture od once a day
LPS lipopolysaccharide OGDC oxoglutarate dehydrogenase complex
LYDMA lymphocyte-determined membrane OMIS overall misclassification score
antigen OMPC outer membrane porin C
mAbs monoclonal antibodies P450 sec P4S0 side-chain cleavage enzyme
MAG myelin-associated glycoprotein PA pernicious anaemia
MAOI monoamine oxidase inhibitor PACNS primary angiitis of the CNS
MAST multiple allergosorbcnt tests PAF platelet-activating factor
MBL mannan-binding lectin PAN polyarteritis nodosa
MBP maiman-binding protein P-ANCA perinuclear ANCA
MCP macrophage chemotactic peptide PANDAS paediatric autoimmune neuropsychiatric
MCTD mixed connective tissue disease disorders associated with Streptococcus
MCV mean corpuscular volume PBC primary biliary cirrhosis
MDP muramyl dipeptide PCNA proliferating ceil nuclear antigen
MDS myelodysplastic syndrome PCP Pneumocystis carinii pneumonia
•ME 'myalgic encephalomyelitis' PCR polymerase chain reaction
MFE matemo-fetal engraftment PDC pyruvate dehydrogenase complex
ajMG ot,macroglobulin PDGF platelet-derived growth factor
(J2MG Pr-microglobulm PE pulmonary embolism or phyco-
MG myasthenia gravis erythrin
MGUS monoclonal gammopathy of unknown PEFR peak expiratory flow rate
significance PEG percutaneous endoscopic gas-
мне major histocompatibility complex trostomy or polyethylene glycol
Ml myocardial infarction PFAPA periodic fever with aphthous ulcers.
MIS misclassification score pharyngitis, and cervical adenopathy
MLA medical laboratory assistant PGE2 prostaglandin E2
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PHA phytohaemagglutinin Scl scleroderma
РЮ primary immunodeficiency SCLC small-cell lung carcinoma
PLL prolymphocyte leukaemia SCT stem cell transplantation
PM polymyositis SD standard deviation
PMA phorbol myristate acetate SERPIN serine protease inhibitor
PMR polymyalgia rheumatica SIFTR service increment for teaching and
PNH paroxysmal nocturnal haemoglobinuria research
PNP purine nucleoside phospborytase SIRS systemic inflammatory response syn-
PNU protein nitrogen units drome
POEMS polyneuropathy-organomegaly- SLA sohtble liver antigens
endocrine abnormalities-monoclonal gammopathy- SLE systemic lupus erythematosus
skin changes SLVL splenic lymphoma with circulating
TOTS postural orthostatic tachycardia syn- villous lymphocytes
drome Sm Smith antibodies
PPD purified protein derivative (of tubercu- SMA smooth muscle antibodies
lin) SOP standard operating procedure
PPV positive predictive value SPET single-photon emission tomography
Pr3 proteinase 3 SPS stiff person syndrome
PrP prion protein SPT skin-prick test
PRU Protein Reference Unit SRP signal recognition particle
PSC primary sclerosing cholangitis SRSV small round structured virus
PSS progressive systemic sclerosis SS Sjogren's syndrome
PTH parathyroid hormone SSc systemic sclerosis
PTLD post-transplant lymphoprol i ferative ssDNA single-stranded DNA
disease SSOP sequence-specific oligonucleotide
PUO pyrexia o f unknown origin probes
PUPP pruritic urticaria and plaques of preg- SSP-PCR sequence-specific primer PCR
nancy SV40 simian virus 40
PUVA photochemotherapy using psoralens T3 triiodothyronine
with ultraviolet A irradiation T4 thyroxine
PV pemphigus vulgaris TAME tosyl-L-arginine methyl ester
PWM pokeweed mitogen ТВ tuberculosis
QA quality assurance TC transcobalamin
QC quality control Ter T-cell receptor
QMS quality management system TdT terminal deoxytransferase
RANA rheumatoid-associated nuclear antibod- TFT thyroid function tests
ies TGF T-cell growth factor
RAST radioallergosorbent test TGSI thyroid growth stimulating antibody
RBCs red blood cells Thl T helper-1
RFLP restriction fragment length polymor- Th2 T helper-2
phism THI transient hypogammaglobulinaemia of
RFT respiratory function tests infancy
RhA rheumatoid arthritis Т1А transient ischaemic attack
RhF rheumatoid factor TIL tumour-invading lymphocytes
RIA radioimmunoassay TLI total lymphoid irradiation
RID radial immunodiffusion TNF tumour necrosis factor
RNA ribonucleic acid TPMT thiopurine methyltransferase
RNP ribonucleoprotein TPN total parenteral nutrition
rRNP ribosomal ribonucleoprotein TPO thyroid peroxidase
RS Reed-Sternberg TRAB thyrotropin receptor antibody
RSCA reference-strand-mediated conforms- TRAPS TNF-receptor-associated periodic syn-
tion analysis drome
RSV respiratory syncytial virus TREC T-cell receptor excision circle
SAA serum amyloid A TSH thyroid stimulating hormone
SAC Staphylococcus strain A Cowan TSH-R thyroid stimulating hormone receptor
SAP serum amyloid P TS1 thyroid stimulating antibody
SAPHO synovitis-acne-pustulosis-hyperostosis- tTG tissue transglutaminase
osteitis TTP thrombotic thrombocytopenic purpura
SBE subacute bacterial endocarditis UC ulcerative colitis
SC subcutaneously) UNG uracil-DNA gtycosylase
SCAT sheep-cell agglutination test USS ultrasound scan
SCID severe combined immunodeficiency UV ultraviolet
scig subcutaneous immunoglobulin VCA viral capsid antigen
и
VCAM vascular celt adhesion molecule vWF von Willebrand factor
VCF velocardiofacial syndrome VZV varicella zoster virus
VDRL Venereal Disease Research Laboratory WAS Wiskott-Aldrich syndrome
VEGF vascular endothelial growth factor WASP Wiskott-Aldrich-associated protein
VGCC voltage-gated calcium channel WG Wegener's granulomatosis
VGKC voltage-gated potassium channel WHIM warts, hypogammaglobulinaemia, infec-
VI variance index don, myelokathexis (syndrome)
VIP vasoactive intestinal polypeptide XLA X-linked agammaglobutmaemia
VIS variance index score XLPS X-linked lymphoproliferative syndrome
VKH Vogt-Koyanagi-Harada syndrome XLT X-linked thrombocytopenia
VLA
VNTR
very late antigen
variable N-tenninal repeat analysis
ZAP zeta-associated protein
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INTRODUCTION
The immune system
The immune system is a remarkable defense mechanism. It provides the means to make rapid, 
highly specific, and often very protective responses against the myriad potentially pathogenic 
microorganisms that inhabit the world in which we live. The mechanisms of immunity act in a 
wide range of clinical conditions, including recovery from infectious diseases, rejection of tu­
mors, transplantation of tissue and organs, autoimmune and other immunopathologic conditions, 
and allergy.
Many of die functions of cells of the immune system are mediated through the production of a 
set of small proteins referred to as cytokines. Many of the cytokines are T-cell products; their 
production represents one of the means through which the wide variety of functions of T-cells 
are effected. Most cytokines are not constitutive products of the T-cell. Rather, they are produced 
in response to T-cell activation, usually resulting from presentation of antigen to T cells by A PCs 
in concert with the action of a costimulatory molecule, such as the interaction of CD80/86 with 
CD28. Although cytokines are produced in small quantities, they are very potent, binding to their 
receptors with equilibrium constants of approximately Ю10 M'1. In some instances, cytokines are 
directionally secreted into the limited space between the T cells and the A PCs, so that they act in 
a paracrine manner and have limited action at a distance from the cell that produced them. This 
appears to be particularly true of many of the type I cytokines. However, other cytokines act by 
diffusion through extracellular fluids and blood to target cells that are distant from the producers. 
Among these are cytokines that have proinflammatory effects, such as IL-I, IL-6, and TNF.
Hematopoiesis and Immunopoiesis
Hematopoiesis is the dynamic and complex developmental process of the formation of new 
blood cells, which includes red blood cells (erythrocytes), white blood cells (leukocytes), and 
platelets. Per day, hematopoiesis yields approximately 17S billion red cells, 70 billion granulo­
cytes (neutrophils, eosinophils, basophils), and 175 billion platelets. If needed, production can be 
increased S-10 fold.
Hematopoiesis taking place prior to the development o f the fetal liver is referred to as primitive 
hematopoiesis, which is transient and restricted to the production of erythrocytes and megakar­
yocytes. The fetal liver is the site of definitive hematopoiesis early during embryonal develop­
ment. The term definitive hematopoiesis is used to describe blood formation after the formation 
of the fetal liver. It takes place in spleen and lymph nodes and, from fetal week 20 up, in bone 
marrow. The bone marrow with its intersinusoidal spaces is also the site responsible for the gen­
eration of blood cells in the post-natal phase. Red marrow (hematopoietically active marrow) 
usually becomes restricted to proximal ends of long bones, and flat bones (ileum, sternum, verte­
brae, ribs). During growth, the red marrow is gradually replaced by yellow marrow, which is 
mostly fat.
The sinusoids (venous channels) feed into the marrow venous drainage system. The sinusoids are 
lined with specialized fenestrated endothelial cells. They produce growth factors and cytokines, 
which influence proliferation and differentiation of hematopoietic cells and thus play an impor­
tant regulatory role. Mature blood cells enter the blood stream by passing through the sinusoidal 
wall to get into the sinuses. In order to do this, maturing cells become more deformable and no 
longer express adherence receptor.
Immature hematopoietic cells bind to the stromal matrix and to receptors on the stromal cells by 
expressing special receptors that recognize proteoglycans on the target cells. This is also the 
mechanism underlying the homing of bone marrow cells that have been injected intravenously. 
The nature of hematopoietically active structures is determined predominantly by a network of 
stromal cells. The microenvironment of a cell plays an important role in the differentiation of 
individual bone marrow cells. Further differentiation o f cells into one of several lineages criti-
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cally depends on the nature of factors acting on these cells at a particular time, at a particular 
concentration, and/or in a particular sequence.
The bone marrow stroma contains many different cell types, including macrophages, fibroblasts, 
endothelial cells, smooth muscle cells, T-lymphocytes, monocytes etc. These cells, in combina­
tion with components o f the extracellular matrix and basement membranes as well as a plethora 
of soluble and membrane-bound cytokines and growth factor, form the so-called hematopoietic 
inductive microenvironment, which maintains the functional integrity o f this complex system of 
resident and circulating cells. Cells o f the hematopoietic microenvironment show low or no de­
tectable cell growth and are believed to be in the GO phase of the cell cycle. Without bone mar­
row stromal cells, hematopoietic stem cells cannot be maintained in vitro, even when they are 
cultured with a cocktail of growth factors and cytokines.
All different types of blood cells are derived from a small common pool of totipotent cells, called 
hematopoietic stem cells, laid down in hematopoietic organs early during embryogenesis. These 
totipotent stem cells are referred to also as HSC (hematopoietic stem cells), PHSC (primitive (or 
pluripotent) hematopoietic stem cells), PLSC (pluripotent lymphoid stem cells), PPSC (pluripo- 
tent stem cells, or PSC), and THSC (totipotent hematopoietic stem cells).
These cells have the unique property of self-renewal (abbr. SRP for Self-renewal potential), i.e., 
they give rise to progeny identical in appearance and differentiation potential. These cells persist 
throughout adult life and are therefore responsible for the maintenance o f hematopoiesis. This 
process is called also Steady-state hematopoiesis or Constitutive hematopoiesis.
Pluripotent stem cells are quiescent cells. This is shown by their resistance to treatment with 
Fluorouracil or 4-HC (4-hydroperoxycyclophosphamide), which spare them and eliminates di­
viding cells without adversely affecting the long-term repopulating ability o f bone marrow.
These cells are of interest not only because o f their developmental capacity but also because of 
their potential usefulness as a  source o f autologous bone marrow cells for die treatment o f hema­
tological disorders and as vectors for gene therapy. This type o f cell is found not only in bone 
marrow but also in peripheral blood (PBPC, peripheral blood progenitor cells). Treatment o f  pa­
tients with colony stimulating factors such as G-CSF and GM-CSF induce an impressive rise o f 
up to 100-fold in levels o f progenitor cells o f all lineages in the peripheral blood. Stem cells are 
elevated in this response, with the blood populations being capable of initiating long-term re­
population of irradiated recipients. The mechanisms responsible for the release o f progenitor and 
stem cells from the marrow probably involve changes in adhesion to marrow stromal elements 
and also CSF induced changes induced in the cells destined to leave the marrow.
The totipotent hematopoietic stem cells give rise to transit populations with restricted differentia­
tion capacity. Differentiation o f stem cells in vivo has long thought to be a stochastic process but 
it appears that hematopoiesis progresses through an ordered restriction process rather than ran­
dom processes with a hierarchy in the lineage restriction process. The Progenitor cells arising as 
the result of stem cell differentiation are called Committed cells, or, for historical reasons, col­
ony-forming units because experimentally they were detected by their ability to form colonies in 
soft agar in a colony formation assay (BFU-E, CFU-E, CFU-Eo, CFU-G, CFU-GEMM, CFU- 
GM, CFU-M, CFU-MEG).
Committed cells, which can be identified by expression o f  specific lineage markers, comprise 
multipotent (MPSC), bipotent (BPSC), and unipotent (UPSC) cell types which are determined to 
differentiate into any o f the hematopoietic lineages, i.e., lymphoid cells that ultimately give rise 
to В-cells and T-cells, and myeloid cells that eventually give rise to monocytes, platelets, granu- 
locytes/monocytes (neutrophils, eosinophils, basophils), and erythrocytes.
These lineages are defined by the nature o f the fully differentiated cells eventually evolving from 
these precursor cells. The developmental potential o f these cells is generally limited to only one 
or two of the hematopoietic lineages, and these cells progressively display die antigenic, bio­
chemical, and morphological features characteristic o f the mature cells o f the appropriate line­
ages and lose their capacity for self-renewal. Their proliferation is normally tightly controlled 
and coupled to development. Cells leaving the bone marrow usually possess little or no prolifera­
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tive potential; erythrocytes and platelets do not contain genetic material, and neutrophils have 
condensed DNA and cannot undergo replication. Some hematopoietic cells, including pre-T- 
cells, mast cells, and monocytes can undergo further replication and development in various tis­
sues.
Pluripotent stem cells are still difficult to characterize morphologically. The pool of determined 
stem cells can usually be differentiated in functional assays. Most o f the distinct intermediate 
forms can be distinguished from each other by the stage-specific expression of cell surface 
markers and by their dependence on the presence of one or several growth factors or cytokines 
that are absolutely required for their survival and proliferation. All members of a particular line­
age that are still capable o f proliferation can give rise to malignant variants at all stages of differ­
entiation.
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Im mune responses are initiated by the encounter o f an individual with a  foreign antigenic sub­
stance, generally an infectious microorganism. The infected person rapidly responds with the 
production o f  antibody molecules specific for die antigenic determinants o f  the immunogen and 
with the expansion and differentiation o f  antigen-specific regulatory and effector T-lymphocytes. 
The latter include both cells that produce cytokines and killer T-cells, capable o f  lysing infected 
cells. Generally, the initial immune response is sufficient to control and eradicate the microbe. 
Indeed, the most effective function o f the immune system is to mount a response that eliminates 
the infectious agent from the body.
Immunoglobulin class
In the human there are five main classes o f immunoglobulin heavy chains have been demon­
strated: IgM, IgD, IgG, IgA, and IgE. In addition, four subclasses o f IgG are produced IgGi, 
IgG2, IgG3, and IgG4. In the human, there are also two classes o f IgA (IgA| and IgA2). In addi­
tion to differences in size and valency, differences in the structures o f the heavy chains o f the 
different isotypes result in differences in in vivo half-life, binding to cellular receptors, comple­
ment fixation, sensitivity to digestion by proteolytic enzymes, and the tendency to form aggre­
gates.
General functions of immunoglobulins
Ag binding - Immunoglobulins bind specifically to one or a few closely related antigens. Each 
immunoglobulin actually binds to a specific antigenic determinant Antigen binding by 
antibodies is the primary function o f antibodies and can result in protection o f the hosL
• Valency - the valency o f antibody refers to the number o f  antigenic determinants that an 
individual antibody molecule can bind. The valency o f ail antibodies is at least two and in 
some instances more.
Effector Functions - Often the binding o f an antibody to an antigen has no direct biological 
effect. Rather, the significant biological effects are a consequence o f  secondary "effector 
functions" o f antibodies. The immunoglobulins mediate a variety o f these effector functions. 
Usually the ability to carry out a particular effector function requires that the antibody bind to 
its antigen. Not every immunoglobulin will mediate all effector functions.
• Fixation o f complement - lysis o f cells, release o f  biologically active molecules.
• Binding to various cell types - phagocytic cells, lymphocytes, platelets, mast cells, and 
basophils have receptors that bind immunoglobulins and the binding can activate the cells 
to perform some function. Some immunoglobulins also bind to receptors on placental 
trophoblasts. The binding results in transfer o f  the immunoglobulin across the placenta 
and the transferred maternal antibodies provide immunity to the fetus and newborn
The mucosal immune system
The human has evolved organized secondary lymphoid tissues in the upper respiratory and GI 
tract regions feat facilitate antigen uptake, processing, and presentation for induction o f mucosal 
immune responses. Collectively, these tissues are known as inductive sites. Alfeougih fee gut- 
associated lymphoreticular tissues (GALT), e.g., Peyer’s patches, are major inductive sites in all 
o f fee most common experimental mammalian systems, fee degree o f bronchus-associated lym­
phoreticular tissue (BALT) developed at airway branches for defense against intranasal/inhaled 
antigens differs considerably among species. In rabbits, rats, and guinea pigs, such BALT devel­
opment is significant, whereas in humans and mice it is negligible unless chronic inflammation, 
such as panbronchiolitis or rheumatoid arthritis, occurs. Instead, fee major inductive tissues for 
intranasal/inhaled antigens in humans appear to be the palatine tonsils and adenoids (naso­
pharyngeal tonsils), which together form a physical barrier of lymphoid tissues termed fee 
Waldeyer’s ring, now more frequently referred to as a nasopharyngeal-associated lymphoreticu­
lar tissue (NALT). To summarize, then, NALT and GALT in humans and mice and NALT, 
BALT, and GALT in other human comprise a mucosa-associated lymphopdiciilar tissue.
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(MALT). Two major features distinguish MALT from the other systemic lymphoid tissues. First, 
the epithelium, which separates the tissue from the lumen, contains a specialized cell type termed 
M cells that are closely associated with lymphoreticular cells. Together this epithelial cell net­
work is called the follicle-associated epithelium (FAE). Second, MALT contains organized re­
gions that include a subepithelial area (dome), В-cell zones with germinal centers containing 
IgA-committed В cells (surface IgA+ В-cells) and adjacent T-cell regions with APCs and high 
endothelial venules (HEVs). Naive, recirculating В and T lymphocytes enter MALT through 
HEVs. Antigen-activated and memory B- and T-cell populations then emigrate from the induc­
tive environment via lymphatic drainage, circulate through the blood stream, and home to muco­
sal effector sites. These effector sites include more diffuse tissues, where antigen-specific T- and 
B-lymphocytes ultimately reside and perform their respective functions (cytotoxic T- 
lymphocyte, and regulatory functions or antibody synthesis, respectively) to protect mucosal sur­
faces.
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Normal ranges (adults) 
Serum immunoglobulins
IgG
IgA
IgM (males)
IgM (females)
IgG subclasses
IgG,
IgG2
lgG3
IgG4
IgA subclasses
IgA,
IgA2
Total IgE 
IgD
6.8-15.4 g/1 
0.84-2.97 g/1 
0.54-1.90 g/1 
0.81-2.30 g/1
4.2-10.8 g/1 
1.5-6.0 g/1 
0.5-1.9 g/1 
0.2-1.4 g/1
0.7-2.4 g/1 
0.2-0.9g/l
<100 kU/1 or <100 IU/ml 
0.01-0.04 g/1
Antibacterial antibodies (protective level)
Diphtheria >0.1 IU/ml 
Pneumococcal (Pneumovax) >20 u/1
Tetanus >0.1 IU/ml
Haemophilus influenzae В >1 gg/ml
Complement
Clq
C3
C3a
C4
C4a
C4BP
C5a
Cl-esterase inhibitor 
Factor H 
Factor I
Lymphocyte subsets 
Total T cells (CD3+)
T helper cells (CD3+CD4+)
T cytotoxic cells (CD3+CD8+) 
Total В cell (CD19+ or CD20+) 
NK cells (CD 16+CD56+CD72)
50-250 mg/1
0.68-1.80 g/1
10-570 gg/1
0.18-0.60 g/1 
102-212 gg/1
140-220 gg/1
< 10 gg/1
0.18-0.54 g/1 
430-610 mg/1 
38-58 mg/1
800-2540 cells/mm3 - 150-70%| 
570-1590 cells/mm3 - 135-45%| 
400-1140 cells/mm3 - 127-35%| 
190-660 cells/mm3 ' |22-30%| 
170-590 cells/mm3 ' |14-24%|
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Classification of immunodeficiency 
Genetic
• Autosomal recessive
• Autosomal dominant
• X-linked
• Gene deletions, rearrangements.
Biochemical and metabolic
• Adenosine deaminase deficiency
• Purine nucleoside phosphorylase (PNP) deficiency
• Biotin-dependent multiple carboxylase deficiency
• Deficient membrane glycoproteins.
Vitamin or mineral deficiency
• Zinc deficiency
• Bu deficiency
• Biotin.
Undefined primary
• Common variable immunodeficiency
• Specific antibody deficiency
• IgG subclass deficiency
• IgA deficiency.
Matu rational
• Transient hypogammaglobulinaemia of infancy.
Secondary
• Viral infections (HIV, CMV, EBV, rubella)
• Chronic infections (ТВ, leishmania)
• Malignancy
• Lymphoma/leukaemia
• Extremes of age
• Transfusion therapy
• Drugs
• Plasmapheresis
• Radiation
• Nutrition
• Chronic renal disease (including dialysis)
• Toxins (including alcohol, cigarettes)
• Splenectomy
• Tonsiiectomy
• Bums.
Clinical features of immunodeficiency 
Recurrent infections
There is no universally accepted definition of what constitutes 'recurrent infection' and therefore 
it is difficult to be categorical about who should be investigated for immunodeficiency. The fol­
lowing should be used as guidance.
• Two major or one major and recurrent minor in 1 year.
• Unusual organisms (Aspergillus, Pneumocystis).
• Unusual sites (liver abscess, osteomyelitis).
• Chronic infections (sinusitis).
• Structural damage (bronchiectasis).
• Other suspicious features.
Other features raising suspicion of an underlying immunodeficiency
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• Skin rash (atypical eczema): Wiskott-Aldrich syndrome, hyper-lgE syndrome, Omenn's syn­
drome.
• Chronic diarrhoea: SCID, antibody deficiencies.
• A major infection is severe infection, usually requiring parenteral treatment in hospital, with 
objective evidence of infection (elevated CRP, positive culture). Minor infection is less severe, 
usually treatable in the community with oral therapy, buf with objective evidence o f infection.
• Failure to thrive: any immune deficiency in childhood.
• Hepatosplenomegaly: common variable immunodefciency (CVID), Omenn's syndrome.
• Chronic osteomyelitis or deep-seated abscesses: chronic granulomatous disease.
• Mouth ulceration (cyclical): neutropenia
• Autoimmunity: CVID, hyper-IgM syndrome.
• Family history.
Features associated with specific immunodeficiencies
Some features are diagnostic o f  particular immunodeficiencies.
• Ataxia: ataxia telangiectasia, PNP deficiency.
• Telangiectasia: ataxia telangiectasia.
• Short-limbed dwarfism: X-linked immunodeficiency.
■ Skeletal abnormalities: ribs in ADA deficiency.
• Cartilage-hair hypoplasia.
• Ectodermal dysplasia.
• Endocrinopathy (particularly with hypocalcaemia): chronic mucocutaneous candidiasis.
• Partial albinism: Chediak-Higashi disease; Griscelli syndrome.
• Thrombocytopenia (particularly with small platelets): X-linked thrombocytopenia; Wiskott- 
Aldrich syndrome.
• Eczema: Wiskott-Aldrich syndrome; hyper-lgE syndrome; Omenn's syndrome.
• Neonatal tetany: 22ql 1 deletion syndromes (DiGeorge).
• Abnormal facies (leonine; fish-shaped mouth, low-set ears): hyper-lgE (leonine), 22ql 1 dele­
tion syndrome (fish-shaped mouth, low-set ears); 1CF syndrome.
• Mental retardation: 22ql 1 deletion syndromes, PNP deficiency; other genetic immunodeficien­
cies.
Investigation of immunodeficiency
History
• History o f all infections: site, severity, need for antibiotics, hospitalizations.
• Operations (lobectomies, etc.).
• Immunization history.
• Family history, especially for serious infections, unexplained sudden deaths, diagnosed immu­
nodeficiencies, and autoimmune diseases.
Examination
• Weight and height (failure to thrive).
• Structural damage from infections (ears, sinuses, lungs).
• Autoimmune features: vitiligo; alopecia; goitre.
• Other suspicious/diagnostic features, as above.
Formulate differential diagnoses in rank order.
Laboratory investigation
• Target investigations to differential diagnosis.
• Do not blanket screen.
• Ensure basic tests are done before exotic tests.
• Think whether tests will contribute to diagnosis or management: if  they will not then do not do 
them.
B-celt function
• Serum immunoglobulins (be sure to use low-level detection system for IgA to confirm ab­
sence).
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• Serum and urine electrophoresis (evidence for bands and urinary loss).
• IgG subclasses.
•IgE.
• Antibacterial, antiviral antibodies (appropriate to immunization and exposure history).
• Immunization responses (protein and polysaccharide antigens).
• Isohaemagglutinins (IgM, dependent on blood group).
• В lymphocyte numbers; class-switch memory В cells (CD27+/IgD'/IgM').
• Pokeweed mitogen (PWM) and antigen-stimulated antibody production in vitro (clinical indi­
cations limited).
T-cell function
Use absolute T-cell counts, not percentages.
• T-cell numbers and surface phenotype.
• CD2, CD3, CD4, CD8, CD7, TCR (o0, T8), CD40 and CD40L, MHC class II; CD45RA and
RO, CD27.
• CD40-ligand expression on activated T cells.
• T-cell proliferation to antigens, mitogens (OKT3, PHA, phorbol myristate acetate (PMA), cal­
cium ionophore, cytokines).
• T-cell cytokine production in vitro.
• In vivo skin (delayed-type hypersensitivity, DTH) testing: the Multitest CMI is a convenient 
tool, but responses will depend on prior exposure.
Neutrophil function Neutrophil function tests are not widely available, so if  there is suspicion 
o f a neutrophil defect, specialist help should be sought Interpretation is difficult and tests may 
be influenced by intercunent infection and drug therapy.
• Neutrophil markers (CD1 la, CD1 lb, CD1 lc, CDI8, CD15).
• Upregulation of neutrophil markers (PMA, fMLP).
• Oxidative metabolism (quantitative and qualitative nitroblue tetra-zolium reduction (NBT test); 
flow cytometric determination of oxidative burst).
• Phagocytosis.
• Bacterial or fungal killing (relevant organisms should be selected).
• Chemotaxis (difficult to standardize, with wide normal range).
NK-cell function
This is of research use only at present.
• NK-cell numbers by flow cytometry (absolute counts).
• K562 killing assay (radioimmunoassay, flow cytometry).
■ Cytokine-stimulated killing (lymphokine-activated killer cell (LAK) assay).
Complement assays
■ Measurement of specific components.
• Functional assays (haemolytic assays).
Genetic studies Genetic studies form an essential part o f the investigation and management of 
primary immunodeficiencies.
• Cytogenetics (deletions, translocations).
• Ig and Ter gene rearrangements (clonality).
• X-linked gene studies.
• 22ql 1 microdeletions (FISH-fluorescent in situ hybridization).
• Protein expression studies (SAP, btk).
• MHC studies.
• Prenatal diagnosis.
O ther investigations
• Detection of autoimmunity:
anti-red cell, platelet, neutrophil antibodies; 
anti-endocrine autoimmunity (thyroid autoantibodies).
• Exclusion of secondary causes:
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renal disease, bowel disease (loss of immunoglobulins); 
malignancy (lymph-node biopsy); 
nutritional deficiencies ( zinc, B12, iron); 
drugs (cytotoxics, anticonvulsants).
• Detection of nodular lymphoid hyperplasia (CT scanning, barium follow-through, endoscopy, 
and biopsy).
• Lung function (including FEV|, FVC, transfer factor).
• Imaging studies (lungs, sinuses).
• Direct isolation of pathogens: bacteria, fungal, and viral (serology is usually unreliable—use 
PCR-based tests where culture is not possible).
Major B-lymphocyte disorders
• X-linlced agammaglobulinaemia (Bruton's agammaglobulinaemia; XLA).
• Common variable immunodeficiency (acquired hypogammaglobulinaemia; CVID).
• Selective IgA deficiency.
■ IgG subclass deficiency.
• Specific antibody deficiency with normal immunoglobulins.
Rare antibody deficiency syndromes
• X-linked hyper-IgM syndrome (HIGM-1); CD40-ligand deficiency.
• Autosomal hyper-lgM syndromes (HIGM-2-4):
• HIGM-2, autosomal recessive activation-induced cytidine deaminase deficiency;
• HIGM-3; autosomal recessive CD40 deficiency;
• HIGM-4; similar to HIGM-2, molecularly undefined;
• HIGM due to uracil-DNA glycosylase (UNG) deficiency.
• X-linked hypogammaglobulinaemia with growth hormone deficiency.
• Selective IgM deficiency.
• X-linked lymphoproliferative syndrome (Duncan's syndrome; XLPS).
• Hyper-lgE syndrome (Job's syndrome).
• Selective IgE deficiency.
• Transient hypogammaglobulinaemia of infancy.
• Mu-chain deficiency.
• Ig alpha or MB1 (CD79a) deficiency.
• BLNK deficiency.
• ICOS deficiency.
• X5/14.1 (surrogate light chain) deficiency.
• SWAP-70 deficiency.
■ к and X light chain deficiency.
• Thymoma with immunodeficiency (Good's syndrome).
•CD 19 deficiency.
X-linked agammaglobulinaemia (Bruton's disease)
It has an incidence of 1 in 100 000-200 000 and a prevalence of 1 in 10 000.
Cause
■ Genetic disorder due to mutations on the X chromosome affecting the btk gene.
• btk codes for a tyrosine kinase involved in В-cell maturation.
• Defects in the gene prevent В-cell maturation from pro-B-cetl to pre-B-cell.
• Gene is located at Xq21.3-22. Mutations include deletions and point mutations, either conser­
vative or leading to premature termination.
• Phenotype correlates poorly with genotype.
• Mild phenotypes occur with some limited B-celt development.
• New mutations common, so a family history may be absent.
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Presentation
- Usually early in childhood, after 6 months o f age, when maternal antibody has largely disap­
peared.
• Recurrent infections o f  lungs and ears (children o f this age don't have sinuses):
Haemophilus influenzae and pneumococci (upper and Iowa- respiratory tract, meningitis); 
meningococcus (meningitis);
staphylococcus (septic arthritis);
Gtardia, Salmonella, and Campylobacter infections o f  the gut.
Diagnosis-key features
• Early onset bacterial infections in a male child with a family history.
• Family history often absent.
• Neutropenia very common at presentation but goes away with treatment and is probably due to 
chronic bacterial sepsis.
• Failure to thrive and chronic diarrhoea common.
• Distinction o f milder forms, with some В cells and low but not absent IgG, from CVID is diffi­
cult and relies on the demonstration o f abnormalities o f  the btk gene. Some patients previously 
classified as CVID will turn out to be XLA
• Specific antibody deficiency only reported with btk mutations.
• XLA may rarely be associated with growth hormone deficiency (and short stature).
• Occasional females will be identified with the immunological features o f XLA.
• Differential diagnosis will include coeliac disease and cystic fibrosis, although the laboratory 
tests will rapidly identify antibody deficiency.
Immunology
In the complete forms file immunology is fairly distinctive.
• All immunoglobulins are absent or very low.
• В cells are low or absent.
• Btk protein absent (confirm with genetic studies where there is a  good history, to exclude pro­
duction o f non-functional protein).
• Lymph nodes show no germinal centres; no tonsils; pre-B cells in bone marrow.
• T-cell numbers and function are normal.
• NK-cell numbers and function are normal.
Mild or incomplete variants may be difficult to distinguish from СУШ.
• Variable numbers of В cells including normal.
• Variable immunoglobulins.
• Poor/absent specific antibodies to polysaccharide antigens.
Complications
The major complications relate to delay in diagnosis.
• Structural lung damage (bronchiectasis, sinusitis). Inadequate therapy will lead to progression 
of lung damage and the development o f chronic sinus damage.
• Chronic meningoencephalitis due to echoviruses and coxsackieviruses may cause a progressive 
and fatal dementing illness; there is often muscle involvement, with a myositis and contractures. 
Diagnose by viral culture of CSF or by PCR-based techniques. Antiviral pleconaril is helpful 
(though not licensed by the FDA). This disease appears less often since the introduction o f intra­
venous immunoglobulin (IVIg) therapy as standard, but has not disappeared completely.
• Ureaplasma/Mycoplasma septic arthritis. This is difficult to diagnose without special culture 
facilities. It is a highly destructive chronic infection and requires prolonged treatment (6 months) 
with tetracyclines and/or erythromycin.
• Haemophilus conjunctivitis.
• Crohn's-like disease of intestines. Possible increased risk of colonic cancer.
Treatment
• I intravenous IgG should be started at the earliest opportunity; dose of 200-600mg/kg/month 
given at intervals of 2-3 weeks. Longer intervals do not give satisfactory replacement.
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• Subcutaneous immunoglobulin given weekly (same total dose) is an alternative.
• Trough IgG levels should be monitored regularly, with the aim o f maintaining a level well 
within the normal range (6-9 g/1). Early institution o f IVIg and adequate trough levels preclude 
the development o f  bronchiectasis.
• Prompt antibiotic therapy (course o f  10-14 days) for upper and lower respiratory tract infec­
tions together with physiotherapy and postural drainage, if  lung damage has already occurred. 
Ciprofloxacin is a valuable antibiotic (though not licensed for small children). Use cystic fibrosis 
approach o f zero tolerance to cough.
• As children get older and can comply, perform regular lung function testing, including transfer 
factor.
• High resolution CT scanning (HR-CT) is useful for identifying subclinical bronchiectasis, but 
imposes a significant radiation burden and should not be overused.
• Do not give oral poliovaccine as patients often fail to clear it, which increases the risk o f rever­
sion to wild type, with consequent paralytic disease.
• Genetic counselling o f  the patient and family once genetic basis confirmed. Identify and coun­
sel carriers.
• Long-term immunological follow-up (plus additional specialist input as required).
XLA with growth hormone deficiency
This is a very rare disorder with immunological features identical to XLA, in association with 
short stature (as opposed to failure to thrive). The disease maps the region o f the X chromosome 
containing the btk gene, but not all cases appear to have mutations in the btk gene. Prognosis ap­
pears to be good. It is treated with IVIg and growth hormone.
Common variable immunodeficiency (CY1D)
CVID is the commonest symptomatic antibody deficiency with an estimated incidence o f 1 in 25 
000-66 000.
Cause
• Cause o f CVID is unknown: one hypothesis suggests that an environmental insult (virus infec­
tion) in a genetically susceptible individual triggers the disease. No conclusive viral trigger has 
been identified.
• Some evidence for a genetic background (linked to HLA A1 B8 C4 DR3QO and to polymor­
phisms in the TNF-a gene).
• May be a family history of other antibody deficiencies (especially IgA deficiency and IgG sub­
class deficiency) in up to 50% o f cases, although other family members may be entirely asymp­
tomatic.
• Disease is heterogeneous in phenotype and immunological findings.
• Diagnosis is now one of exclusion, once other genetic diseases have been ruled out. 
Presentation
• May present at any age from childhood through to old age, although the peak o f presentation is 
in early childhood and early adulthood.
• Usual presentation is with recurrent bacterial infections, as for XLA.
• May present with autoimmune problems, especially thrombocytopenia, haemotytic anaemia, 
and organ-specific autoimmunity (e.g. thyroid, diabetes, vitiligo, and alopecia); these are com­
mon and may precede the development of recurrent infections.
• Nodular lymphoid hyperplasia o f bowel (polyclonal hyperplasia of Peyer's patches) is unique to 
CVID. The cause is unknown, but it is possibly premalignant. This has characteristic features on 
small-bowel radiology.
• Granulomatous disease with lymphadenopathy and (hepato-) splenomegaly, and often involv­
ing the lung, is common in the severe form of СУШ (about 25% of cases). Disease resembles 
sarcoidosis, but is Kveim-test negative (although this test is now rarely used). Specifically asso­
ciated with complete absence of class-switch memory В cells.
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Diagnosis
• History gives die clues. Clues are usually missed by general physicians and an average diag­
nostic delay of over 7 years is typical, by which time structural lung and sinus damage is severe 
and irretrievable.
• Immunoglobulin levels are variably low: test immunization and exclusion of secondary loss 
(gut, urine) may be required.
- Lymphopenia affecting predominantly the CD4+ T cells (CD45RA* naive cells in particular) 
and В cells is common.
• When splenomegaly is present it may be difficult to exclude lymphoma, without CT scanning, 
lymph node biopsy, and bone marrow examination.
Immunology
• Immunoglobulin levels are highly variable, and IgG may be only marginally reduced; specific 
antibodies are invariably low with poor/absent immunization responses.
• IgM may be normal, which contrasts with lymphoma, when the IgM is the first immunoglobu­
lin to drop.
• В cells may be normal or low but some cases in males may be late-presenting XLA.
• CD4+ T cells are low, with specific depletion of CD45RA+ T cells. T-cell function in vivo and 
in vitro to antigens and mitogens is poor and there is poor NK-cell function, with reduced NK- 
cell numbers.
• Abnormalities o f S'-nucleotidase activity on the lymphocyte surface have been described but 
this is not a separate syndrome as is sometimes stated. The significance o f the abnormality is not 
known.
Classification
Three groups are identified on the basis o f В-cell responses to IL-2 and anti-IgM in vitro.
• Group A: severe disease, with granulomata (hepatosplenomegaly); no IgG or IgM production
in vitro.
• Group B: rare; IgM production only in vitro (cryptic hyper-IgM).
■ Group C: mild disease; IgG and IgM production in vitro.
This technique is unsuited to routine diagnosis; identification o f class-switch memory В cells is 
more useful (group A patients lack class-switch memory В cells).
Complications
• Major complications of CV1D relate to the delay in diagnosis with structural.damage from in­
fection: bronchiectasis and chronic sinusitis.
• Patients may also have unusual infections, such as Campylobacter cholangitis, and My- 
coplasma/Ureaplasma arthritis. Rarely, opportunist infections such as Pneumocystis occur (but 
this should suggest hyper-IgM syndromes).
• Malabsorption may occur due to a  coeliac-like enteropathy, with villous atrophy.
• Inflammatory bowel disease may occur with strictures.
• In group A patients with splenomegaly, hypersplenism may occur with marked thrombocyto­
penia: splenectomy may be required.
• 40-fold increase in the risk o f lymphoma, including intestinal lymphoma; Any patient with 
lymphadenopathy should have a  lymph node biopsy and BM examination to exclude the diagno­
sis. Lymphomas are often high-grade and respond poorly to treatment.
• Increase in gastric carcinoma, not related to Helicobacter pylori colonization.
• Autoimmune disease is common and patients should be monitored for the development o f overt 
disease (hypothyroidism, pernicious anaemia, diabetes).
• Thymomas (benign or malignant) are also associated with CVID: this is Good's syndrome. 
These frequently give rise to myasthenia gravis and haematological problems such as aplastic 
anaemia and immune thrombocytopenia.
Treatment
• The earlier the diagnosis is made, the better the prognosis.
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• Treatment is identical to that of XLA, with IVIg/SCIg, antibiotics, and physiotherapy for chest 
disease.
• Prophylactic antibiotics should be considered if there is an inadequate response to optimal im­
munoglobulin therapy.
• Patients with complete IgA deficiency may have a higher risk of developing anti-IgA antibod­
ies to IVIg therapy, and a product low in IgA should be selected for them; most IVIg products 
now have reduced IgA content. The value of monitoring anti-IgA antibodies is questionable.
• Patients with splenomegaly may catabolize IgG faster and may require larger doses or more 
frequent doses (weekly).
• Regular lung function tests (volumes and transfer factor) and HR-CT scanning is required. De­
teriorating lung function requires more aggressive therapy.
• Chronic sinus disease requires ENT review, with endoscopic inspection.
• Granulomatous disease responds well to steroids (alkaline phosphatase is a good marker); these 
are essential if  there is interstitial lung disease (reduced transfer factor). They are not necessary 
for asymptomatic splenomegaly. Steroid use is associated with an increased risk of disseminated 
shingles. Splenectomy may be necessary for hypersplenism: such patients must have prophylac­
tic penicillin, but immunizations are o f little value. There is, however, an additional risk of infec­
tion splenectomy in CVID patients and caution is required.
• Treat inflammatory bowel disease as for Crohn's disease.
• Gluten-free diet may help if there is coeliac-like disease.
< Monitor for the development o f malignant disease. Review frequency of cervical smears.
• PEG-IL-2 has been used successfully in a smalt cohort.
• Retinoic acid has been shown to benefit some patients.
• Cimetidine may also improve immunological function.
Selective IgA deficiency
Selective IgA deficiency is the most common primary immunodeficiency, but mostly passes un­
noticed. Depending on the racial group, 1 in 400-800 individuals will be affected.
Cause
• Cause is unknown, although it forms part o f the spectrum o f disease with CVID and shares the 
HLA type (A l, B8, C4, DR3, QO). It occurs in relatives of patients with CVID in 50% o f cases.
• Rarely due to a gene deletion, often including !gG2/lgG4.
• Defects o f class switching have been identified in a few patients.
• Selective deficiencies o f IgA 1 or lgA2 have been reported (all due to gene deletions).
• May be associated with other chromosomal abnormalities, usually involving chromosome 18 
(18q syndrome and ring chromosome 18). Also with variant Turner's syndrome (Xq), multi- 
branched chromosomes, Klinefelter's syndrome, and a,antitrypsin deficiency.
• Associated with drug therapy, particularly with phenytoin and penicillamine, although in many 
reports it is not clear whether the defect was present before drug therapy was introduced.
• IgA-bearing В cells are present. IgA is synthesized but not secreted.
• In terms o f mucosal protection, there is evidence that IgG and IgM may substitute as secretory 
immunoglobulins.
Presentation
• Most cases are asymptomatic.
• There is an increased incidence o f allergic disease, including food allergies and intolerances.
• Connective tissue diseases (SLE, rheumatoid arthritis, and juvenile chronic arthritis), coeliac 
disease, pernicious anaemia, and other organ-specific autoimmune diseases.
• Infections are rarely a problem unless there are additional humoral defects present.
• Occasional cases will come to light as a result o f adverse reactions to blood products. This is 
deemed to be very rare (incidence I in 15 million, transfusions).
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Diagnosis
• Requires the demonstration of undetectable IgA, not just a low IgA. Automated analysers do 
not read low enough to ascertain this beyond doubt. Check with low-level radial immunodiffu­
sion or Ouchterlony double-diffusion assays.
• Beware of the presence of anti-animal antibodies in IgA deficiency which give false readings in 
immunoassays using antisera.derived from sheep, goats, horses.
• Patients should be screened for evidence of other humoral defects: IgG subclasses and specific 
antibodies if  there is a history of infections. If  there is doubt, then test immunization should be 
undertaken.
• IgA antibodies can be measured but current assays detect IgG and IgM antibodies and therefore 
do not identify risk o f anaphylaxis. The significance of IgG and IgM anti-IgA antibodies is un­
certain: high levels may be seen in the absence of reactions. There is very seldom detection of 
IgH anti-IgA antibodies.
Immunology
• The IgA will be undetectable (< 0.05 g/1), but total IgG and IgM will be normal. IgG subclasses 
may be reduced (G2 and G4). Secreted IgA will be absent (secretory piece deficiency is vanish­
ingly rare), but testing for this is o f little clinical value.
• T-cell function is normal (PHA and antigens).
• Autoantibodies may be present (anti-IgA antibodies). There will be an increased IgE in the 
presence of atopic disease.
• In the absence of IgA, IgM and IgG appear on mucosal surfaces.
Complications
• Major problem with IgA deficiency is the possibility o f  transfusion reactions thought to be due 
to anti-IgA antibodies. These are extremely rare (1 in 15 million).
• Malignancy may be increased, although this may depend on other diseases present in associa­
tion with IgA deficiency, especially lymphoma and gastric adenocarcinoma.
• It is possible that there may be progression to more significant humoral immunodeficiency with
time.
Treatment
• Treatment is directed at the presenting disease.
• Avoid IgA-containing products if  possible: no longer routinely provides blood products from 
IgA-deficient donors. Use an IVIg/SCIg with a  low IgA content.
• Where immunoglobulin replacement therapy is required for recurrent infections, this has been
shown to be safe.
• In view of the low risk o f reactions, the wearing or canying of an alert card is now of doubtful
value.
Selective lgA2 deficiency
Cases have been reported with selective lgA2 deficiency, with normal IgAl. This does not ap­
pear to be due to heavy chain gene deletions affecting the o2 gene in all cases.
IgG subclass deficiency
Cause
• Cause of IgG subclass deficiency is unknown, but it too forms part of the spectrum with CVID 
and IgA deficiency. It is possible that some cases represent CVID in evolution. Rarely, cases 
may be due to gene deletions, but these individuals may be entirely healthy.
• IgG subclass levels are related to allotypes of IgG; different racial groups may therefore have 
different normal ranges, depending on the prevalence of different allotypes. This should be taken 
into account when diagnosing IgG subclass deficiency.
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Presentation
• Presentation, as for СУШ, can be at any age. Recurrent infections may be a feature, particu­
larly for IgG2 and lgG4 deficiency. IgG« deficiency occurring alone has also been associated with 
bronchiectasis.
• Conditions associated with subclass deficiency include: asthma (lgG] deficiency); sinusitis 
(lgG) deficiency); intractable epilepsy of childhood (though this may be due to anticonvulsants); 
and autoimmune disease (SLE).
Diagnosis
• Measurement o f IgG subclasses on more than one occasion is required and it is important to 
check that appropriate age-specific normal ranges are used.
• Detection o f low levels of lgG4 may require more sensitive assays to detect true absence: earlier 
normal ranges using less-sensitive assays found a significant number of individuals with unde­
tectable lgG4. Most o f these have detectable lgG4 on sensitive assays.
• There is a poor correlation of specific anti-pathogen responses and IgG subclass levels. All pa­
tients should have specific antibodies measured and be test immunized.
• Detection o f low or absent subclasses does not necessarily correlate with clinical disease. 
Immunology
• A normal total IgG is entirely compatible with subclass deficiency, although low lgGl usually 
reduces the total IgG (this also behaves like CVID for practical purposes). The IgA is normal or 
low; IgM is normal.
• B- and T-cell numbers are usually normal.
• Poor specific antibody responses to bacterial and viral antigens may be present in some pa­
tients.
Complications
Long-term progression to СУШ is a possibility. Bronchiectasis may occur in lgG4 defi­
ciency.
Treatment
• If recurrent infections are a problem, then the first step might be to use continuous antibiotics, 
followed by fVIg if  infections are not controlled.
• IVIg has been shown to be of benefit in asthma due to IgGj deficiency, and in chronic sinusitis.
• It is possible to bypass lgG2 deficiency using protein-conjugated polysaccharide vaccines to 
generate a protective lgGi response.
Specific antibody deficiency with normal serum immunoglobulins
Normal serum immunoglobulins and IgG subclasses do not exclude humoral immune deficiency! 
This syndrome is probably much more common than hitherto realized.
Cause
• Cause is unknown. It is unrelated to IgG subclass deficiencies. There is usually a  failure to re­
spond to polysaccharide antigens (T-independent) and possibly other protein antigens (HBsAg).
• In small children, it may be due to a maturations] delay that resolves spontaneously. 
Presentation
• Recurrent bacterial infection of upper and lower respiratory tract (Haemophilus, Pneumococ­
cus, Moraxella)  is the usual presentation.
• In immunization programmes for hepatitis B, about 5% o f individuals fail to respond to die 
standard three-dose schedule; a fourth dose still leaves 1-2% who fail to make a serological re­
sponse. These patients clearly have some form of specific immune deficit.
Diagnosis
• There is a history of recurrent typical infections with normal immunoglobulins and IgG sub­
classes.
• Proof requires demonstration o f failure to respond to specific antigens (test immunization).
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Immunology
• Immunoglobulins and IgG subclasses are normal, but there are low specific antibodies, espe­
cially to capsulated organisms, and poor responses to test immunization, especially to polysac­
charide antigens (Pneumovax).
• Children under the age of 2 years do not respond to Pneumovax. However the inability to re­
spond to polysaccharide antigens in infants may be bypassed by conjugation of the polysaccha­
ride to a protein, for example, the Prevenar (heptavalent pneumococcal polysaccharide vaccine).
• T- and B-Iymphocyte numbers and T-cell function are normal.
Complications
Inevitable long delay in diagnosis leads to structural lung damage. The delay for such patients 
may be on die order o f 15-20 years because clinicians fail to recognize immunodeficiency in the 
presence o f normal total immunoglobulins.
Treatment
Treatment is still controversial. Continuous antibiotics are inadequate for patients with estab­
lished lung disease: these should be managed on IVIg/SCIg. In small children, spontaneous im­
provement may occur, and continuous prophylactic antibiotics and close supervision may be suf­
ficient.
X-linked hyper-IgM syndrome (HIGM 1)
Originally this was thought to be a В-cell disorder, but the demonstration in the X-linked form o f 
a primary T-cell defect means that this form should be reclassified as a T-cell defect. The pre­
dominant effect, however, is o f a humoral immune deficiency.
Cause
• X-linked form has now been shown to be due to a deficiency of the CD40-ligand (CD1S4) on T 
cells (gene located at Xq26-27), required for В-cell immunoglobulin class switch.
■ CD40 is also expressed on monocyte-macrophages and the interaction with CD40L is integral
to antigen presentation.
Presentation
• Presentation is with recurrent bacterial infections; this may include Pneumocystis carinii
pneumonia.
• There is often neutropenia and thrombocytopenia. Autoimmune disease o f all types is common.
Diagnosis
• There is usually an early onset; the diagnosis should always be considered when Pneumocystis 
pneumonia is the presenting illness. The differential diagnosis includes SCID and HIV infection.
• There will be a normal or high IgM, with low IgG and IgA.
• Most cases can be identified by failure to upregulate expression of CD1S4 on activation o f  T 
cells; this does not identify cases where point mutations permit expression o f non-fimctional 
CD154.
• Genetic identification is possible.
Immunology
• IgM (and IgD) are normally raised with a low IgG and IgA. However, the IgM may be normal 
in the absence of infection. There will be high isohaemagglutinins. Specific IgM responses are 
present but may be short-lived. IgM* and IgD* В celts are present
• T-cell function may be normal or poor. Some patients have reduced celt-mediated immunity, as 
evidenced by the occurrence of Pneumocystis infection. The expression o f CD40-ligand on acti­
vated T cells may be defective (use PMA and ionophore).
• Mild variants exist, compatible with minimal disease and survival into adult life.
Complications
• Complications include IgM* lymphomas (due to chronic overstimulation), opportunist pneu­
monias, autoimmune disease, and aplastic anaemia. There appears to be a particular risk o f 
Cryptosporidium  infection o f the biliary tree, leading to a severe cholangitis and liver failure.
• Long-term prognosis without transplantation is poor (infections and liver disease).
30
Treatment
• lVIg/SCIg should be started at the earliest opportunity: the IgM returns to the normal range 
with adequate therapy. Doses should be in the range 0.4-0.6 g/kg every 2-3 weeks.
• Prompt antibiotics are required for infections, as for other antibody deficiencies.
• Consideration should be given to the use o f  PCP prophylaxis (co-trimoxazole 480 mg bd, 960 
mg od, or 960 mg three times per week, azithromycin, and atovaquone are alternatives where co- 
trimoxazole cannot be tolerated).
• All drinking water, even if  bottled, should be boiled as domestic supplies cannot be guaranteed 
to be free o f  Cryptosporidium.
• Bone manow/stem cell transplantation is the treatment o f choice, where the diagnosis is made 
early in life and where compatible donors are available.
• Liver transplantation may be required for liver disease secondary to Cryptosporidium  infection. 
Autosomal hyper-lgM  syndromes (HIGM 2-5)
Four rare types o f autosomal hyper-lgM have now been identified.
HIGM-2
Caused by defects in the activation-induced cytidine deaminase gene (AID gene, 12pl3). This 
causes an intrinsic В-cell defect with failure to class-switch. T-celi function is normal and thence 
opportunistic infections such as Pneumocystis do not occur. Presentation is with recurrent bacte­
rial and gastrointestinal infections from early in childhood. Lymphoid histology is abnormal with 
hyperplasia and giant germinal centres. В cells express CD19, slgM, and sigD. T-cell expression 
o f CD154 is normal.
Treatment is with IVIg/SCIg.
H1GM-3
Caused by deficiency o f CD40 expression on В cells, due to a genetic defect (20ql2-13.2). 
Clinical features are identical to those of HIGM-1, and opportunist infections can occur. Class- 
switch memory В cells are markedly reduced or absent. Monocyte function is also defective 
(CD40 is expressed on monocytes). CD40 is also expressed on endothelial cells. Treatment is the 
same as for HIGM-1 with IVIg/SCIg, prophylaxis against PCP, and consideration of BMT/SCT, 
although the latter will not completely restore CD40 expression in non-haematopoietic cell line­
ages.
HIGM-4
Clinically a mild variant o f HIGM-2, but with normal AID levels. The molecular defect is un­
known.
HIGM-5
Due to defects in uracil-DNA glycosylase (UNG) and clinically resembles HIGM-2.
From the limited clinical experience, IVIg/SCIg would appear to be the treatment o f choice.
X-linked ectodermal dysplasia with HIGM (NEMO deficiency)
Cases have been reported o f X-linked ectodermal dysplasia with HIGM due to loss-of-function 
mutations in the NEMO gene (Xq28), coding for IKK-y, which block the release of NFkB on cel­
lular activation. Gain o f function mutations in IkBo, with which IKK-y interacts, have been re­
ported to produce an autosomal dominant ectodermal dysplasia similar to NEMO deficiency. 
Hypomorphic NEMO mutations have also been associated with ectodermal dysplasia associated 
with osteopetrosis and lym-phoedema, and incontinentia pigmenti.
Treatment with lVIg is helpful.
X-linked lymphoproliferative disease (Duncan's syndrome)
This is a very rare genetic disorder, leading to failure to handle EBV correctly.
Cause
• Genetic defect has been localized to Xq26, and the gene has now been cloned.
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• Gene product, SAP (SLAM-associated protein) controls the activation o f  T and В cells via 
SLAM (signalling lymphocyte activation molecule), a surface protein. SLAM is involved in 
IFN-y production and the switch fromTh2 toThl.
• Reason for the failure to handle EBV appropriately is not yet known.
Presentation
• Patients are fit and well until. EBV is encountered. Upon infection with EBV, five outcomes are 
possible:
- Fulminant EBV infection (58%); mortality is 96%.
- EBV+ non-Hodgkin’s lymphoma (30%); risk of lymphoma is 200-fold greater than the 
normal population.
- Immunodeficiency, usually profound hypogammaglobulinaemia (30%).
- Aplastic anaemia, often associated with hepatitis (3%).
- Vasculitis, lymphomatoid granulomatosis (3%).
• Overall mortality is 85% by the age o f 10 years.
Diagnosis
• Diagnosis is difficult, especially if there is fulminant EBV infection. There are no diagnostic 
immunological findings. Protein studies to confirm the absence of SAP and genetics may help. 
Immunology
• Immunology is usually normal before infection, but it is rarely checked unless there is a family 
history. Carriers may have subtle immunological abnormalities, such as unusually high anti-EBV 
VCA antibodies.
• After infection, in those who survive, there are reduced immunoglobulins (all three classes). T- 
cell proliferation to mitogens and antigens is poor, and there is reduced IFN-y production NK- 
cell function is also poor. CD8+ T cells may be persistently elevated.
• Antibodies to EBV may be poor or even absent
Treatment
• IVIG/SClg should be used for the hypogammaglobulinaemia.
• Bone marrow transplantation may be an option, as part o f the treatment o f  lymphoma.
• Prophylactic use of aciclovir in at-risk family members is of unproven value.
• During acute fulminant EBV, therapy directed against the abnormal CD8+ T cells (Campath) 
and transformed В cells (ritwcimab, anti-CD20) may be valuable.
Transient hypogammaglobulinaemia of infancy (TH1)
Cause
• THI is thought to be due to a delay in immune development, leading to a prolongation of the 
physiological trough of antibody after the age of 6 months, when maternal antibody has largely
disappeared.
• Common in the families of patients with other antibody deficiencies.
• Diagnosis excludes hypogammaglobulinaemia by reasons of prematurity.
Presentation
• Usual presentation is with recurrent bacterial infections, typically of the upper and lower respi­
ratory tract, occurring after 6 months of age. It may last up to 36 months before spontaneous re­
covery takes place.
• Transient neutropenia and thrombocytopenia have been reported.
Diagnosis
• There will be an early onset.
• Presence of normal В-cell numbers differentiates THI from XLA. IgM is frequently normal, 
and there may be evidence of specific antibody responsiveness.
• Check for btk expression, to exclude XLA.
• No specific diagnostic features and the diagnosis can only be made for certain after full recov­
ery of immune function has taken place.
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Immunology
• IgG and IgA are low for age; IgM is usually normal. В cells are present; T-cell numbers and 
function are normal. IgG must be reduced on more than one occasion. A reduction to < 2 SD be­
low die lower end of the normal range has been suggested by some authorities.
• Vaccine responses may be normal or reduced.
Treatment
• Mild cases may be managed with prophylactic antibiotics.
• IVIg/SCIg treatment may be required in more severe cases, used for a fixed period, and be 
withdrawn at intervals to check for spontaneous recovery.
• By definition all recover! If there is no recovery, then die patient has an alternative diagnosis. 
Hyper-lgE syndrome (Job's syndrome)
The underlying cause for this curious illness is unknown. It is frequently classified with neutro­
phil defects, but the neutrophil defects are secondary to the dysregulation o f T- and В-cell func­
tion and the very raised IgE.
Cause
• Some families have shown autosomal dominant inheritance mapping to a locus on chromosome 
4. In some cases there is incomplete penetrance.
• Autosomal recessive inheritance has also been described.
Presentation
• Patients present with atypical eczema and recurrent invasive bacterial infections. Staphylococci 
and Haemophilus are usual pathogens. Invasive candidiasis may occur.
• Pneumatocoeles due to staphylococcal infection are a  diagnostic feature.
• Osteopenia, probably due to abnormal osteoclast function, is a  feature and may lead to recur­
rent fractures.
• Coarse 'leonine' fades, but not all patients have red hair as originally described.
Diagnosis
• The clinical history is typical, especially the occurrence o f  pneumatocoeles.
• IgE levels are massively elevated and are usually much higher than in atopic eczema.
• The occurrence o f invasive as opposed to cutaneous infections distinguish HIGE from atopic 
eczema.
Immunology
• IgE is massively elevated (>50 000 kU/1) and there may be IgG subclass and specific antibody 
deficiencies, with poor/absent immunization responses.
• Variable abnormalities o f neutrophil function, affecting chemotaxis, phagocytosis, and micro­
bicidal activity have been reported, but are likely to be due to inhibition by the high IgE.
• The underlying defect seems to involve an imbalance o f cytokine production due to a Th2 pre­
dominance (IL-4, IL-5), and decreased Thl cytokines (IFN-y and TNFa).
• Absent CD45RO on T cells has been reported 
Treatment
• IVIg/SCIg should be used for the antibody deficiency.
• Cimetidine (as an immunoregulatory agent) has been recommend, although the value appears 
to be limited. IFN-y is a treatment in the light o f  proposed Th2 predominance, but has not yet 
been shown to be effective in small open trials. Cyclosporin A may be very helpful.
• Surgery for pneumatoceles and deep-seated abscesses may be required.
• Bone marrow transplantation has been tried in some cases, although with no clear benefit.
R are antibody deficiency syndromes
Antibody deficiency, presenting as common variable immunodeficiency, has been associated 
with the following extremely rare genetically identified disorders.
• Kappa and lambda light chain deficiency.
• ICOS (inducible co-stimulator, 2q33) deficiency.
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• Surrogate light chain deficiency (Х5/14.1).
• Mu chain deficiency.
• SWAP-70 deficiency.
• CD79a (Iga) deficiency.
• BLNK deficiency.
• CD 19 deficiency.
Routine genetic tests for these are not yet available; screenings of large cohorts o f СУЮ patients 
have shown that these disorders account for very few cases currently diagnosed as СУШ.
Severe combined immunodeficiency (SCID)
Severe combined immunodeficiency involves both the T-cell arm and the В-cell aim. Often the 
major defect is on the T-cell side: В cells may be present, but, in the absence o f T cells, fail to 
respond or develop appropriately. The diagnosis is frequently missed at first, which reduces the 
chance of a successful outcome from treatment. It is estimated that the incidence is 1 per 50 000 
births. Almost all cases are now accounted for by identified genetic defects.
Successful management of SCID requires a multidisciplinary team used to dealing with very sick 
small infants. Management should be restricted to centres experienced in the diagnosis and care 
of вСЮ. It should not be undertaken in haematology-oncology bone marrow transplant units as 
the requirements are very different from those of leukaemic patients.
Presentation
Most cases of SCID present with common clinical features, no matter what the underlying de­
fect.
• Typical features include:
- early onset infections (bacterial, viral, fungal, opportunist);
- persistent candidiasis;
- chronic enteric virus excretion;
- failure to clear vaccines (BCG, oral polio);
- failure to thrive;
- matemofetal engrafbnent, with GvHD, causing erythroderma (often with eosinophilia);
- lymphopenia: an absolute lymphocyte count of < 2.0 ' 109 IL in a baby less than 6 
months old is pathological and indicates SCID until proven otherwise. Looking at the differential 
white count is therefore mandatory in all babies with recurrent infections.
• If SCID is suspected investigation is urgent-seek advice at once from a paediatric immunolo­
gist.
Infections in SCID
There is onset of infections soon after birth.
• Recurrent bacterial infections (pneumonia, otitis media, sepsis).
• Persistent thrush.
• Persistent viral infections (RSV, enteroviruses, parainfluenza, CMV, other herpesviruses, rota­
virus, small round structured virus (SRSV)).
• Opportunist infections (PCP; fungal infections, including aspergillus).
• There are very significant risks from the administration of live vaccines especially BCG and 
polio.' BCG should not be given to babies where there is a family history of SCID.
Other features ofSC ID
• Failure to thrive.
• Diarrhoea (consider chronic enteroviral infection, rotavirus, SRSV).
• Skin rash (Omenn's syndrome, matemofetal engraftment).
• Bone abnormalities (flared ribs-ADA deficiency malabsorption-rickets).
• Short-limbed skeletal dysplasia.
• Hepatosplenomegaly (BCGosis, graft-versus-host disease (GvHD) from MFE or blood transfu­
sions; Omenn's syndrome).
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SCID: investigations in suspected cases
On suspicion, first-line investigations
• Lymphocyte subpopulations (T-, B-, NK-, and T-cell subpopulations, with absolute numbers).
• Immunoglobulins.
■ If the results are suspicious, then baby should be referred at the earliest opportunity to a spe­
cialist centre with facilities for managing SCID.
Further investigations in the specialist referral centre
• T-cell proliferation.
• Cytokine assays.
• NK-cell function.
• Protein studies.
• Specific antibodies.
- Biochemical (exclusion of ADA deficiency) and genetic studies.
• HLA typing as part o f work up for bone marrow transplantation.
Aim s o f the initial investigations
• To confirm the diagnosis o f SCID.
• To identify unusual variants, as this may affect the conditioning protocol used prior to bone 
marrow transplantation.
• To provide evidence for subsequent genetic counselling o f  the family.
• To provide a baseline against which success o f bone marrow therapy (BMT) can be measured. 
Patterns o f lymphocyte subpopulations in SCID and variants
• It cannot be stressed too often how important a  low total lymphocyte count is as a  marker o f 
SCID: low lymphocyte counts should never be ignored.
• Typical pattern is of very low/absent T cells with normal or absent
В cells; immature T cells may be present in low numbers (CD3+, CD2*, CD4', CD8").
• SCID with matemofetal engraftment (MFE): T cells are present but are usually CD8+ and acti­
vated (CD25+, DR’); В cells are usually low or absent. Maternal origin o f the cells may be con­
firmed by genetic studies.
• Omenn's syndrome (leaky SCID): T cells may be present, including CD4 T cells; clonal restric­
tion with limited Ter pi-chain repertoire (this requires genetic analysis).
• Bare lymphocyte syndrome (HLA class I deficiency (bare lymphocyte syndrome type I) and 
HLA class II deficiency (bare lymphocyte syndrome type II): absence or marked reduction of 
HLA class II antigen expression with variable HLA class I antigen expression; T  cells are normal 
or low.
• ZAP-70 kinase deficiency and z-chain deficiency: marked reduction/absence o f  CD8* T cells; 
low normal CD4+ T cells.
• Absence o f CD3/TCR complexes (CD3 y-, 5 -, or (-chains) variable expression o f CD3: T-cell 
numbers are usually normal.
Proliferation assays
• Functional studies are useful in cases when T cells are present.
• PHA response: invariably absent in all major forms o f SCID, including Omenn's and SCID 
with MFE; may be low-normal in ZAP-70 kinase deficiency.
• Phorbol esters (PMA) and calcium ionophore: will be normal where there is a  membrane defect 
(ZAP-70 kinase or CD3 complex) that can be bypassed (PMA acts intracellularly on protein 
kinase C).
• Anti-CD3 and IL-2: abnormal when the defect involves the CD3/TCR complex (CD3 defi­
ciency, ZAP-70 kinase deficiency). The normal newborn anti-CD3 response is lower than in 
adults.
• Reconstitute o f proliferation to mitogens with IL-2 may suggest a failure to produce this cyto­
kine.
• Other stimuli used may include antigens, anti-CD2, anti-CD43 (Wiskott-Aldrich syndrome). 
Cytokine assays are rarely used: IL-2 deficiency has been reported but is exceptionally rare.
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N К-cell assays. The role o f these assays in the management o f SCID is experimental. It may be 
useful as a baseline marker for monitoring against graft failure.
Immunoglobulins. If  the diagnosis is made within the first few weeks o f life, maternal antibody 
will still be present Even if  the child has В SCID, immunoglobulins and specific antibody are not 
produced. It may be worth checking for specific antibodies if  there is late presentation and the 
child has been immunized.
Biochemistry and genetics
• Check for ADA deficiency: abnormal metabolites (dATP, S-adenosyl homocysteine) will be 
present.
• It is possible to test genetically for specific genetic abnormalities, e.g. X-linked SCID (common 
cytokine receptor у-chain gene), Jak-3, IL-7Ra, RAG-1/RAG-2 HLA class II deficiency (СПТА 
or RFX-5 genes), ZAP-70 kinase deficiency, CD3 y-, 8 or ^ -chains deficiency.
«The genetics department will be able to assist in the distinction of Omenn's syndrome from 
SCID with MFE: skin biopsies are helpful. Cytogenetics can be used if  it is a male baby; other 
wise molecular genetics are required.
SCID: treatm ent and outcomes
Treatment
The approach to treatment is also common to all types.
• Isolation to prevent further infection.
• Do not give any live vaccines.
• Irradiate all cellular blood products, to prevent engraftment o f any donor lymphocytes.
• Ensure all blood products are from CMV-negative donors.
• Identify and treat all infections: use direct culture and PCR-based techniques.
• Transfer immediately diagnosis is suspected to nearest specialist paediatric immunodeficiency 
centre with facilities for definitive treatment
• Do not initiate investigations for underlying cause. Delay in transfer significantly reduces the 
chances of a successful outcome (90% success rate for babies diagnosed and treated immediately 
after birth, compared to 40% where treatment is delayed).
Once in the tertiary centre, management will include the following.
• Isolation in laminar flow.
• Establish venous access and commence nutritional support (enteral or parenteral) if  required.
• Initiation of diagnostic tests: T- and В-cell numbers; baseline T-cell function; serum immu­
noglobulins; screen for pathogens (nasal secretions, bronchial lavage, stool, urine, blood). Biop­
sies as required (lymph nodes, skin for GvHD).
• Undertake genetic testing to identify gene defect, if possible.
■ Tissue typing of baby and family; initiation of search for matched unrelated donor on bone 
marrow registries.
• Counsel family about diagnosis and treatment.
• Initiation of IVIg replacement.
• Use PEG-ADA as a temporizing measure in ADA-deficient SCID.
• Initiate aggressive treatment for identified infections with antibacterials, antivirals, and anti- 
fungals as appropriate-good microbiological and virological control is essential.
• Cytoreductive conditioning of recipient (to prepare space for incoming stem cells).
• T-cell depletion of donor marrow (for mismatched grafts).
• Undertake BMT, SCT as appropriate; consider gene therapy (currently suspended due to devel­
opment of leukaemias arising from the insertion of genes close to the proto-oncogene LMO-2). 
BMT may be:
- sibling (identical);
- parent (haploidentical);
- matched unrelated donor (MUD);
- stem cells.
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• Undertake post BMT/HSCT immunological monitoring, treating infection and GvHD as ap­
propriate.
Outcomes
• Outcome is dependent on the promptness o f the diagnosis and what infections are present at the 
time o f  diagnosis. Poor prognostic indicators are late diagnosis and chronic viral infections (es­
pecially parainfluenza pneumonitis).
• Meticulous care is required during the aplastic phase between conditioning and engraftment: 
this will require cell support (platelets, red cells), infection prophylaxis and treatment (fungi, vi­
ruses, and bacteria), management o f  the complications o f  conditioning (veno-occlusive disease 
o f  the liven pneumonitis) and o f graft-versus-host disease (mismatched donors).
• Survival should be > 80% with early diagnosis, good matching o f  donors, and no pretransplant 
infections. This fails to <  40% with late diagnosis, chronic infections, and poorly matched do­
nors. Regular monitoring post-BMT is required to follow engraftment and development o f  im­
mune function. This should include the following.
• Lymphocyte subpopulations: the return o f T- and В-cells, expression o f  activation markers in 
association with GvHD, effectiveness o f immunosuppression.
• T-cell proliferation: this is only valuable when T-cells have returned to the circulation. The re­
turn o f a PHA response defines probable safety for release from laminar flow confinement
• NK-cell function and numbers may correlate with graft survival.
• Immunoglobulins: adequacy o f replacement IVIg therapy, return o f IgA and IgM synthesis,
IgG subclass development (off IVIg).
• Specific antibodies: return o f functional antibodies-isohaemagglutinins; immunization re­
sponses.
• Genetic studies: chimerism of lymphocytes (DNA studies on separated T- and B-cells).
• Biochemical reconstitution (ADA deficiency; enzyme deficiencies, e.g. ZAP-70 kinase).
SCID: RAG-l/RAG-2 deficiency 
Cause
• Autosomal recessive. Mutations in RAG-l/RAG-2 genes, required for V(D)J recombination of 
the T- and В-cell antigen receptors. Located at 1 lp l3 .
Presentation
• Typical SCID.
Diagnosis
• Typical presentation with recurrent infections and lymphopenia on full blood count.
• Confirmed by immunological and genetic studies.
Immunology
• Low or absent serum immunoglobulins, severe lymphopenia (T , B' SCID). NK cells are pre­
sent and comprise the majority o f circulating lymphocytes.
• Matemofetal engraftment is common.
SCID: Omenn's syndrome
Cause
• Autosomal recessive. Mutations in RAG-l/RAG-2 genes, required for V(D)J recombination of 
the T- and В-cell antigen receptors. Located at 1 lp l3 .
• Partial activity present, allowing the development o f oligoclonal, peripherally expanded T-cell 
clones.
Presentation
• Presents with erythroderma rash, lymphadenopathy, and hepatosplenomegaly; must be distin­
guished from matemofetal engraftment. Cytogenetics o f the peripheral blood cells may identify 
maternal cells.
Diagnosis
• Cytogenetics is required to exclude MFE.
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• Immunological tests are variable.
• Oligoclonal T-cell pattern is distinctive.
Immunology
• Eosinophilia.
• Leucocytosis, variable CD4+ and CD8*' T-cell numbers; high level o f activation marker expres­
sion (DR, CD25, CD45RO),
• В-cells absent; hypogammaglobulinaemia usual.
• Oligoclonal TCR usage.
• Abnormal lymph node histology; excess eosinophils, lymphocyte depletion 
SCID: Artemis deficiency
This defect causes a TB 'N K 1' radiation-sensitive phenotype o f SCID, similar to RAG-1/RAG-2 
deficiency.
Cause
• Mutation in the Artemis gene, located on chromosome 10pl3, involved in DNA repair probably 
through interaction with DNA-PKcs.
Presentation
• As for вСЮ, but prone to oral and genital ulcers.
Diagnosis
• Should be considered in cases o f TB'NK* SCID, where RAG-1/RAG-2 mutations are not 
found.
Immunology
• Profound T- and В-cell lymphopenia with normal NK-cell numbers and function
• Matemofetal engraftment common.
SCID: Jak-3 kinase deficiency (autosomal recessive I B* SCID)
This form, in which T-cells are absent but В-cells are present in normal numbers, accounts for 
about 10% of cases.
Cause
• Mutations in the gene encoding Jak-3 kinase, which prevent signalling through the surface cy­
tokine receptors containing the common gamma chain. Signals from IL-2, IL-4, IL-7, IL-9, IL- 
15, and IL-21 are blocked.
• T-cell but not В-cell differentiation is blocked Presentation Presents with typical SCID fea­
tures.
Diagnosis
• Typical SCID presentation.
• Absent T-cells with normal or increased B- and decreased NK-cells; overall total lymphocyte 
count may be normal.
• Western blotting of lymphocyte lysates may identify the absence of Jak-3 protein and genetic 
studies will confirm the gene defect.
Immunology
• T cells are very low or absent; NK-cells are reduced, B-ceils are normal or increased; absent 
mitogenic responses.
• Mild variants may exist with significant numbers o f poorly functioning T-cells.
• Hypogammaglobulinaemia is usual.
SCID: Common gamma chain deficiency (X-linked T B + SCID)
This accounts for 50-60% of SCID.
Cause
• Mutations in the common cytokine receptor gamma chain; signals from IL-2, IL-4, IL-7, IL-9, 
IL-15, and IL-21 are blocked.
• Gene is located at X ql3 .1-13.3.
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• Missense mutations may lead to the expression o f a mutant non-functional gamma chain. 
Presentation
• Typical SCID features in male infant.
Diagnosis
• Pattern o f infections.
• Low or absent T-cells, NK-cells; normal or increased B-cells.
• Demonstration of absent common gamma chain and genetic mutations. As levels of common - 
•у-chain on lymphocytes are low, demonstration of absence is difficult, and may be confused if 
there is matemofetal engraftment.
Immunology
• Low serum immunoglobulins.
• Normal or increased В-cells, low or absent T-cells and NK-cells (dependent on IL-15).
■ Poor mitogen responsivness. В-cells may make IgE in vitro via a common у-chain independent 
IL-4 receptor.
SCID: Interleukin-7 receptor-u deficiency 
Accounts for 1-2% of SCID patients.
Cause
• Autosomal recessive mutation in IL-7Ra.
• Gene is located at 5pl3.
• Missense mutations may lead to the expression of a mutant nonfunctional protein that binds IL- 
7 poorly.
Presentation
• Typical SC ©  features in infant.
Diagnosis
• Pattern o f infections.
• Low or absent T-cells, normal or increased В-cells, and normal NK-cell numbers.
• Demonstration of absent IL-7Ra and genetic mutations.
Immunology
• Low serum immunoglobulins.
• Normal or increased В-cells, low or absent T-cells, and normal NK-cells.
• Poor mitogen responsiveness.
SCID: ZAP-70 kinase deficiency
This is a rare cause o f  autosomal recessive SC©.
Cause
• Autosomal recessive mutation in CD3 zeta-associated protein, ZAP-70.
• Gene is located at 2q l2.
• Mutations cluster in region o f  gene encoding the site for enzymatic activity.
• ZAP-70 is involved in signal transduction from the membrane CD3 complex to the internal 
cascade.
• ZAP-70 is crucial in thymic devlopment, especially in the development o f CD8 T-cells from 
double-positive precursors.
Presentation
• Typical S C ©  features in infancy, with an early presentation.
• Lymph nodes and thymic shadow may be present 
Diagnosis
• Pattern o f infections.
• Characteristic selective absence o f  circulating CD8+ T-cells.
• Demonstration o f absence o f ZAP-70.
• Thymic biopsy may show double-positive cells in the cortex but only CD4* T-cells in the me­
dulla.
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Immunology
• Serum immunoglobulins may be normal.
• Normal or increased В-cells, absent CD8+ T-cells, normal or low CD4+T-cells, and normal 
NK-cells.
• Failure o f response to membrane acting mitogens, PHA and anti-CD3 monoclonal antibodies, 
with normal responses to pborbol esters and ionophores (acting at the level of protein kinase.C). 
Treatment
• Gene therapy may be possible.
SCID: purine metabolic disorders: Adenosine deaminase (ADA) deficiency
This is the first genetically identified cause o f SCID. It accounts for 20% of cases of SCID.
Cause
• Mutations in the ADA gene on chromosome 20ql3.11. This gene has now been cloned and se­
quenced
• Gene product is involved in purine metabolism.
• In the absence o f ADA, there is a progressive reduction of T- and В-cells due to toxic effects of 
dATP and S-adenosyl homocysteine, with increased lymphocyte apoptosis.
Presentation
• Typical SCID features in infancy, with (usually) an early presentation.
• Liver enzymes are often raised.
• There is abnormal flaring of the rib ends, pelvic dysplasia, and neurological features, including 
cortical blindness.
• Presentation with mild form in adult life has been repeated; presentation is with recurrent bacte­
rial infections and opportunist infections such as PCP; evidence o f immune dysregutation (auto­
immunity and allergy).
• Relatives may show reduced levels o f red cell ADA activity.
• Lymphocytes may be normal at birth (due to maternal ADA), but fall rapidly after delivery. 
Diagnosis
• Pattern o f infections (in early childhood); diagnosis of adults may be difficult
• Lymphopenia.
• Bone changes are not specific, although suggestive in the context o f the immunological abnor­
malities.
• Measurement o f ADA in erythrocytes, together with serum levels o f toxic metabolites is essen­
tial.
Immunology
• Serum immunoglobulins may be normal initially, but fall rapidly.
• Progressive severe lymphopenia, affecting all cell types.
• Poor or absent responses to all mitogens.
Treatment
• BMT or stem cell transplant is treatment o f choice, as for other types o f SCID.
• Red cell transfusions restore ADA levels and improve immune function; PEG-ADA is avail­
able and is highly effective in restoring immune function (although this makes BMT harder).
• Antibodies to PEG-ADA may occur.
• Gene therapy has been used successfully, but has been complicated in several cases by acute 
leukaemia, due to insertion o f the retroviral vector into known oncogenes; gene therapy has 
therefore been suspended.
SCID: purine metabolic disorders: purine nucleoside phosphorylasc (PNP) deficiency 
This is a rare genetic deficiency (about SO cases worldwide).
Cause
• Absence o f  PNP leads to a  build-up o f the toxic metabolite dGTP, which preferentially dam­
ages T-cells in die early stages, but later damages В-cells also.
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• Disease is autosomal recessive; gene is located at 14ql3.1.
Presentation
• Onset tends to be later than for other forms o f SCID, and in this respect it behaves more as a 
combined immunodeficiency.
• Neurological signs (spasticity, tremor, ataxia, and mental retardation) occur early.
• Infections are common, especially disseminated varicella, but also other bacterial, viral, and 
opportunist pathogens.
• Haemolytic anaemia, immune thrombocytopenic purpura and thyroiditis are also common. 
Diagnosis
• Combination o f progressive neurological signs and infections should raise suspicion.
• A low serum urate is a useful marker.
• Diagnosis is made by enzymatic studies and by detection o f elevated levels o f the metabolite 
dGTP.
Immunology
• Immunoglobulins are normal or low, but some patients have elevated levels with monoclonal 
gammopathies.
• Poor specific antibody responses to immunization.
• Autoantibodies may be detected.
• В-cells are normal in numbers until late disease, but there is a progressive decrease in T-cell 
numbers with time.
• Mitogen responses are variably reduced.
Treatment
BMT or HSCT is probably best, although gene therapy is a future possibility.
SCID: HLA class I  deficiency (bare lymphocyte syndrome type I)
This is a rare cause o f combined immunodeficiency (about 20 cases worldwide).
Cause
• Deficiency o f  either TAP-1 or TAP-2 (transporter associated with antigen presentation).
• Causes unstable peptide/HLA class I/flfe-microglobulin complex, which rapidly dissociates and 
cannot be expressed on the cell surface.
Presentation
• Recurrent bacterial sinopulmonary infections.
• Granulomatous skin lesions, with ulceration.
• Presentation at any age.
• May be asymptomatic.
Diagnosis
Symptoms plus failure o f  class I expression on cells.
Immunology
• Minor abnormalities o f humoral immunity only.
• Lymphocyte subsets may be normal; abnormalities when present are minor and inconsistent. 
Treatment
• Unsatisfactory; chest and sinus disease treated similarly to cystic fibrosis with aggressive anti­
biotics and physiotherapy.
• Skin disease is difficult to treat: immunosuppressive therapy and interferons may make the 
condition worse.
• Role of BMT/SCT undefined (but class I expression occurs on all nucleated cells, so this is not 
a  pure stem cell disorder).
SCID: MHC class II deficiency (bare lymphocyte syndrome type II)
It is autosomal recessive, but genetically complex. This rare disease is found predominantly in 
North Africa and Mediterranean area (80 cases worldwide).
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Cause
• СПТА, RFX-5, RFXAP, RFXANK, RFX-B transcription factor components are abnormal.
• Four genetic complementation groups.
Presentation
• Presentation is usually early (first 6 months o f  age) with severe diarrhoea, hypogammaglpbu- 
linaemia, and malabsorption.
• Recurrent bacterial and vital chest infections.
• Viral infections of the nervous system (HSV, enteroviruses).
• Haemolytic anaemia.
• Hepatitis, cholangitis.
• Rarely, it is asymptomatic.
Diagnosis
• Diagnosis is made on clinical suspicion (differential diagnosis includes X-linked immune dys- 
regulation with polyendocrinopathy syndrome (IPEX) due to FOXP3 deficiency).
• Absence of MHC class II expression on lymphocytes.
Immunology
• Immunoglobulins are normal or low.
• В-cell numbers are normal; T-cell numbers may be normal but there may be low CD4* T-cells 
and increased CD8+ T-cells, reversing the normal ratio.
• MHC class I expression is variable.
• MHC class II expression will be absent (DR, DP, DQ) but may be inducible with y-IFN.
• Poor but variable mitogen responses.
Treatment
• BMT or HSCT is the treatment o f choice, but is surprisingly difficult to do successfully.
• y-IFN may have some beneficial effect.
SCID: reticular dysgenesis
This is a rare defect of the maturation of stem cells for both lymphoid and myeloid lineages. No 
genetic cause has yet been identified. There is marked granulocytopenia, lymphopenia, and 
thrombocytopenia (sometimes no cells at all). It presents with early overwhelming infections and 
often death before the diagnosis is made.
Treatment
Matemofetal engraflment is common. BMT/SCT is required.
SCID/CID: Nezelofs syndrome
Mainly a T-cell deficiency, with no identified molecular causes, presenting with recurrent si- 
nopulmonary and gastrointestinal infections and malabsorption, warts, allergic disease autoim­
munity (haemolytic anaemia, immune thrombocytopenic purpura, neutropenia, hepatitis). Un­
clear whether this is a discrete diagnostic entity or represents early onset CVID. T lymphopenia, 
variably reduced immunoglobulin levels, poor humoral function, autoantibodies.
Prognosis seems to be poor despite prophylactic antibiotics, antifimgals, and IVIg: BMT/SCT 
suggested.
SCID/CID: CD3 £-cbain deficiency 
Similar to ZAP-70 kinase deficiency.
SCID/CID: CD3 deficiency
Deficiencies o f CD3 y-, S-, and E-chains have been described in small numbers of patients; there 
is variable expression of CD3.
Cases present as mild combined immunodeficiency, with later onset than SCID, recurrent si- 
nopulmonary infections, and autoimmune phenomena. Reduced expression of the CD3 complex
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on T-cells is suspicious; proliferative responses to mitogenic anti-CD3 monoclonal antibodies 
are absent but responses to phorbol esters and ionophore are normal.
BMT/SCT is probably the treatment o f  choice. IVIg is helpful in mild cases.
SCID/CID: CD25 (IL-2 receptor-a) deficiency
Single patient reported, presenting with severe T-lymphopenia and diffuse lymphocyte infiltrates 
associated with mutation in CD25 gene similar in presentation to autoimmune lymphoprolifera- 
tive syndrome. Recurrent viral, bacterial, and opportunist infections.
SCID/CID: CD45 deficiency
Two cases presenting with SClD-like illness due to complete absence o f surface CD45.
SCID/CID: Human nude phenotype (whn mutation) FOXN1 (17q ll) nude human
One Italian family with complete alopecia and SCID-like syndrome reported, associated with 
winged-helix nude mutation, similar to nude mouse. Thymic function impaired.
SCID/CID: O ther rare defects
• CD7 T-cell deficiency.
• Autosomal SCID with multiple intestinal atresias.
• Multiple cytokine deficiency.
• Lack of nuclear factor of activated T-cells (NF-AT).
• IL-2 deficiency: presented as SCID; no transcription o f IL-2.
• Other signat-transduction defects, including T-cell calcium flux defects.
Disorders with predom inant T-cell disorder
« DiGeorge syndrome (including all the variants).
• Wiskott-Aldrich syndrome (also includes X-linked thrombocytopenia and GATA-I defi­
ciency).
• Ataxia telangiectasia.
• Other chromosomal breakage syndromes:
- Nijmegen breakage and Seemanova syndrome;
- Bloom's syndrome:
- Fanconi anaemia;
- ICF syndrome;
- Xeroderma pigmentosa.
• Chronic mucocutaneous candidiasis.
• AIRE gene deficiency.
• APECED.
• IPEX syndrome (including FOXP3 deficiency).
• Idiopathic CD4 lymphopenia.
• Autoimmune lymphoproliferative syndromes:
- fas deficiency;
- fas-ligand deficiency;
- caspase 8 and 10 deficiencies.
• Cartilage-hair hypoplasia.
• WHIM syndrome.
• y-lnterferon/lL-12 pathway syndromes:
- y-IFNRl deficiency;
- y-IFNR2 deficiency;
- IL-12-Rpl deficiency;
- IL-12p40 deficiency;
- ST ATI deficiency.
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DiGeorgc (22 q li deletion complex) syndrome
DiGeorge originally described one phenotype o f what is now realized to be a broad and complex 
array of developmental defects, probably due to more than one genetic lesion.
The range o f defects is large and includes the CATCH-22 syndrome (cardiac abnormalities, ab­
normal fades, thymic hypoplasia, cleft palate, and hypocalcaemia, associated with 22q l 1 dele­
tions), Shprintzen syndrome, velocardiofacial syndrome (VCF), cono-truncal face anomaly syn­
drome, Opitz-GBBB syndrome, CHARGE associations, Kallman syndrome, and arrhinen- 
cephaly/holoporencephaly. Similar features may also arise in the fetal alcohol syndrome, mater­
nal diabetes, and retinoid embryopathy.
Cause
• Microdeletions at 22ql 1, possibly affecting a zinc-finger (DNA-binding) protein involved in 
early development, have been associated with many of the phenotypic variants.
■ Candidate genes include TBX1, Crkol, and UFD1L
• Other mutations, including lOp deletions, may give a similar phenotype.
• Abnormal development o f branchial arch-derived structures, including heart, thymus, and para­
thyroid glands.
Presentation
• Hypocalcaemic tetany, often occurring in first 48 hours after delivery, and due to parathyroid 
gland maldevelopment.
• Cardiac abnormalities, typically those of a truncus arteriosus type, interrupted aortic arch, or 
tetralogy of Fallot. Severity of the cardiac abnormalities often determines outcome.
• Dysmorphic face with cleft palate, low-set ears, and fish-shaped mouth.
• Highly variable immunodeficiency, associated with absence or reduction of thymic size; this 
often improves with age. Severe forms may present as SCID with absent T  cells. Partial syn­
dromes may occur without any immunological features (VCF and Shprintzen syndromes).
• Infections are mainly viral (adenovirus, CMV, rotavirus).
• GvHD from non-irradiated blood transfusions may occur if  the diagnosis is not thought o f  dur­
ing surgery for cardiac abnormalities.
• Increased risk of autoimmune disease and В-cell lymphomas.
• 10% have cleft palates.
• Development delay common, especially language.
Diagnosis
• Diagnosis is by clinical suspicion, based on the facial features, typical cardiac abnormalities, 
and abnormally low calcium in full-blown cases. Partial variants may be more difficult to iden­
tify.
• All children with relevant cardiac abnormalities should be screened for 22ql 1 deletions by 
FISH and for other cytogenetic abnormalities. If positive, screen parents and refer for genetic 
counselling (50% of subsequent pregnancies will be affected).
• Patients with an identified 22ql 1 deletion should be screened for immunological defects, both 
humoral and cellular (immunoglobulins, IgG subclasses, specific antibodies, lymphocyte surface 
markers, and proliferation assays).
Immunology
• Immunology is highly variable and tends to improve with age; extra-thymic development o f T- 
cells may occur.
• SCID-like immunology is possible.
• Variable reduction in T-cells, with normal or low T-cell proliferation to mitogens.
• Immunoglobulins may be normal or reduced and specific antibody production may be poor, 
with low/absent immunization responses.
• Deficiency of IgA increased, and associated with autoimmunity.
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Treatment
• Optimum treatment is uncertain: the cardiac abnormalities define prognosis and repair of these 
takes priority.
• Irradiated blood should be used until it is known how severe the immunological abnormality is. 
Children with normal T-cell function are probably at very low risk of developing transfusion- 
related GvHD.
• Calcium supplementation for hypoparathyroidism.
• As mild immune defects may improve, simple measures such as prophylactic antibiotics may 
be all that is required. If there is evidence for significant humoral deficiency, then IVIg may be 
required
• Severe defects, with absent T-cells, should be considered for BMT/HSCT, although in the ab­
sence of a thymus it is probable that reconstitution is due to engraftment of mature T-cells.
• Thymic transplants (inserted into muscle peripherally) have been tried and are said to be of 
value.
Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia (XLT)
Wiskott-Aldrich syndrome is an X-linked disorder causing thrombocytopenia with small plate­
lets, eczema, and a progressive immune deficiency. The same gene is also responsible for X- 
linked thrombocytopenia, a milder variant in which the eczema and immune deficiency is absent. 
Cause
• X-linked disease, the gene is located at Xpl 1.23 encoding WASP (Wiskott-Aldrich-associated 
protein). The same gene is responsible for X-linked thrombocytopenia.
• WASP is a multifunctional protein, with GTPase binding activity. It is involved in intracellular 
actin polymerization, intracellular signalling, apoptosis, and phagocytosis.
• Carrier females show non-random X-inactivation, indicating that WASP expression carries a 
selective advantage in cell development.
• Abnormal O-glycosylation of surface proteins of both lymphocytes and platelets is well de­
scribed. One such surface antigen is CD43 (sialoglycophorin). However, the gene for CD43 is 
normal in WAS. N-linked glycosylation is normal.
Presentation
• Presentation is early in childhood in males with severe eczema, which has an atypical distribu­
tion compared to atopic eczema. Molluscum contagiosum, warts, and HSV may infect eczema­
tous skin.
• Abnormal bleeding is due to the low platelet count, and bleeding complications occur early
• Infections develop more gradually, usually affecting the respiratory tract, and are bacterial.
• Autoimmunity (vasculitis and glomerulonephritis) is well described.
• Allergic reactions to food may occur.
• There is often a family history.
• XLT, a mild variant with thrombocytopenia alone, but without eczema and immune deficiency 
is recognized.
• Two forms of WAS exist: a  severe form culminating in early lymphoma, and a milder form 
compatible with survival to adult life. There is no phenotype-genotype correlation.
• Symptomatic female carriers have been reported (skewed X-inactivation).
Diagnosis
• Clinical features: there is thrombocytopenia (variable in range < 70) with abnormally small 
platelet volume (<6.0 fl is diagnostic).
• Identification of low/absent WASP with subsequent mutation analysis is required.
• No absolutely diagnostic immunological features 
Immunology
• There is a progressive reduction of T-cells with poor proliferative responses to CD3, CD43, 
and periodate (specific for О-linked sugars). Proliferation to galactose oxidase and neuramini­
dase, which act via N-linked sugars, is normal.
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• There are reduced IgM and IgA with a normal or high IgG and elevated IgE. There is a pro­
gressive loss o f antipolysaccharide responses (including isohaemagglutinins) with poor/absent 
responses to test immunization with polysaccharide antigens. В-cell numbers are normal.
• CD43 (sialophorin) on lymphocytes and gplb on platelets are unstable and tend to fall off cells 
when they are kept in vitro. Abnormalities of the cytoskeleton in T-cells and platelets, with fail­
ure of actin bundling, have also been described.
• Variable thymic hypoplasia.
Treatment
• Splenectomy may be beneficial for thrombocytopenia, which is usually resistant to steroids. 
XLT patients are highly susceptible to overwhelming sepsis if splenectomy is undertaken, even 
though normally they do not have a problem with infection.
• Platelet transfusions should be avoided unless essential to control bleeding.
■ IVIg should be used for patients with poor antipolysaccharide responses, if recurrent bacterial 
infections are a problem and after splenectomy, as responses to post-splenectomy vaccination 
schedules will be poor.
• Consider prophylactic antibiotics; mandatory post-splenectomy.
• Treat eczema.
• Avoid aspirin and related drugs (increased risk o f bleeding).
• Early (<5 years of age) BMT/HSCT should be considered to prevent the development o f lym­
phoma: it cures all the features o f the disease, including eczema
• The role of BMT/HSCT in adult patients is unclean development o f lymphoma is an indication 
for aggressive chemotherapy followed by transplantation in first remission, with matched unre­
lated donor for the graft-vs-lymphoma effect.
Outcome
• Death may occur from infection or intracranial haemorrhage.
• Very significant risk of death in late adolescence/early adulthood from high-grade lympho- 
reticular malignancy - this may be preventable by early BMT.
• Mild variants exist and may have fewer problems with bleeding or infection in adulthood.
Ataxia telangiectasia
Cause
• Cells from AT patients have a disorder o f the cell cycle checkpoint pathway, resulting in ex­
treme sensitivity to ionizing radiation. Lymphocytes show frequent chromosomal breaks, inver­
sions, and translocations; the major sites affected are the genes for the T-cell receptors and Ig 
heavy chains.
- Disease is autosomal recessive; six genetic complementation groups (А, В, C, D, E, V I, V2) 
have been described and all but V2 map to 1 lq22-23.
• One of the genes has now been identified and appears to be a DNA-dependent kinase related to 
phosphatidylinositol kinase-3 (ataxia telangiectasia mutated protein (ATM)). Function appears to 
be to sense double-stranded DNA breaks.
• ATM phosphorylates BRCA1 (may explain increased risk of breast cancer in carrier females). 
Presentation
• Progressive cerebellar ataxia, with typical telangiectasia, especially of the ear lobes and con- 
junctivae.
• Accompanied by recurrent bacterial sinopulmonary infections.
• Opportunist infections uncommon, but extensive warts are not unusual.
Diagnosis
• Clinical history is usually diagnostic, although the disease may be difficult to identify in the 
early stage when signs are minimal.
• a-fetoprotein in serum is usually raised.
• Genetic testing is difficult due to the large size of the gene and the lack of clustering o f the mu­
tations.
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• Spontaneous cytogenetic abnormalities occur, and will be increased by radiation exposure. 
Immunology
• Immunoglobulins are variable: there is often a reduction of IgCh/IgG4, IgA, and IgE, with poor 
anti-polysaccharide responses. There is an increased incidence of autoantibodies.
• T-cell numbers and function are usually reduced.
Treatment
• No treatment is effective in what is a relentless disease with progressive neurological deteriora­
tion.
• PEG feeding may be required in the later stages when bulbar function deteriorates, to prevent 
recurrent aspiration.
• IVIg reduces the incidence of infections and improves quality of life but does not affect the 
outcome.
• Minimize radiation exposure.
Outcome
• Ataxia is progressive and patients become wheelchair-bound early (late teens, early twenties).
• High incidence of malignancy, especially high-grade lymphoma, and the incidence of malig­
nancy is raised in other family members (fivefold increase in breast cancer).
• Death usually ensues in early adult life from infections or neoplasia.
• Heterozygotes for abnormal ATM genes may have an increased risk of chronic lymphocytic 
leukaemia.
Other chromosomal instability disorders 
Ataxia-telangiectasia-like disorder
An AT-like disorder, without telangiectasia has been identified linked to a gene at 11 q21, 
hMrel 1, also involved with ATM in DNA repair, а-fetoprotein and serum immunoglobulin lev­
els were normal Patients were radiosensitive.
Nijmegen breakage and Sccmanova syndromes
These are syndromes of severe microcephaly, mental retardation (not in the Seemanova syn­
drome), bird-like face, and recurrent infections. There is increased chromosomal sensitivity to 
ionizing radiation. Gene has been identified on chromosome 8q21, encoding a protein nibrin 
(NBS1), involved in DNA repair. Most patients have reduced immunoglobulins and lym­
phopenia. T-cell responses to mitogens are poor. Cytogenetic analysis shows chromosomal ab­
normalities, and the most commonly involved chromosomes are 7 and 14, where the Ig and TCR 
genes are located. Malignancy is increased (lymphoma, neural tumours), and is the major cause 
of death. There is no specific treatment.
Bloom's syndrome
An autosomal recessive syndrome commonest in Ashkenazi Jews and presenting with marked 
sun sensitivity, short stature, patchy vitiligo, and very high incidence of cancer. Gene located at 
15q26,1, coding for BLM, a nuclear protein, with similarities to helicases. The immunodefi­
ciency is characterized by low IgM, normal or poor specific antibody responses, poor T-cell 
function, poor В-cell IgM production, and NK-cell defects. Malignancy is the major complica­
tion and is difficult to treat because of the inability to repair DNA damage.
Fanconi anaemia
This is an autosomal recessive disease with chromosomal breaks. There are multiple organ de­
fects, bone marrow failure (pancytopenia), radial hypoplasia, abnormal face, and leukaemic 
transformation. Presentation is usually with short stature, abnormalities of pigmentation, and or­
gan defects. Seven genes (FANCA-FANCG) have been identified, on different chromosomes, 
with eight different complementation groups. Decreased T-cells, NK-cells, increased IgE, and 
low IgA, and poor responses to polysaccharides have been reported but immunological abnor­
malities are not a major feature.
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ICF (immunodeficiency, centromeric instability, and abnormal fades)
This is due to abnormalities o f chromosomes 1, 9, and 16, marked by a dysmorphic face, mental 
retardation, and malabsorption with failure to thrive. A gene has been identified, DNMJ3B, in­
volved in DNA methylation. The immunodeficiency occurs in all patients and is mainly humoral, 
with severe hypogammaglobulinaemia, but T-cell numbers are usually reduced. However, in vi­
tro functional tests o f T-cells are usually normal.
Cockayne syndrome
A disorder of nucleotide excision and repair, associated with extreme sun sensitivity. Not nor­
mally associated with immunological abnormalities.
T richotbiodystrophy 
Similar to Cockayne syndrome.
Xeroderma pigmentosa
Extreme sun sensitivity leading to bullae, keratoses, and squamous cell carcinoma are the fea­
tures o f this syndrome, which is a DNA repair defect. There is an immunodeficiency with low 
CD4+ T-cells and poor in vitro and in vivo T-cell function in some patients; low IgG levels may 
also occur.
DNA ligase I deficiency
A single patient reported with short stature, sun sensitivity, low IgG, absent IgA, poor specific 
antibody responses, and death from lymphoma. Genetic defect was identified as DNA ligase I 
deficiency.
Chronic mucocutaneous candidiasis syndromes
Multiple syndromes, presenting with mucocutaneous candidiasis; rarely with invasive candidi­
asis. Often in association with endocrinopathy.
Cause
• Cause of many cases o f CMC is unknown.
• Cytokine abnormalities have been documented.
• Autosomal dominant and recessive forms as well as sporadic cases are all documented.
• AIRE on chromosome 21 (21q22.3) is abnormal in autoimmune polyglandular syndrome type 1 
(APECED (autoimmune polyendocrinopathy-candidiasis-ectodeimal dysplasia).
Presentation
• Early onset of superficial candidiasis affecting nails and mouth and occasionally the oesopha­
gus; persistent; invasive candidiasis is very rare and should raise questions of other diagnoses.
• There may be a family history.
• May be associated with an endocrinopathy causing hypocalcaemia due to parathyroid insuffi­
ciency, hypothyroidism, and adrenal insufficiency (consider APECED).
• Other autoimmune phenomena may occur: vitiligo, alopecia, hepatitis, pernicious anaemia.
• Increased susceptibility to bacterial infections (particularly of the respiratory tract), tuberculo­
sis, herpesviruses, and toxoplasmosis. Severe forms may progress to a more generalized com­
bined immunodeficiency, similar to SC1D.
• May be associated with thymoma.
Diagnosis
• There is no unequivocal diagnostic test.
• In vivo and in vitro T-cell responses to Candida antigens are poor or absent but anti-candida 
IgG antibodies are high.
• Acquired immunodeficiency and other risk factors for Candida (diabetes, steroid inhalers, 
Sjogren's syndrome, proton-pump inhibitor use) should be excluded.
• Presence of superficial candidiasis with an endocrinopathy, either overt or cryptic (autoanti­
body positive without symptoms), is highly suspicious: AIRE gene should be checked. 
Immunology
• Anti-candida antibodies (IgG) are raised, often with multiple precipitin lines on double diffu­
sion tests.
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• IgG2/IgG4 are often reduced and there are poor anti-polysaccharide responses with low immu­
nization responses.
• Poor in vitro proliferation to Candida antigens, with abnormal cytokine production (high IL-6). 
T-cell responses to mitogens are usually normal. Cutaneous reactivity to Candida is absent, al­
though other DTH responses are often normal. T-tymphocyte subsets are usually normal.
• Autoantibodies may be detectable to endocrine organs (parathyroid, adrenal, ovary, thyroid).
• Mannan-binding lectin deficiency has been suggested as a cofactor.
Treatment
• Treatment is difficult: Candida will respond well to antifiingals (fluconazole or itraconazole) 
but inevitably relapses when the antifungal is withdrawn. Resistance to these antifiingals may 
occur. Prolonged therapy is undesirable and increases the chances o f hepatotoxicy. Newer anti- 
fungals are voriconazole and caspafungin - these should be used sparingly.
• Avoid the use o f proton-pump inhibitors as these increase the ride of oesophageal candidiasis.
• IVIg should be considered for patients with recurrent bacterial infections. Continuous antibiot­
ics tend to exacerbate the candidiasis.
• y-IFN may have some beneficial effect..
• BMT/HSCT should be considered for severe forms but the procedure is difficult in heavily in­
fected patients.
• Maintain regular surveillance for significant endocrine disease, in particular adrenal insuffi­
ciency, which may be insidious in its onset. Treat endocrine disease normally.
Outcome
• CMC is not as benign as the books would have you believe!
• Cases may die from overwhelming sepsis, in addition to deaths from unrecognized adrenal in­
sufficiency.
X-linked immune dysregulation with polvendocnnopathy syndrome (IPEX) due to ЮХРЗ
deficiency
An X-linked disorder characterized by severe endocrine autoimmimit diarrhoea, eczema, and se­
rious infections.
Cause
• Gene defect identified as FOXP3 gate, also responsible in the mouse few the scurfy phenotype. 
Gene is close to WASP on the X chromosome, Xpl 1.23.
• FOXP3 is a  forkhead DNA-binding protein.
• Clinical phenotype has also been seen in patients without mutations it FOXP3, indicating that 
other genes may also be involved.
Presentation
• Presoitation early in life with severe watery diarrhoea, failure to thriv severe eczema, and en­
docrine autoimmunity (early onset diabetes mellitus, thyroid disease).
• Also associated with autoimmune haemolytic anaemia, ГГР, neutropenia, splenomegaly.
• Infections may include meningitis and pneumonia 
Diagnosis
• Clinical features.
• Anaemia, thrombocytopenia
• Eosinophilia.
• Multiple autoantibodies.
■ Genetic testing may be possible.
Immunology
• Markedly elevated IgE, with normal IgG, IgA, and IgM; normal specific antibody responses.
• Autoantibody to  small bowel antigen AIE-75.
• T- and В-cells usually normal.
Treatment
• BMT/HSCT, preferably before organ damage occurs.
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Idiopathic CD4* T-cell lymphopenia
Initially recognized in adults presenting with AIDS-like opportunist infections but with no evi­
dence o f retroviral infection. Unclear whether this is a discrete immunodeficiency or secondary 
to an unidentified pathogen.
Cause
• Unknown.
• Some cases associated with p561ck and CD45 abnormalities.
Presentation
• Presents with opportunist infections (PCP, mycobacteria, Candida).
• Bacterial sepsis with unusual organisms.
• Increased incidence of lymphomas and autoimmune disease.
• Increased in IV drug users and haemophiliacs.
• May occur in children.
Diagnosis
• Pattern of opportunist infections in the absence o f identified retroviral infection.
• Reduced CD4+ T-cell numbers.
Immunology
• Persistently reduced CD4+ T-cell numbers on more than one occasion.
• CD8+ T-cells may also be reduced.
Treatment
• Treat infections.
• IL-2 has been helpful in some cases.
Autoimmune lymphoproliferative syndromes (ALPS; Canale-Smith syndrome)
A series of disorders characterized by failure o f apoptosis, leading to uncontrolled lymphoprolif-
eration and autoimmunity.
Cause
Genetic defects have been identified in a number o f genes controlling apoptosis.
• Fas (TNFRSF6/CD95/APO-1), ALPS la.
• Fas-ligand (TNFSF6/CD95L), ALPS lb.
• Caspase 8 and Caspase 10, ALPS II.
• No identified abnormality but typical phenotype, ALPS III.
Presentation
• Occurs in males and females, but with skewing to males; usual onset in childhood.
• Occasionally may be asymptomatic.
• Persistent splenomegaly, lymphadenopathy (typically neck), hepatomegaly.
• Autoimmunity: haemolytic anaemia, ITP (made worse by hyperspelehism), hepatitis, uveitis, 
Guillain-Barrf syndrome.
• Increased incidence of lymphoma (Hodgkins > non-Hodgkins) and other malignancies (carci­
noma).
Diagnosis
• Unexplained lymphoproliferation with autoimmunity in a child is highly suspicious.
• Lymphocytosis, often with eosinophilia in peripheral blood.
• Abnormal expression of Fas and Fas-ligand or caspases (genetic testing is required but not 
widely available).
• Abnormal apoptosis assays.
• Histology of lymph nodes shows infiltration of double-negative T-cells, with no evidence of 
EBV.
Immunology
• Lymphocytosis with increase in peripheral ap+, CD45RA+ double-negative T-cells (CD4‘CD8‘) 
> 1% of total lymphocytes.
• Increase in yS* double-negative T cells.
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• Poor T-cell proliferative responses and abnormal apoptosis.
• Increased CD5+ В cells; reduced CD27 expression.
• Increased immunoglobulins.
• Multiple autoantibodies.
Treatm ent
• Splenectomy may be required but increases risks.of infection.
• Autoimmune disease may require treatment with corticosteroids and immunosuppressive drugs 
(all available drugs have been tried).
• Anti-malarial drugs may be helpful (effects on TNF-e).
• BMT/HSCT has been used successfully.
Outcome
■ May improve spontaneously over time, with regression of lymphadenopathy and splenomegaly.
• Increased risk o f lymphoma.
Cartilage-hair hypoplasia (CHH) syndrome
An autosomal recessive T-cell immunodeficiency associated with short-limbed dwarfism and 
distinctive fine sparse hair.
Cause
• Autosomal recessive and linked to chromosome 9p21.
• Gene is RNAase RNP (RMRP), involved in the metabolism o f RNA primers.
• Occurs particularly in Finland and old-order Amish in America.
Presentation
• Short-limbed skeletal dysplasia, with fine sparse hair and ligamentous laxity.
• Anaemia (macrocytic), neutropenia.
• Infections, especially varicella, a problem in one-third; may rarely present as SCID, with op­
portunist infections. Recurrent bacterial infections may occur.
• Megacolon (aganglionic).
Diagnosis
• Typical radiographic appearances o f joints; sparse hair, and macrocytic anaemia.
Immunology
• Immunology is variable.
• IgA and/or IgG subclass deficiencies are reported.
• Neutropenia, together with a T-cell lymphopenia. В-cell numbers may be normal.
• Poor proliferative responses to mitogens.
Treatment
• IVIg if  infections are a problem.
• BMT/SCT if  presenting as SCID; will not cure dwarfism.
• Consider varicella vaccine.
W arts, hypogammaglobulinaemia, infection, myelokathexis (WHIM) syndrome 
WHIM syndrome is a rare immunodeciency and is the first to be associated with deficiency o f a 
chemokine receptor (CXCR4). CXCR4 is also the co-receptor for HIV.
Cause
• Deficiency of CXCR4 chemokine receptor for stromal-derived factor 1 (SDF-1).
• SDF-1 essential for normal myeloid maturation and differentiation; absence o f SDF-1 increases 
granulocyte apoptosis and causes myelokathexis (white blood cell retention).
• Autosomal recessive; gene located at 2p21.
Presentation
• Presents early in childhood with recurrent bacterial infections, developing into bronchiectasis.
• Warts (papillomavirus infection) develop later and are extensive and confluent; genital warts 
will predispose to cervical carcinoma.
• Rare patients have cardiac defects.
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• Severe granulocytopenia and lymphopenia; bone marrow shows granulocyte hyperplasia. 
Diagnosis
• Clinical and laboratory features.
• Protein and molecular diagnosis not yet routinely available.
Immunology
• Hypogammaglobulinaemia; reduced В-cell numbers, especially memory В-cells.
• Neutrophil function is normal.
Treatment
• IVIg for bacterial infections.
• G-CSF may be helpful, even though levels may be raised in some patients, by increasing neu­
trophil emigration.
y-lnterferon/IL-12 pathway defects
Multiple defects have been identified in association with inherited susceptibility to mycobacterial 
infection, especially low virulence mycobacteria (BCG, environmental mycobacteria), and sal­
monellosis. Other infections are rare. Autosomal dominant, autosomal recessive, and X-linked 
inheritances have been reported.
Causes
Defined genetic disorders identified so far include:
• y-interferon receptor-1 mutations, leading to autosomal recessive loss o f expression o f the re­
ceptor or loss or y-IFN binding; these map to the extracellular domains. Partial defects with re­
duced y-IFN responses have been reported. Dominant defects have also been repotted, involving 
mutations in the intracellular domain, leading to surface overexpression o f a truncated receptor.
• y-interferon receptor-2 mutations, causing either complete or partial deficiency o f  the receptor.
• Autosomal dominant mutations in STAT1 (signal transducer and activator o f transcription-1) 
that impair the intracellular signal transduction o f y-IFN.
• 1L-12 p40 subunit mutations.
• IL-12R pi deficiency due to mutations in the IL-12RB1 gene.
• An acquired autoimmune syndrome with autoantibodies against y-IFN has also been described.
Diagnosis
• Lack of surface y-IFNR can be identified by flow cytometry; but loss o f function mutations re­
quire genetic identification.
• IL-12R defects so far reported lack surface expression, amenable to detection by flow cytome­
try.
Treatment
• y-IFN in high doses may be helpful in autosomal dominant y-IFNRI and IL-12R defects, in 
combination with conventional antimycobacterial treatment; infection tends to recur.
• BMT has been used in y-IFNR defects, but outcomes have been poor with GvHD, infections, 
and generalized granulomatous disease.
• IL-12-related defects appear not to lead to recurrent infections.
IRAK-4 deficiency
Deficiency o f interleukin-1 receptor associated kinase-4 (a Toll-like receptor) has been reported 
in association with recurrent pyogenic infections, including Pneumococcus, Staplytococcus, and 
Shigella, and poor inflammatory response (absent inflammatory markers). Specific antibody re­
sponses are poorly maintained after immunization. Interestingly, infections seem to become less 
problematic with increasing age.
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M ajor defects of phagocytic cells
• Chronic granulomatous disease:
- X-linked;
- autosomal recessive.
• Leucocyte adhesion defects (LAD):
- LAD-1: defects o f CD18, common (P-cjiain for LFA-1, Mac-1, and CR4 (CD1 la, 
C D llb , C D llc);
- LAD-2: defects in synthesis o f fucose from GDP-mannose; lack o f expression o f  Lewis 
X ligand.
• Glucose 6-phosphate dehydrogenase (G6PD) deficiency.
• Myeloperoxidase deficiency.
• Secondary granule deficiency.
• Cyclic neutropenia and severe congenital neutropenia.
• Schwachman-Diamond syndrome.
• Chediak-Higashi and Griscelli syndromes.
• Familial lymphohistiocytosis and haemophagocytic syndromes.
• NK-cell deficiency.
• Rare causes: rac2 deficiency.
Chronic granulomatous disease
This is the most significant neutrophil defect, although not the most common, it is also the easi­
est to diagnose.
Cause
• There is a defect o f intracellular bacterial killing in neutrophils and monocytes, due to a failure 
o f superoxide, oxygen radical, and peroxide production.
• X-linked and autosomal recessive forms are described. There is a  deficiency o f  components of 
cytochrome b558: 91 kDa protein (X-linked; Xp21.1), 22 kDa protein (16q24), or NADPH oxi­
dase p47 (7ql 1.23) or p67 (lq25).
• As phagocyte hydrogen peroxidase is normal, organisms that are catalase-negative are killed 
normally, whereas catalase-positive organisms (Staphylococcus aureus, Aspergillus, Nocardia, 
and Serratia) cause major problems.
• Kell blood group antigens are encoded adjacent to the X-CGD locus.
Presentation
• Infections with catalase-positive organisms, especially deep-seated abscesses, osteomyelitis, 
and chronic granulomata (including orofacial granuloma).
• May mimic inflammatory bowel disease and lead to malabsorption and obstruction o f  die 
bowel.
• Liver abscess is a common first presentation, and any child with a liver abscess has CGD until 
proven otherwise.
• Usually presents initially in childhood but, rarely, first presentation may occur in adults.
• Is a cause o f  atypical hepatic granulomata in the absence of infection.
• Carriers o f XL-CGD are at increased risk o f  discoid lupus and photosensitivity.
Diagnosis
• Neutrophil oxidative metabolism is abnormal.
• Easiest screening test is the nitroblue tetrazolium reduction (NBT test), but this may miss some 
cases. The preferred test is a flow cytometric assay using dihydrothodamine (some patients may 
have abnormal DHR but normal NBT)
• Bacterial killing will be absent
• X-linked CGD patients should be tested for deficiency o f Kell antigens.
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Treatment
• Long-term antibiotics (co-trimoxazole and itraconazole) are the mainstay of treatment. Use the 
liquid formulation o f itraconazole (better absorption) and monitor trough levels, adjusting dose 
accordingly.
• Low-dose prophylactic y-lFN tends to be used instead.
• Acute infections should be treated promptly with intravenous antibiotics, supplemented with 
high-dose y-IFN.
• Drainage of large abscesses may be required.
• Inflammatory bowel disease may be significantly helped by high-dose steroids, particularly 
where there are obstructive lesions due to granulomata. This increases infection risk.
• BMT/HSCT is the treatment of choice and should be carried out early before infective compli­
cations become a threat to life. Results from transplantation in adults are now good.
■ Kell-negative XL-CGD patients are a transfusion hazard, and need to be transfused with Kell­
negative blood.
Outcome
Outcome has been much improved by use of prophylactic antibiotics and y-IFN, but it is still a  
life-shortening illness (death usually by 5th decade).
Leucocyte adhesion molecule deficiency (LAD-1, LAD-2)
Cause
• LAD-1 is due to a deficiency of the f)-chain (CD18) for LFA-1 (CD1 la), Mac-1 (CD1 lb), and 
CR4 (CD1 lc).
• The gene is located at 21q22.3. There may be variable expression: the severe phenotype has < 
1% expression, while in the moderate (incomplete) phenotype there may be as much as 10% of 
control expression.
• Rare cases may be due to defects in other chains (CD1 lc) and the Lewis X tigand (LAD-2), 
caused by an inability to synthesize fucose.
Presentation
• Presentation is variable, depending on the phenotype.
• Delayed umbilical cord separation is a significant feature (> 10 days).
• Skin infections, intestinal and perianal ulcers, and fistulae are typical.
• Periodontitis occurs in older children and may lead to loss o f teeth.
■ Immunizations may leave scarred nodules.
• Lack of inflammatory change at the sites o f infection and an absence o f pus formation.
Diagnosis
• Diagnosis is dependent on the demonstration of reduced/absent molecules on lymphocytes and 
granulocytes by flow cytometry.
• PMA stimulation o f granulocytes may be necessary to identify the moderate phenotype in 
which some upregulation occurs.
• There is usually a peripheral blood neutrophilia, which is often extreme.
• Neutrophil migration is impaired.
Treatment
• Prompt antibiotic therapy is required.
• BMT/SCT is necessary for the severe phenotype: graft rejection is not possible in the absence 
of LFA-1. This observation led to the use o f anti-LFA-1 monoclonal antibodies as anti-rejection 
therapy. Moderate phenotypes may be more difficult to transplant.
• LAD-2 has been treated with high-dose oral fucose with benefit.
Rac-2 deficiency
An autosomal dominant mutation in the rho-GTPase Rac-2, (22ql2.13) has been associated with 
a presentation similar to that of LAD-1, with delayed umbilical cord separation, absence o f pus,
54
and perirectal ulceration. Chemotaxis was abnormal, and neutrophil granule exocytosis was im­
paired. BMT was curative.
G6PD deficiency 
Cause
• An X-linked (Xq28) condition; the gene is prone to frequent mutations (200 variants have been 
recorded).
• Absence o f functional G6PD (1-5% o f  normal activity) impairs the NADPH system o f  oxida­
tive metabolism, with effects similar to those of CGD. However, most variants have enzyme ac­
tivity o f 20-50% normal and have no phagocytic defect.
Presentation and diagnosis
• The presentation is similar to that of CGD, when < 5% enzyme activity is present.
• Haemolytic anaemia is often present, and can be triggered by certain foods (fava beans) and 
drugs (sulphones such as dapsone; primaquine, salicylates).
• The NBT test is diagnostic and the enzyme activity can be measured.
Myeloperoxidase deficiency
This deficiency is not uncommon (the gene is located at 17q21.3-q23). The prevalence is be­
tween 1/2000 and 1/4000 in the USA. Cases are usually asymptomatic, although occasional de­
fects in killing Candida have been reported, and infection may occur, particularly if the patient is 
diabetic.
Schwachman-Diamond syndrome
This is an autosomal recessive syndrome o f hereditary pancreatic insufficiency, accompanied by 
neutropenia, abnormal neutrophil chemotaxis, thrombocytopenia, and anaemia. NK-cell lym­
phopenia is common. A gene has been identified (SBDSPX but the function is as yet unknown. 
Short stature is usual. Hypogammaglobu-linaemia with recurrent sinopulmonary infections may 
also occur. Responses to polysaccharide antigens may be absent Treatment with IVIg may be 
helpful, and G-CSF has been used, although there is concern over potential risk o f myeloid leu­
kaemias. HSCT has also been tried.
Secondary granule deficiency
Neutrophil structure is abnormal with bilobed nuclei. Secondary Qactoferrin) granules are absent 
and there is a deficiency of other neutrophil enzymes (alkaline phosphatase). This leads to defec­
tive neutrophil oxidative metabolism and bacterial killing, resulting in skin and sinopulmonary 
infections. The diagnosis can be made by careful examination of the blood film, supplemented 
by cytochemical studies for neutrophil enzymes (NAP score). Some cases have been associated 
with defects in the CIEBPe gene (14ql 1.2), a CCAAT enhancer protein-binding protein, which 
acts as a transcription factor in myetopoiesis.
Cyclic neutropenia
This is a rare syndrome characterized by cyclic reductions in neutrophils, but it is perhaps more 
common than previously thought, with milder variants escaping notice.
Cause
• Autosomal dominant disorder due to mutations in ELA2 gene, encoding neutrophil elastase. 
Mutations affect whether elastase localizes to granules or to cell surface membrane. Membrane 
expression is associated with disease. Similar mutations in ELA2 also cause severe congential 
neutropenia.
• Similar disease in dogs (grey collie syndrome) is due to different gene defect and has a 14 day 
cycle.
• The cycle is usually 21 days ±  3 days, but the molecular cause of cycling is unknown.
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Presentation
• Mouth ulceration typically occurs at the neutrophil nadir, more significant invasive infection 
may occur.
• Mood change just before the nadir is often marked. Symptoms may improve with age. 
Diagnosis
• The clue is usually a low neutrophil count during an infective episode.
• Diagnosis is confirmed by serial full blood counts with full differential, 3 times weekly over 4 
weeks. Neutrophils may disappear completely. Symptoms usually occur if the count drops below 
1 x 109/L.
• There is a compensatory monocytosis at the time of the neutrophil nadir.
Management
• G-CSF prevents a dramatic drop but does not abolish the cycle, which shortens to approxi­
mately 14 days.
• There is, however, a risk o f myeloid leukaemia with chronic G-CSF therapy and this should be 
used with circumspection. Data suggest that ELA2 mutations increase the risk o f AML and 
MDS, and this may be increased further by G-CSF use.
• Prophylactic co-trimoxazole either side of the predicted nadir may be valuable in preventing 
infection.
Cohen syndrome
This rare autosomal recessive syndrome is due to mutations in the COHl gene, whose product is 
involved in vesicle sorting and intracellular protein transport. Neutropenia is associated with dys­
morphic features and mental retardation.
Severe congenital neutropenia (SCN)
Four different genetic variants o f SCN have been reported. The majority o f  cases have defects in 
the ELA2 gene, as in cyclic neutropenia, and are at risk o f developing myelodysplasia (MDS) 
and acute myeloid leukaemia (AML). The disorder is autosomal dominant and homozygous de­
fects have not been reported. The neutropenia is, however, static. Rare cases have been associ­
ated with autosomal dominant mutations in the transcriptional repressor G fll gene, causing over- 
expression of elastase and overflow on to the cell membrane: these cases also have lymphopenia. 
WASP mutations have been associated with X-linked neutropenia. Mutations have also been re­
ported in the gene encoding the receptor for G-CSF: these cases do not develop MDS or AML. 
Other possible defects in the ELA2 promoter region may also contribute to SCN cases.
Kostmann's syndrome
This is a congenital severe neutropenia due to a neutrophil maturation defect with anest at the 
pro-myelocyte stage. This is genetically distinct from severe congenital neutropenia and has only 
been reported in one family, with an autosomal recessive pattern o f inheritance. It presents with 
recurrent severe infections. Immunoglobulins are raised; there is a compensatory monocytosis, 
eosinophilia, and a thrombocytosis. BMT may be used as treatment Co-trimoxazole prophylaxis 
is necessary.
fi-Actin deficiency
Patients with defective P-actin present with recurrent bacterial infections, including abscesses, 
mental retardation, and joint problems. Neutrophil chemotaxis is abnormal.
Disorders of pigmentation and immune deficiency
There have been major advances in the understanding of the genetics o f immune deficiencies 
that are associated with pigmentary disorders.
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Chediak-Higashi syndrome 
Cause
• An autosomal recessive disease, due to mutations in the CHS1 gene (also known as LYST- ly­
sosomal trafficking regulator), located at lq42.1.
• CHS is the human equivalent o f  the beige mutant mouse.
• Exact function o f the LYST protein is not known.
Presentation
• Benign and aggressive presentations occur.
• Characteristic features are partial oculocutaneous albinism (due to abnormal melanocytes), 
leading to silver streaks in the hair (prematurely) and pigmentary changes in the iris and also the 
skin.
• Recurrent infections, especially periodontitis and pyogenic infections.
• CNS abnormalities: peripheral and central, with neuropathy, cranial nerve palsies, parkinsonian 
features, fits, and mental retardation.
• Hepatosplenomegaly occurs frequently.
Diagnosis
• There are giant primary cytoplasmic granules in leucocytes and platelets.
• Hair shafts show diagnostic clumping o f  pigment granules.
Immunology
• Granulocyte and monocyte chemotaxis is abnormal with delayed intracellular killing (correct­
able by ascorbate in vitro).
• Defective NK-cell function is common.
• Neutropenia.
Prognosis
Outcome is poor in the accelerated phase with neurological deterioration and a haemophagocytic 
syndrome like familial lympho-histiocytosis. Expression o f CTLA-4 has been associated with 
development of the accelerated phase. This should be treated with etoposide followed by 
BMT/HSCT.
Partial albinism (Griscelli syndrome)
This is similar to Chediak-Higashi syndrome but is distinguished from it by the absence of giant 
granules. Three types have now been identified, and mouse models exist for all types. The genes 
identified are all involved in the intracellular movement o f melanosomes, mechanisms that are 
also used in granule-containing cells to undertake exocytosis.
• GS type 1 due to mutations in the MYOSA gene (15q21.1) encoding myosin Va. This type pre­
sents with albinism and severe neurological disease with mental retardation and developmental 
delay.
• GS type 2 due to mutations in RAB27A gene (15q21.1), encoding a GTPase Rab27a involved in 
the secretory pathway. Patients have hypopigmentation and a severe immune defect, culminating 
in an accelerated phase o f fulminant haemophagocytosis. Treatment is with BMT/SCT.
• GS type 3 due to mutations in the MLPH  gene, coding for melanophilin, and leading to im­
paired interaction with Rab27a.
Diagnosis can be confirmed by microscopy o f hairs, to examine pigment deposition. Delayed 
hypersensitivity and NK-cell function are defective; reduced immunoglobulins and neutrophil 
problems have also been described.
Hermansky-Pudlak syndrome type 2
Type 2 HPS is an autosomal recessive disorder associated with mutations in the AP3B1 gene. 
The clinical features are severe congenital (non-cycling) neutropenia, defects o f platelet dense 
bodies, with a bleeding tendency and oculocutaneous albinism. The equivalent gene defect in 
dogs causes the grey collie syndrome; the mouse mutant is pearl. Other forms o f  HPS are recog­
nized with distinct gene defects but these do not have neutropenia and infections.
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Other pigmentary disorders
Other genetic disorders o f pigmentation not associated with immune deficiency include:
• Piebaldism due to mutations in the KIT  gene.
• Waardenburg syndrome, characterized by piebaldism with sensorineural deafness, caused by 
multiple gene defects: PAX3, MJTF. SLUG, EDN3, EDNRB, SOXIO.
• Oculocutaneous albinism (four genes: TYR, P, TYRP, MATE).
• Hemansky-Pudlak syndrome, types 1 and 3-6 (HSP1.3-6).
Fam ilial lym phohistiocytosis, haem ophagocytic syndrom e in  o th er  conditions, 
and  N K -cell deficiency  
Familial lymphohistiocytosis (FLH)
FLH is an autosomal recessive disease o f childhood, presenting with infiltrations o f polyclonal 
CD8* T-cells and macrophages into many organs following viral infections. It is associated with 
the FLH I gene (9q21.3) and the FLH2 gene (10q21), which encodes perforin, the cytotoxic pro­
tein of cytotoxic T-cells and NK-cells. FLH2 defects are particularly common in patients with 
FLH in Turkey. NK-cell and cytotoxic T-cell function is markedly reduced. Perforin deficiency 
is the main cause o f rapidly fatal FLH. Failure o f apoptosis has been suggested as a mechanism 
for the excessive cellular infiltrates.
Haemophagocytic syndrome in other conditions
Haemophagocytosis has been reported to occur as part o f die accelerated phase of type 2 Gris- 
celli syndrome patients, Chediak-Higashi syndrome, and X-linked lymphoproliferative syndrome 
triggered by ЕВ V exposure. It is also seen in SLE, adult onset Still's, juvenile rheumatoid arthri­
tis, and Casdeman's disease. It has been suggested that IL-18 may be responsible in the autoim­
mune secondary cases.
NK-cell deficiency
Primary NK-cell deficiency has been reported, causing severe or fatal infections with herpesvi­
ruses and varicella, usually presenting in the teens or early adult life. Both sexes are affected.
The differential diagnosis includes XLPS. Homozygosity for a polymorphism in the FcR-yllla 
receptor (CD 16) on NK-cells has been associated with increased susceptibility to herpesviruses; 
this change also interferes with the ability o f certain anti-CD16 monoclonal antibodies to bind.
Immunodeficiency in association with other rare genetic syndromes
Down's syndrome
This is due to trisomy 21. There is a progressive decrease in IgM, dysplastic thymus, low NK 
activity, and an unusual sensitivity to у-interferon, whose receptor is located on chromosome 21. 
There is an increase in TCR y6 cells at the expense of TCR op cells. T-cell proliferation to mito­
gens is reduced, with poor IL-2 production. There is an increase in infections and also in malig­
nancy and autoimmune disease.
Chromosome 18 syndromes
Ring chromosome 18 and deletions of the long and short arms o f chromosome 18 are associated 
with facial hypoplasia, mental retardation, and low or absent IgA.
Immunodeficiency with generalized growth retardation 
Schimke immuno-osseus dysplasia
An autosomal recessive syndrome characterized by nephropathy, skeletal dysplasia, and lenti- 
genes. There is a lymphopenia of CD4+ T-cells with poor T-cell mitogen responses. Pancyto­
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penia is common. Immunoglobulin levels may be reduced. The gene is SM ARCALI, encoding a 
chromatin remodelling protein.
Immunodeficiency with absent thum bs (TAR syndrome)
There is radial dysplasia, ichthyosis, and anosmia in this syndrome. Recurrent infections and 
chronic mucocutaneous candidiasis occur. There are poor T-cell mitogen responses and absent 
IgA, with low IgG and IgM.
S k in  d isease  and  im m u n od efic ien cy
Dyskeratosis congenita
Dyskeratosis congenita is characterized by cutaneous pigmentation, nail dystrophy, and oral leu- 
coplakia, and is complicated by malignancy and bone marrow failure. Autosomal dominant or 
recessive and X-linked forms occur. The X-linked form is associated with mutations in the 
DKCJ gene encoding dyskerin, a nucleolar protein. Variable immune defects are found: hypo- 
gammaglobulinaemia and poor delayed-type hypersensitivity. Thymic aplasia may occur.
The same gene defect also causes the HOyeraal-Hreidarsson syndrome (microcephaly, growth 
failure, and pancytopenia, which may mimic SCID).
Netherton syndrome
There is trichorrhexis, ichthyosis, and atopy; some patients have low IgG, abnormal neutrophil 
function, and poor T-cell mitogens responses. Mutations in the gene SPINKS, encoding a  serine 
protease inhibitor, have been identified in some patients
Acrodermatitis enteropathies This is caused by zinc deficiency, leading to eczema, diarrhoea, 
malabsorption, and sinopulmonary infections. T-cell numbers and function are reduced and im­
munoglobulins are low. All the defects are correctable with supplemental zinc.
Anhidrotic ectodermal dysplasia
This family o f diseases is associated with defective NFkB signalling. Autosomal recessive or X- 
linked forms of this syndrome occur. Defects in the NEMO gene have been reported in the X- 
linked form, associated with significant immunodeficiency. Autosomal dominant and recessive 
forms have mutations in the EDA 1 gene encoding ectodysplasin (a TNF cyokine family mem­
ber) or its receptor EDAR, a member o f the TNF-receptor superfamily, encoded by EDA3. 
EDAR mutations have been associated with autosomal recessive disease. Hypohydrosis and 
faulty dentition are the key features. Upper respiratory infections occur. There is variable T- and 
В-cell function; specific antibody responses may be poor.
Papillon-Lefevre syndrome
Abnormal neutrophil chemotaxis and reduced neutrophil killing have been reported in this syn­
drome of hyperkeratosis and pyoderma, with periodontitis. The gene defect has been identified 
as mutations in cathepsin C (also known as dipeptidyl peptidase I), an enzyme involved in pro­
tein degradation.
Immunodeficiency w ith metabolic abnorm alities 
Transcobalamin И deficiency
Autosomal recessive deficiency of ТС II (22ql 1.2), a vitamin Bi2-binding protein essential for 
transport of B12, has been repotted in association with diarrhoea, failure to thrive, megaloblastic 
anaemia, lymphopenia, neutropenia, and thrombocytopenia. Abnormal neutrophil function and 
hypogammaglobulinaemia are present. All the features are reversible with B )2 therapy.
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Type I hereditary orotic aciduria
This is an autosomal recessive disease of retarded growth, diarrhoea, and megaloblastic anaemia. 
Fatal meningitis and disseminated varicella may be complications. There is a T-cell lymphopenia 
and impaired T-cell function.
Biotin-dependent carboxylase deficiency
An autosomal recessive condition characterized by convulsions, ataxia, alopecia, candidiasis, 
and intermittent lactic acidosis. The severe neonatal form presents with severe acidosis and re­
current sepsis. There is increased urinary P-hydroxypropionic add, methyl citrate, 0- 
methylcrotonglycine, and 3-hydroxyisovalerate excretion. Decreased T- and В-cells with low 
IgA are noted. It is treated with biotin.
Mannosidosis
This is a lysosomal storage disease that is associated with abnormal neutrophil (chemotaxis, 
phagocytosis, and killing) and lymphocyte function (hypogammaglobulinaemia and poor PHA 
responses).
Hypercatabolism of immunoglobulin 
Familial hypercatabolism of IgG
Familial hypercatabolism of IgG has been associated with bone abnormalities, abnormal glucose 
metabolism, and recurrent infections. IgG is very low with a very short half-life; serum albumin 
may be normal or low.
Intestinal lymphangiectasia
This is due to a failure of normal lymphatic development in the bowel, with abnormally dilated 
lymphatics. Similar abnormalities may occur elsewhere, causing localized oedema, effiisions, 
and ascites. There is enteric loss of lymphocytes and malabsorption, particularly o f fats. There is 
a profound lymphopenia, with hypoalbuminaemia and hypogammaglobulinaemia; IgM may be 
in the normal range and infections may be less severe than the IgG level might predict. Specific 
responses may be normal but very short-lived. IVIg may be given but weekly therapy may be 
required to maintain adequate levels. Fat malabsorption may be severe and medium-chain 
triglyceride supplements may be required.
S p l e n i c  d i s o r d e r s
Congenital asplenia and Iveraark syndrome Asplenia may occur alone or in association with 
partial situs inversus and cardiac defects. Early infections, especially with capsulated organisms, 
are a typical feature. Sudden unheralded death from overwhelming sepsis may occur and the di­
agnosis may only be made at post-mortem. Survival into adult life is possible without serious 
infection. Blood film will show Howell-Jolly bodies; ultrasound will demonstrate absence of the 
spleen, which can be confirmed by absence o f uptake on a labelled white cell scan or on a red 
cell clearance scan. Initial poor polysaccharide responses may improve after the first 3 years of 
life. However, there remains a risk of overwhelming sepsis and lifelong prophylactic antibiotics 
should be administered, together with regular immunizations against pneumococci, Haemophilus 
influenzae type b (Hib), and meningococci.
Tuftsin deficiency
Tuftsin is a tetrapeptide released from the CHj domain of IgG by the actions of a membrane leu- 
cokinase and a splenic endocarbocypeptidase. It stimulates the bactericidal function of phago­
cytic cells. Primary tuftsin deficiency has been described in five patients, in association with in­
creased infections. Administration of immunoglobulin replacement may be beneficial. Secondary 
tuftsin deficiency occurs in splenectomy, asplenia, and hyposplenia (coeliac disease). Tuftsin 
production may also be impaired by parenteral nutrition, probably by lipid.
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C om plem ent deficiencies
Cause
• Genetic deficiencies o f all complement components have been described, including the regula­
tory inhibitors, C l inhibitor, factor I, and factor H.
• Properdin deficiency is X-(inked; all the others are autosomal recessives, except Cl-inhibitor 
deficiency which is autosomal dominant
• Factors В, C2, and C4 form part o f  the extended HLA complex (short arm o f  Chromosome 6, 
located between HLA-D and HLA-B loci).
• Complement deficiencies are common in South Africa and in the countries o f  die north African 
coast and eastern Mediterranean. C2 and C4 deficiencies are relatively common. An increasing 
number o f C4 null alleles increases substantially the risk o f developing lupus.
Presentation
• Increased susceptibility to pyogenic infections in C3, factor I, and factor H deficiencies.
• Increased susceptibility to neisserial infections in CS, C6, C7, C8a, C8b, C9, factor D, and 
properdin deficiencies.
• Recurrent neisserial infection, especially meningitis, should always prompt a  screen for com­
plement deficiency; the disease may be milder than in complement replete individuals.
• C9 deficiency is common in Japan and may be asymptomatic, as slow lysis through C5-C8 may 
take place without C9.
• Increased susceptibility to SLE-like syndrome in C lq, C lr/C ls, C4, C2, C5, C6, C7, C8a, and 
C8b. C2-deficient lupus is often atypical with marked cutaneous features.
• Factor H, factor 1, and MCP deficiencies are associated with the non-dianhoea-associated 
haemolytic-uraemic syndrome.
Diagnosis
Diagnosis is by the screening for classic, alternate, and terminal lytic sequence by functional 
complement assays (classic and alternate pathway CHso-see Part 2), followed by measurement o f 
individual components, as indicated by the screening tests.
Treatment
• No specific treatment is available; use o f  fresh frozen plasma (FFP) may make the acute prob­
lems worse.
• Recurrent neisserial infection may be prevented by prophylactic antibiotics and meningococcal 
vaccination may help, although there are concerns dial disease may be more severe if  it occurs in 
a complement-deficient person after vaccination.
« Prophylactic penicillin (penicillin V 500 mg bd adult dose; erythromycin 250 mg bd if allergic 
to penicillin) is highly desirable.
■ Autoimmune disease is treated in the normal way.
M annan-binding lectin (MBL) deficiency
MBL (lOql 1.2) is involved in the initiation of complement activation via the lectin pathway, 
triggered by binding to mannose residues on bacterial cells' surfaces. Although deficiency o f 
MBL has been associated with infections, many mutations (the gene is highly polymorphic) re­
ducing MBL levels have been identified in asymptomatic families, indicating that MBL defi­
ciency alone is insufficient to cause disease, in the absence of other host-defence problems. It has 
been estimated that up to 5% of the population lack functional MBL and this has led to sugges­
tions that MBL deficiency may have a beneficial effect in later life. MBL deficiency in cystic 
fibrosis has been associated with a worse prognosis. The risk of infection in children with low 
MBL seems to be highest in the first 2 years o f life, when specific polysaccharide responses are 
poor. MBL's value may therefore be early protection, before specific antibody production is op­
timum, with its role diminishing in later life, replaced by antibody.
61
H ereditary angioedema and C4-binding protein deficiency
Hereditary angioedema
Cause
• Two main types o f HAE are recognized: type I (85%; gene deletion, no protein produced) and 
type II (15%; point mutation in active site o f enzyme). The gene is located on chromosome 11.
• Condition is autosomal dominant as one normal gene is insufficient to protect against symp­
toms.
• An X-linked type III HAE has been proposed. The abnormality is unknown.
• There is failure o f inactivation of the complement and kinin systems, but the angioedema is 
most likely to be due to the latter (bradykinin) rather than the former.
Presentation
• There is an angioedema (deep tissue swelling) of any part of the body, including airway and 
gut; the latter presents with recurrent abdominal pain and repeated laparotomies may be under­
taken before the diagnosis is made.
• There is no urticaria or itch, although patients often describe an uncomfortable prodromal tin­
gling.
• Attacks begin in later childhood/teenage years and may be precipitated by trauma (beware den­
tal work and operations) and infections.
• Frequency o f attacks may be increased by oral contraceptives and by pregnancy. There is an 
increased risk o f immune complex disease.
Diagnosis
• Typically C4 and C2 are undetectable during an acute attack and low/absent in between.
• In type I, there will be a tow Cl-inhibitor level immunochemically and this will become unde­
tectable in an acute attack.
■ In type II, there will be a normal or high level o f inhibitor measured immunochemically, but 
function will be low or absent.
• Angioedema may be acquired secondary to SLE or lymphoma and these may be distinguished 
from HAE by the reduction in C lq, although this is not always reliable.
Treatment
• Treat major attacks with purified (steam-treated) inhibitor (1000-1500 IU, i.e. 2-3 ampoules) by 
slow intravenous injection.
• FFP may be an emergency alternative but there are the usual risks o f transmitted infection and 
it is also possible for FFP to exacerbate attacks by providing more substrate.
• Tracheostomy may be required if there is significant laryngeal oedema.
• Prophylaxis may be obtained with modified androgens (danazol, 200-600 mg/day; or stano- 
zolol, 2.5-10 mg/day) or anti-fibrinolytics (tranexamic acid 2-4 g/day). Regular liver function 
tests and liver ultrasounds are required for monitoring therapy with all these agents.
• Prophylactic purified inhibitor should be used before high-risk surgical procedures, although 
tranexamic acid may be adequate for minor procedures.
• Dental work should always be carried out in hospital in view o f the risk o f developing oral oe­
dema and airway obstruction.
• Abdominal attacks respond poorly to purified inhibitor—treatment should be conservative: an­
algesia (NSAIDs), IV fluids, and avoidance o f unnecessary laparotomies (unless there is good 
evidence for other pathology).
C4-bindiog protein (C4bp) deficiency
C4bp inhibits the classical pathway o f  complement activation by blocking the formation o f  the 
C3 convertase C4bC2a. Deficiency o f C4bp may cause angioedema and, because o f  its interac­
tion also with protein S, may be a cause o f purpura fulminans.
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C4-binding protein (C4bp) deficiency 
Classification o f secondary immunodeficiency
• Viral infections
- HIV, CMV, EBV, rubella, echoviruses, coxsackieviruses, measles, influenza
• Acute bacterial infections
- Septicaemia
• Chronic bacterial and parasitic infections
- Tuberculosis, leishmaniasis
• Malignancy
• Plasma cell tumours and related problems
- Myeloma, plasmacytoma, Waldenstrom's macroglobulinaemia
- Amyloidosis
• Lymphoma/leukaemia
- Hodgkin's disease, non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, other 
chronic and acute leukaemias
• Extremes o f age
- Prematurity, old age
• Transfusion therapy
- Whole blood; clotting factors
• Drugs and biologicals
- As an undesirable side-effect; immunosuppressive drugs
• Physical therapies
- Plasmapheresis and variants, radiation (see Chapter 16)
• Nutrition
• Starvation, anorexia; iron deficiency
• Chronic renal disease
- Uraemia, dialysis, nephrotic syndrome
• Gastrointestinal disease
- Protein-losing enteropathies; secondary to cardiac disease
• Metabolic disease
- Diabetes mellitus, glycogen storage disease, mannosidosis
• Toxins
- Cigarettes, alcohol, other chemicals
• Splenectomy
- In conjunction with other diseases (lymphoma; coeliac disease; sickle-cell disease); 
traumatic (congenital asplenia)
• Bums
• Myotonic dystrophy
Human immunodeficiency virus 1 and 2
HIV-1 and HIV-2 are retroviruses, responsible for the acquired immunodeficiency 
syndrome AIDS.
Immunological features
• Virus enters the cells via a cognate interaction o f the gpl20 env with CD4+ and a chemokine 
receptor, either CxCR4 or CCR5.
• It also infects other CD4* cells (macrophages, dendritic cells) and other cells expressing CD4- 
like surface proteins (neuronal cells).
• Macrophage tropic viruses use CCR5, and infect T-cells poorly; T-cell tropic viruses use 
CXCR4 for entry and form syncytia.
• Resistance to viral infection is associated with polymorphism in the chemokine receptors.
• A viral isolate entering T-cells via CD8* has been described.
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• Uptake o f virus into phagocytic cells may be augmented by antibody, and complement. HIV 
activates complement
• High levels o f viral replication may take place in lymph nodes.
• Initial viraemia after infection is controlled by CD8+ cytotoxic T-cells (increased cell numbers). 
The asymptomatic phase is characterized by strong cytotoxic responses, but viral replication still 
detectable intermittently, HIV is not a  true latent virus.
• The antibody response to major viral proteins appears after a  lag phase of up to 3 months and 
persists through the asymptomatic phase but declines in late-stage disease.
• Marked В-cell dysfunction with polyclonal increase in immunoglobulins and the appearance of 
multiple autoantibodies.
• In the seroconversion illness there is a dramatic fall in CD4* T-cells and rise o f  CD8* T-cells. 
The levels o f CD4+ T cells may drop to a  level at which opportunist infections may occur at this 
early stage (poor prognostic indicator). Levels then usually recover to within the low normal 
range. There is then a slow decline o f absolute CD4* T-cell count over time (years) following 
infection.
• Passage to the symptomatic phase is characterized by a  rapid drop in CD4* T-cells, loss o f cy­
totoxic activity, and switch o f virus type from slow-growing, non-syncytial-forming strains to 
rapidly growing, syncytial-forming strains (quasi-species evolving through lack o f replica-tive 
fidelity and under immunological selection pressure). This is accompanied by the occurrence of 
opportunist infections.
• Activation ofT-cells enhances viral replication and hence CD4+ T-cell destruction. Therefore, 
opportunist infections enhance the self-destruction o f  the immune system. Long-term non- 
progressors and patients responding to highly active antiretroviral therapy (HAART) show good 
proliferative responses to gag proteins. Progression has been associated with a switch from Thl 
to Th2 responses.
• HIV preferentially infects CD45RO* cells but the depletion of T-cells affects principally 
CD45RA+CD62L+ naive T-cells.
• T-cell depletion is caused by increased apoptosis, impaired production (HIV effects on thy­
mus), and destruction of both infected and uninfected cells.
• HIV replication is suppressed by natural CCR5 chemokine ligands, RANTES, MJP-la, and 
MIP-1P, which are secreted by CD8+ T-cells. SDF-la is the natural ligand for CXCR4. High 
levels of chemokine production have been associated with resistance to infection.
Diagnosis and monitoring
• Diagnosis depends on the detection o f antiviral antibody and/or viral antigen, not on immu­
nological markers. Screening tests for anti-HIV antibody are followed up by PCR-based tests. 
Informed consent must be obtained.
• The most accurate monitoring of disease is now available through measurements of viral load 
by quantitative PCR (viral load). Lymphocyte surface markers (CD4 count) must not be used as 
a way of HIV testing without consent.
• CD4+ T-cell numbers will be reduced and CD8+ T-cells increased in most acute viral infections 
and in seriously ill patients in the intensive care unit setting.
• In the acute seroconversion illness, there is a sharp fall in absolute CD4+ T-cell numbers and 
increase in CD8+ T-cell numbers with T-cell activation markers increased (IL-2 receptor (CD25) 
and HLA class II (DR)); this normally returns rapidly to normal as evidence of viral replication 
disappears. Persistent CD4+ T-cell lymphopenia after seroconversion illness is a poor prognostic 
sign indicating rapid progression to terminal illness.
• Sequential monitoring of the CD4+ T-cell numbers provides guidance on the rate of progression 
of disease and identifies levels at which therapeutic interventions may be indicated (Pneumocys­
tis prophylaxis at 0.2 x 109/1CD4+ T cells).
• Once the CD4+ T-cell count falls below 0.05 x 109/1, further monitoring is of little clinical value 
(except psychologically to patients, who view cessation of monitoring as doctors giving up).
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• Successful treatment with HAART will lead to a rise of CD4* T cells to within the normal 
range and suppression of viral load.
• Immune function will recover in patients with a good response to HAART.
• Serum immunoglobulins are usually polyclonally elevated (TgG levels > 50 g/1 may be re­
corded); serial measurements have no clinical utility. Most o f the antibody is either 'junk' or re­
lates to an anamnestic response.
• Autoantibodies may be detected (including anti-nuclear and dsDNA antibodies, anti-neutrophil 
cytoplasmic antibody (ANCA), and anti-cardiolipin). The presence of autoantibodies may cause 
serious diagnostic confusion, especially if  the clinical presentation is atypical.
• Rare patients, usually children, may suffer from panhypo-gammaglobulinaemia or specific an­
tibody deficiency, presenting with recurrent bacterial infections: these patients may derive sig­
nificant benefit from IVIg. It has been more difficult to demonstrate specific antibody defects in 
adults, although a subpopulation of adult patients do have recurrent sinopulmonary infections 
with Haemophilus and Pneumococcus: IVIg seems to be less helpful.
• Serum p2-microglobulin levels may be elevated, as a marker o f increased lymphocyte turnover; 
however, the range of elevation in HIV patients is small compared to that seen in lymphoprolif- 
erative disease, and its value (except where CD4 T-cell counts are unavailable) is small. Serum 
and urinary neopterin, a marker o f macrophage activation, may also be elevated. There is little to 
choose between these two surrogate markers.
Immunotherapy
• Mainstay of therapy at present is the use of antiretroviral agents. Mono or dual agent therapy is 
not recommended. Complex multi-agent regimes are now used. The reader is advised to consult 
the current HIV literature for information on the current state o f therapeutic options. Most re­
gimes require strict timing of administration and high levels o f compliance. Multiresistant HIV 
strains have been reported.
• IVIg may be helpfiil in certain HIV infants, although not in adults.
• Other immunotherapies (interferons, IL-2) have been uniformly disappointing and are not used 
routinely, a-IFN enjoyed a vogue in the treatment o f  Kaposi's sarcoma (due to HHV-8), but the 
latter responds better to cytotoxic therapy and radiation.
- Use of passive immunotherapy has been disappointing.
• No reliable vaccine is yet available, although trials are continuing on a number o f candidate
vaccines.
Epstein-Barr virus
EBV is associated with infectious mononucleosis (glandular fever), Hodg-kin's disease, Burkitt's 
lymphoma, and nasopharyngeal carcinoma. Rare EBV-positive T-cell lymphomas have also 
been described (T/NK-lethal midline granuloma).
Immunological features
• EBV is a transforming B-lymphotropic virus o f the herpes family, binding to the cells via 
CD21 (C3d) receptor and HLA class II antigens. This receptor is also expressed on follicular 
dendritic cells and pharyngeal and cervical epithelium. All these tissues are targets. Pharyngeal 
epithelium is usually affected first, with infection spreading to В cells in the adjacent lymphoid 
tissue of Waldeyefs ring.
• Following infection there is a В lymphoproliferation, triggered by cross-linking of the CD21, 
CD19, CD81 complex by virus, which is controlled rapidly by cytotoxic T-cells, which form the 
'atypical mononuclear cells' seen on smears. Both HLA-restricted and unrestricted cells are pro­
duced, with the latter directly recognizing a virally induced antigen on the cells (LYDMA, lym­
phocyte-determined membrane antigen). The viral BZLF1 protein is a major target antigen.
• Viral persistence occurs, with reactivation of infection in the immunocompromised (immuno- 
suppressed patients, transplant recipients, HIV-infected patients), giving oral hairy leucoplakia, 
lymphocytic interstitial pneumonitis, and lymphoma. Nasopharyngeal carcinoma also occurs, 
although other cofactors are likely to be involved.
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• In patients with a genetic predisposition (Duncan's syndrome, NK-cell deficiency), severe or 
fatal infection can occur on first exposure to EBV.
• Although infectious mononucleosis (glandular fever) is usually a self-limiting illness, some pa­
tients fail to clear the virus and develop an appropriate sequence of IgG antibodies: such patients 
have persistently positive IgM antibodies to EBV and have chronic symptoms (fatigue, malaise, 
sore throats),
• In the acute phase of EBV infection there is suppression o f mitogen and allogeneic responses. 
NK function is also abnormal even though cell numbers are increased. It has been shown that 
EBV-transformed cells secrete a homologue o f IL-10. Monocyte chemotaxis is also abnormal.
• EBV infection may cause severe В-cell lymphoproliferative disease in immunosuppressed pa­
tients, and in patients after BMT. It also causes В-cell lymphomas, especially in solid organ 
transplant recipients on long-term immunosuppression.
Immunological diagnosis
• Usual screening test (Monospot) for acute EBV infection relies on the production o f hetero- 
phile antibodies that agglutinate sheep cells. This test may miss cases. IgM antibodies are de­
tected and are then succeeded rapidly by IgG antibodies to early antigen (EA) and viral capsid 
antigen (VCA); antibodies to EBV nuclear antigen (EBNA) appear weeks to months after infec­
tion.
• Initial lymphopenia is followed by lymphocytosis of CD8+ T cells, which give rise to the atypi­
cal lymphocytes seen on blood films. However, monitoring of lymphocyte subpopulations is o f 
little value, except in unusual variants o f EBV infection.
• There is usually an acute polyclonal rise in immunoglobulins, which may be associated with 
the production o f autoantibodies.
Immunotherapy
■ None is required normally. However, in patients with a persistent EBV syndrome, high-dose 
aciclovir (800 mg 5 times daily for 14 days) may lead to remission of symptoms and disappear­
ance of the IgM anti-EBV antibodies.
• Vaccines are in development, including peptide vaccines.
• Adoptive immunotherapy with EBV-specific CTL is undergoing trials, especially in immuno- 
suppressed or immunodeficient patients.
Cytomegalovirus (CMV)
CMV behaves similarly to EBV, with an early CD8+T-cell lymphocytosis giving atypical lym­
phocytes on a blood film. Proliferative responses are reduced during acute infections. CMV in­
fection o f monocytes with production of an IL-1 inhibitor may be important. However, congeni­
tal CMV infection leads to a prolonged suppression of T-cell function and may also suppress an­
tibody production. In BMT recipients, there may be prolonged suppression o f myeloid differen­
tiation. Reactivation o f the disease may occur in the context o f immunosuppression (HIV, drug 
therapy). High-titre anti-CMV antibodies in the form o f IVIg may help to prevent infection, al­
though once infection is established treatment with antivirals (ganciclovir, foscamet, cidofovir) 
is necessary. Vatganciclovir is an oral prodrug.
Rubella
Congenital rubella, but not acute infection, causes poor lymphocyte responses (reduced PHA 
proliferation) and may lead to long-term depressed humoral immune function. Hypogammag- 
lobulinaemia and a hyper-IgM syndrome, with transiently reduced CD40 ligand expression, have 
beat reported. Rubella appears to directly infect both T- and B-cells.
Measles
Measles virus is capable o f infecting both lymphoid and myeloid cells. Acute measles depresses 
cutaneous type IV reactivity (tuberculin reactivity); this is transient. Similar effects occur with 
measles vaccines. There is also suppression o f NK activity and immunoglobulin production. It is
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possible that acute measles may lead to reactivation o f  ТВ due to immunosuppression. Acute 
measles may cause a transient lymphopenia; PHA- and PPD-driven proliferation is reduced. 
Neutrophil chemotaxis may be impaired transiently (significance). Early inactivated measles 
vaccines led to a response predominantly against viral haemagglutinin but not to the fusion pro* 
tern, sometimes leading to an atypical wild-type infection as a result o f the inappropriate immune 
response.
Influenza virus
Acute influenza may give a marked but transient lymphopenia, accompanied by poor T-cell pro­
liferative responses.
Hepatitis В virus
Non-specific immunosuppressive effects are seen, which may be due to liver damage or to virus. 
Congenital infection with HBV leads to tolerance o f the virus and chronic carriage. 5% of nor­
mal subjects do not make a humoral response to HBV vaccines after the normal 3-injection 
course. Some may respond if a different brand is used. Alternatively, a double dose may be given 
(40 ng), either alone or in combination with y-lFN 2 000 0 0 0 IU. Subjects should be warned of 
severe flu-like symptoms, lnterleukin-2 (I 000 000 IU) has also been used successfully.
Post-viral fatigue syndromes
• Chronic fatigue syndromes, accompanied by muscle/joint pains and neuropsychiatric symp­
toms, may occur after a range o f viral infections, including enteroviruses.
• Immunological abnormalities include: variable lymphopenia, IgG subclass abnormalities; 
atypical anti-nuclear antibodies.
• May be transient or persistent.
Acute bacterial infections
Acute bacterial sepsis may lead to profound changes in immune function on a temporary basis. 
Immunological features
• Neutrophil migration and chemotaxis are increased, while phagocytosis is normal or decreased.
• Lymphopenia affecting CD4+ and CD8+ cells may be marked. Significant and temporary hypo- 
gammaglobulinaemia may be present (release o f  immunosuppressive components from bacteria).
• Massive acute-phase response with elevation o f C-reactive protein (CRP) and other acute-phase 
proteins (complement, fibrinogen, protease inhibitors, armacroglobulin (IL-6 carrier)) and a re­
duction in albumin (negative acute-phase protein).
• Complement components will be consumed rapidly, but synthesis will be increased (all are 
acute-phase proteins), so measurements may be difficult to interpret. Functional assays o f com­
plement are usually highly abnormal.
• Toxic shock may follow certain types o f bacterial infections (staphylococci, streptococci), due 
to release of'superantigenic' toxins, which activate many clones o fT  cells directly, bypassing the 
need for MHC on antigen-presenting cells by binding directly to the T-cell receptor. Effects are 
likely to be due to cytokine excess.
Immunological investigation
• The most important investigations are microbiological, to identify the pathogen, by culture and 
rapid antigen or PCR tests.
• Monitoring of the acute-phase response (CRP) gives a  good indication o f response to therapy. 
Acute measurement of immunoglobulins and complement is usually misleading and may lead to 
erroneous diagnoses of antibody or complement deficiency. It is best to leave these investiga­
tions until convalescence. Functional assays o f  complement may take 2-3 weeks to normalize 
after acute sepsis.
• Acute measurement o f cytokines in toxic shock is currently impractical and the diagnosis is a 
clinical one.
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Chronic bacterial sepsis 
Immunological features
• Hypergammaglobulinaemia is usual, often with small and sometimes multiple monoclonal 
bands developing, representing the immune response against the pathogen. Chronic antigenae- 
mia will cause immune complex reactions and secondary hypocomplementaemia (subacute bac­
terial endocarditis (SBE)).
■ The acute phase becomes a chronic phase: anaemia of chronic disease, iron deficiency due to 
sequestration (defence against pathogen); see below. There is the risk o f amyloid development
• T-cell function may be significantly impaired. The best example is mycobacterial infection, 
with energy to PPD and third-party antigens. 10% of ТВ cases do not respond to tuberculin. My­
cobacterial products (arabino-D-galactan) interfere with in vitro proliferative responses to PHA, 
PWM, and PPD; the effect is possibly via macrophages and may involve prostaglandins (inhibi- 
table by indomethacin). There is often a lymphopenia. Persistently raised CRP may also be sup­
pressive.
• Miliary ТВ may cause neutropenia, generalized bone marrow suppression, and leukaemoid re­
actions.
• Untreated leprosy is a potent suppressor o f cell-mediated immunity: T-cell responses to mito­
gens and antigens are reduced. This defect disappears with appropriate antibiotic therapy and ap­
pears to be mediated by a glycolipid. The underlying bias of the immune system towards either 
Thl (cellular) orTh2 (antibody) responses determines whether the response to leprosy is tubercu­
loid (Thl) or lepromatous (Th2). Other immunological features include the development o f vas­
culitis (erythema nodosum) and glomerulonephritis (assumed to immune complex with IgG and 
complement).
Immunological monitoring
• Acute-phase markers provide the best guide to progress and response to therapy (but beware o f 
elevations from drug reactions). The erythrocyte sedimentation rate (ESR) is less useful because 
of its long half-life.
• Low complement (C3) and elevated C3d indicates immune-complex reaction (renal involve­
ment likely); monitoring of functional haemolytic complement is not valuable.
• Immunoglobulins are usually high (polyclonal stimulation, monoclonal bands). Electrophoresis 
also shows elevated a2-macroglobulin, reduced albumin; beware apparent monoclonal hands’ 
from very high CRP (use specific antisera on immunofixation to demonstrate this).
• Hypogammaglobulinaemia is rare: consider underlying immunodeficiency.
Measurement of in vitro T-cell function and lymphocyte markers is not valuable unless there is a 
suspicion that the infections are due to an underlying immunodeficiency.
Immunotherapy
у -Interferon offers some possibilities for modifying the Thl :Th2 balance in chronic mycobacte­
rial infections and in leishmaniasis.
Fungal infections
Except for cutaneous infections, invasive fungal infections are usually the markers of, rather than 
the cause of, immunodeficiency, indicating defective neutrophil/macrophage and T-cell immu­
nity.
Parasitic infections
Immunologicalfeatures
• Malaria has no overt effect on cell-mediated immunity but reduces tire humoral immune re­
sponses to bacterial antigens (tetanus toxoid, meningococcal polysaccharide, and Salmonella О  
antigen), presumably through effects on the spleen. There appears to be little interaction between
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HIV infection and malaria where the two diseases overlap. Tropical splenomegaly due to vivax 
malaria is associated with a CD8+ T-cell lymphopenia and raised IgM.
• Trypanosomes suppress cellular responses, but there is often a polyclonal increase of non­
specific immunoglobulin, especially IgM.
• Visceral leishmaniasis is characterized by a polyclonal nypergammag-lobulinaemia, often mas­
sive, but with absent cell-mediated immunity until after treatment Splenomegaly may be mas­
sive and there is often lymphopenia. The cachexia and lymphopenia are mediated by release of 
tumour necrosis factor-а (TNF-a) by infected macrophages.
• Many parasites, including malaria and trypanosomes, escape immunological surveillance by 
antigenic variation. This occurs under selection pressure from the immune system. Other avoid­
ance mechanisms include shedding of surface antigen complexed with antibody.
• Autoimmunity may occur as a consequence o f the chronic infection: schistosomiasis is associ­
ated with anti-nuclear antibodies including anti-calreticulin antibodies. Onchocerciasis is also 
associated with anti-calreticulin antibodies (which cross-react with an onchocercal antigen).
• Parasitic infections are associated with excess eosinophil and IgE responses.
Immunological monitoring There is little value in monitoring anything other than the acute-phase 
response.
Malignancy
Immunological features
• Malignancy, especially lymphoid, is very common in primary immunodeficiencies (Wiskott- 
Aldrich syndrome, CVID, DNA repair defects) and in secondary immunodeficiencies (HIV, 
EBV). Some viruses are directly oncogenic (hepatitis B, EBV).
• Malignancy is also increased in patients with autoimmune disease, possibly secondary to im­
munosuppressive drug therapy, and in transplant patients who are immunosuppressed (skin tu­
mours, carcinoma of the anogenital tract).
• Abnormalities of T- and NIC-cell function have been described in patients with solid tumours, 
leading to the suggestion that impaired immune surveillance is related to the development o f tu­
mours, although they might equally be a consequence, not a cause. T-cell defects include reduc­
tion of IL-2 and TNF-a production, and activation markers such as CD71 (transferrin receptor). 
Cancer cells may alter immune function through the release o f TGF-0, which reduces T-cell pro­
liferative responses and macrophage metabolism, and through inhibitors o f  complement
• Some tumours have a propensity to generate autoimmune responses due to inappropriate ex­
pression o f antigens; these may lead to paraneoplastic phenomena, such as the Lambert-Eaton 
myasthenic syndrome (small cell lung carcinoma) due to an autoantibody against voltage-gated 
calcium channels, and neuronal and retinal autoantibodies in breast, ovarian, and colonic tu­
mours.
• Major immunosuppression may result from radio- and chemotherapy. This may be prolonged 
and lead to secondary infective complications.
Immunological monitoring
• There is little value in immunological monitoring o f aspects such as NK-cell numbers or func­
tion.
• Patients with significant and persistent infective problems post-treatment may warrant investi­
gation o f cellular and humoral immune function, depending on the type o f infections. Lympho­
cyte surface markers, immunoglobulins, IgG subclasses, and specific antibodies to bacteria and 
viruses may be appropriate.
• Paraneoplastic phenomena may suggest a search for unusual autoantibodies (voltage-gated cal­
cium channels, cerebellar Purkinje cells, retinal antigens).
Im munotherapy
• Immunotherapy o f solid tumours has a chequered career. IL-2 therapy has been proposed for 
certain tumours (renal and melanoma) but there are no good controlled trial data to support this 
and it is very toxic. In vitro stimulation of non-specific killers (LAK. cell therapy) by IL-2, using
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either peripheral blood cells or tumour-infiltrating cells, has also been claimed in small open tri­
als to be beneficial but is even more toxic.
• Other immunotherapies tried have included the use of non-specific immunostimulants such as 
BCG, Corynebacterium parvum, and Bordelella pertussis, often given intralesionally. Occasion­
ally spectacular results have been achieved. a-IFN has been used with success in certain lym­
phoid disorders (hairy-cell leukaemia, plateau-phase myeloma).
• Monoclonal antibodies are now being introduced targeted against tumour-specific antigens, 
such as CD20 (rituximab) in lymphoma, anti-CD52 in CLL, and anti-Her-2 (trastuzumab) in 
breast cancer. Monoclonal antibodies have also been used to target radiopharmaceuticals to tu­
mours where the antibody itself may kill tumour cells poorly (anti-CD20 monoclonals labelled 
with yttrium).
• A major benefit o f immunotherapy has been in the use o f colony-stimulating factors to protect 
the bone marrow, allowing higher doses of conventional cytotoxic agents to be used. However, 
there are concerns that this approach may increase the risk of secondary myeloid leukaemias.
Myeloma
Immunological features
• Myeloma is a tumour of plasma cells, leading to clonal proliferation. A single isolated lesion in 
bone is referred to as a plasmacytoma. Waldenstrom's macroglobulinaemia is a clonal prolifera­
tion o f IgM-producing lymphocytes.
• Staging o f disease depends on bone marrow features, paraprotein level, calcium, and haemo­
globin.
• There may be a genetic background (HLA-Cw2, -Cw5) and IgA paraproteins may be associ­
ated with a translocation t(8;14). Other translocations may occur, Ig gene rearrangements are de­
tectable.
• Myeloma cells often express both lymphocyte and plasma cell antigens simultaneously. Ab­
normal В cells may be detectable in the peripheral blood, expressing high levels o f  CD44 and 
CD54. Cells also express CD56 (NCAM), an adhesion molecule, and soluble levels o f NCAM 
are elevated in myeloma.
• IL-6 plays a key role as either autocrine or paracrine factor stimulating proliferation. CRP may 
be raised in consequence. Osteoclast-activating factors are also produced, leading to bone de­
struction (IL-1, IL-6, TNF-P).
• Monoclonal immunoglobulin production parallels the frequency of В cells: 52% IgG; 22%
IgA; 25% free light chain only; and 1% IgD. IgE myeloma is exceptionally rare and is found 
with plasma cell leukaemia. Biclonal myeloma and non-secreting tumours may be found.
• Synthesis o f heavy and light chains is often discordant and whole paraprotein may be accom­
panied by excess free light chains. Free light chains are readily filtered but nephrotoxic. IgD 
myeloma often presents in renal failure.
• Hyperviscosity is common with high levels o f IgM and IgA paraproteins but is rare with IgG 
and free light-chain paraproteins. IgA frequently polymerizes in vivo (dimers and tetramers). 
Paraproteins may have autoantibody activity and may be cryoglobulins (types I and II). Com­
plexes of paraproteins (especially IgM) with coagulation factors may cause bleeding.
• Although myelomatous change probably arises in spleen or lymph node, these are unusual sites 
for disease, which is usually found in bone and bone marrow. Excess clonal plasma cells will be 
found in the bone marrow.
• Normal humoral immune function is impaired and there is suppression of non-paraprotein im­
munoglobulin (arrest of B-lymphocyte maturation). Specific antibody responses are poor.
• T-cell function is also impaired, leading to viral infections.
• Low levels of monoclonal paraproteins are found in other lymphopro-liferative conditions, 
chronic infections, connective tissue diseases, and old age.
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• Where a paraprotein is present without other features o f myeloma (no increase in plasma cells 
in bone marrow), the term 'monoclonal gammopathy o f uncertain significance' is applied. A pro­
portion o f these patients develop myeloma with time and all should be monitored at intervals.
• Heavy-chain disease is rare (ц, у, and a). a-Heavy-chain disease is the most common. All are 
associated with lymphoma-like disease.
• POEMS syndrome (polyneuropathy, organomegaly, endocrine abnormalities, mopoclonal 
gammopathy, and skin rashes) appears to be a plasma-cell variant o f Castleman's disease, a hy­
perplasia o f  lymph nodes, which may occur with autoimmune diseases. It is associated with high 
circulating levels o f IL-1,1L-6, VEOF, and TNF.
Immunological diagnosis and monitoring
• Diagnosis o f a  paraproteinaemia depends on accurate electrophoresis of serum and urine, fol­
lowed by immunofixation. Immunochemical measurements o f immunoglobulin levels (by radial 
immunodiffusion (RID) or nephelometry) may be misleading due to polymerization or, in the 
case o f IgM, monomeric paraprotein.
• Paraprotein levels are best determined by scanning densitometry, provided that the total protein 
in serum can be measured accurately. There are difficulties if  the M-band overlaps the (P-region.
• Urinary light-chain excretion may be helpful as a prognostic monitor o f tumour cell burden, but 
there are difficulties in the calculation of this and renal function affects the output. Measurement 
o f serum (fee light chains (binding site assay) appears to be a more sensitive marker o f donality 
and tumour burden.
• Serum fb-microglobulin is a valuable marker o f  tumour-cell activity. CRP may be a surrogate 
for IL-6 production and soluble NCAM may be o f  prognostic value.
• Degree of humoral immunodeficiency should be assessed by measurement o f exposure and 
immunization antibodies, followed by test immunization with protein and polysaccharide anti­
gens.
Im munotherapy
The disease is probably not curable at present. Standard chemotherapy includes melphalan and
prednisolone; other agents used include vincristine, doxorubicin (or related drugs), and car- 
mustine (BiCNU). a-interferon has a major effect in prolonging the plateau phase. BMT (alloge­
neic and autologous purged marrow) may also prolong remission but it is doubtful if  it is cura­
tive. Colony-stimulating factors should be used with caution as they may enhance tumour cell 
growth.
• Waldenstrom's macroglobulinaemia may be treated with fludarabine or cladribine; rituximab is 
also helpful.
• Radiotherapy may be required for localized plasmacytomas.
• IVIg may be beneficial in dealing with secondary infective problems but should be used with 
great caution in patients with renal impairment and those with rheumatoid activity o f their para­
proteins (both may lead to renal failure). Prophylactic antibiotics may be an alternative.
• Plasmapheresis may be required to deal with hyperviscosity and/or cryoglobulinaemia.
Lymphoma: Hodgkin's disease 
Immunological features
• Hodgkin's disease (HD) is a lymphoma seen predominantly in the young. It is characterized by 
the presence o f typical Reed-Stemberg cells (CD 15, CD30 positive).
• Three major types (nodular sclerosing, mixed cellularity, and lymphocyte depleted) are recog­
nized. Lymphocyte predominant may well be a separate disease, as it occurs later and often re­
lapses to non-Hodgkin's lymphoma. Staging depends on the number of sites affected and by the 
presence or absence o f constitutional symptoms.
• EBV genome is often found in HD, and Reed-Stemberg (RS) cells are usually positive. RS 
cells are thought to be the true neoplastic cell, possibly derived from interdigitating reticulum 
cells.
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• T- and В-cell numbers are reduced. Immunoglobulins are often raised, especially IgE. 10% of 
patients will have hypogammaglobulinemia (severe disease). There may be poor specific anti­
body responses; primary antibody responses are impaired, whereas secondary responses may be 
normal.
• T-cell proliferation is reduced (reversible by indomethacin, suggesting a possible macrophage 
defect). Cutaneous energy is common. Responses to Pneumovax may be present even if  there is 
a lack o f DTH responses
• In some cases the defects have been shown to precede the development o f the disease and also 
to persist long-term after successful treatment (although the role o f the cytotoxic regimes in this 
is poorly understood). It is difficult then to distinguish from a primary immunodeficiency com­
plicated by lymphoma.
• Bacterial infections are common (Pneumococcus and Haemophilus influenzae), related to poor 
humoral function and possibly also to poor neutrophil function.
• Before CT scanning became widespread, splenectomy for staging was common. This is now 
only undertaken for symptomatic hypersplenism. Splenectomy has a  very significant effect on 
immune function in lymphoma, and patients may become unresponsive to bacterial vaccines.
Immunological diagnosis and monitoring
• Diagnosis is made on histological examination of excised lymph node, supplemented by the 
use of immunocytochemistry to identify populations o f cells. This may be useful in the identifi­
cation o f scanty RS cells. However, RS cells may also be found in association with glandular 
fever, reactive hyperplasia, and some non-Hodgkin's lymphomas. There is usually a reactive ex­
pansion o f CD4+ T-cells.
• Molecular techniques should be used to look for evidence o f EBV genome.
• HD is associated with an acute-phase response, with elevated ESR, CRP, and caeruloplasmin. 
This may be a poor prognostic indicator.
• All patients with lymphoma should be monitored for evidence o f  humoral immune deficiency: 
serum immunoglobulins, IgG subclasses, and specific antibodies. Test immunization is appropri­
ate. Particular attention should be paid to apparently cured patients, who may still have a persist­
ing immunodeficiency.
Immunotherapy
• Treatment is with radiotherapy and/or chemotherapy. The latter is used for patients with consti­
tutional ('B') symptoms. There are many regimes for combination chemotherapy.
• Most regimes are myelosuppressive and impose a temporary secondary defect through neutro­
penia.
• Relapse may be treated with autologous bone marrow transplant (harvested in remission) or 
with a stem-cell transplant.
• Secondary neoplasms may occur (myelodysplasia, acute myeloid leukaemia) and the risk is re­
lated to the intensity o f treatment.
• IV Ig may be required for those with a persisting symptomatic humoral defect after treatment.
Non-Hodgkin's lymphoma 
Immunological features
• This category includes all those lymphoid and histiocytic lymphoid malignancies that are not 
Hodgkin's disease. There are many classifications, but the two used most often in the UK are 
Kiel and the Working Formulation. A WHO classification was introduced in 1999. Morphology 
and cellular origin play a major role in classification.
• Tumours are also divided on the basis o f their clinical grade ( -  aggressivity). Low-grade B-cell 
tumours overlap with chronic lymphocytic leukaemia. Waldenstrom's macroglobulinaemia is 
often referred to as an immunocytic lymphoma Both T- and В-cell lymphomas are recognized, 
as well as tumours derived from histiocytic elements.
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• Retrovirus, HTLV-1, has been associated with T-cell lymphomas in areas where it is endemic 
(Japan and the Caribbean).
• EBV has been associated with certain B-ccll lymphomas, particularly associated with immuno­
suppression and endemic Burkitfs lymphoma, which is found in malarial areas. This tumour, but 
also others, is associated with chromosomal abnormalities, normally translocations t(14;8).
• Many other translocations have beat identified. It is thought that these translocations allow 
dysregulated activity o f cellular oncogenes, such as bcl-2 and abl. by placing them in proximity 
to active promoters. In Burkitfs lymphoma it is the oncogene c-myc.
• Often sites o f translocations involve the heavy- and light-chain genes for immunoglobulin and 
the genes for T-cell receptors.
• Secondary lymphomas are usually non-Hodgkin's lymphoma (NHL). These are found with:
- primary immunodeficiencies (WAS, CVID, AT, Chediak-Higashi, DNA repair defects);
- connective tissue diseases (rheumatoid arthritis, Sjogren's syndrome, SLE);
- phenytoin therapy;
- post-transplant (ciclosporin therapy).
• In the case o f  primary immunodeficiency, it is likely that the chronic infections lead to an abor­
tive immune response that predisposes to lymphoma. Perhaps earlier diagnosis and better treat­
ment will prevent this.
• Studies o f humoral and cellular function have shown abnormalities that have not always corre­
lated with the type o f lymphoma. Abnormalities are more likely in high-grade tumours. Both 
hypo- and hypergammag-lobulinaemia may occur and may persist after treatment Monoclonal 
bands, often IgMK, may be found in association with В-cell tumours. Autoantibody activity may 
be noted.
• Acquired angioedema is often associated with an underlying В-cell lymphoma with a parapro­
tein.
- Paraprotein binds to and inhibits Cl-esterase inhibitor.
• As in Hodgkin's disease, splenectomy may have been undertaken in the past, imposing an addi­
tional immunological defect. These patients require careful supervision.
Immunological diagnosis and monitoring
• Diagnosis requires histological examination of lymphoid tissue, accompanied by immunohisto- 
chemistry, using panels o f monoclonal antibodies to identify the predominant cell type.
• Clonality will be established by molecular techniques looking at Ig and Ter gene rearrange­
ments.
• Humoral immune function should be monitored, as for Hodgkin's disease.
• Serial Pi-microglobulin measurements may be helpful as a marker o f lymphocyte turnover.
• Electrophoresis will demonstrate the presence of paraproteins. If autoimmune phenomena are 
present, then association with the paraprotein can be shown by light-chain restriction on im­
munofluorescence.
• Sometimes abnormalities of immunoglobulins precede overt disease. In contrast to primary 
immunodeficiency, IgM disappears first, followed by IgG and IgA.
■ Finding an isolated but marked reduction of IgM in an older person should lead to a review for 
evidence of lymphoma (selective IgM deficiency is vanishingly rare!).
Im munotherapy
• Treatment depends on the type of treatment and its grade. Localized disease may be amenable 
to radiotherapy, while disseminated disease will require chemotherapy. Aggressive chemother­
apy o f high-grade tumours may result in some cures.
• Autologous bone marrow transplantation may be helpful in relapse. IVIg may be required if 
there are infective problems.
• The monoclonal antibody rituximab, with or without attached radioisotope, is valuable for 
treating CD20-positive lymphomas.
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Chronic lymphocytic leukaemia (CLL)
Immunological features
• CLL is a clonal proliferation o f small lymphocytes. It is the most common form o f lymphoid 
leukaemia. 95% are В-cell in origin; 5% are T-cell in origin. Other variants include prolympho- 
cytic leukaemia (B-PLL), hairy cell leukaemia (HCL), and splenic lymphoma with circulating 
villous lymphocytes (SLVL). Cell counts may become very high (> 100 x 10’/1). It is predomi­
nantly a disease o f the elderly (95% of patients are over 50).
• Different variants may be distinguished by flow cytometry:
- B-CLL is usually CD5+, CD23+, FMC7\ CD22+, with weak surface Ig. Clonal restric­
tion can usually be demonstrated with anti-light-chain antisera;
- B-PLL has the phenotype CD5‘, CD23\ FM C7\ CD22+, slg+;
- HCL is CD5\ CD23‘, FMC7+, CD22+, slg+;
- SLVL is CD5*, CD23*, FMC7+, CD22+, slg+;
- Circulating lymphoma cells may be distinguished because they often express CD10 
(CALLA);
- T-PLL is rare: cells are usually CD4+, CD8', but dual-positive or CD4', CD8+ variants 
may occur;
- Large granular lymphocytic leukaemia has the phenotype CD4', CD8+, CD1 lb+, 
CD16/56+, CD57*. The cells may be highly active in an NK assay.
■ Bone marrow examination shows an excess o f lymphocytes.
• Chromosomal abnormalities are common: trisomy 12 and deletions of the long arm o f chromo­
some 13 in В-cell disease, and chromosome 14 abnormalities (inversion or tandem translocation) 
or trisomy 8q in T-cell disease. Recent studies have demonstrated that some CLL patients have 
an abnormal ATM  gene (ataxia telangiectasia mutated).
• Recurrent bacterial infections are a major problem.
• Humoral function is impaired and response to Pneumovax® is a better predictor o f infection 
than total IgG.
• Studies o f normal В-cell function is difficult in vitro due to the predominance of the aberrant 
clone.
• Electrophoresis may show small bands (usually IgM). T-cell numbers may be increased (CD4* 
T-cells), but function may be poor with low/absent PHA responses.
• Viral infections may be a problem (shingles with dissemination, HSV).
- Autoimmune phenomena are common: ITP and haemolytic anaemia Splenectomy may be re­
quired and this exacerbates the immune deficit
• Vaccine responses are frequently entirely absent in this situation and patients must have pro­
phylactic antibiotics.
- HCL may be associated with vasculitis.
Immunological diagnosis and monitoring
• Diagnosis o f straightforward CLL is usually possible from the white count and examination of 
the film. Confirmation requires flow cytometry and examination o f  the bone marrow.
• Studies o f  humoral immune function are necessary and should include test immunization with 
Pneumovax®. As these diseases are chronic, monitoring should be carried out at regular intervals 
to identify deterioration
Immunotherapy
• Treatment is with cytotoxic agents. Chlorambucil is the usual agent but fludarabine, deoxycor- 
fomycin, and 2-chlorodeoxyadenosine are highly effective. The last named produces a  state simi­
lar to ADA deficiency. This leads to a  profound immunosuppression, with T-cell lymphopenia 
and a significant risk o f opportunist infections. Patients treated with these agents should have 
regular T-cell counts by flow cytometry and receive prophylactic co-trimoxazole and irradiated 
blood products (risk o f  engrallment).
• a-Interferon is very effective in HCL Rituximab® is valuable in combination with fludarabine 
and cyclophosphamide. The humanized monoclonal antibody Campath-IH® (alemtuzimab) has
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been used in resistant cases with success, but causes profound immunosuppression. Younger pa­
tients may be candidates for BMT.
• Recurrent infections may require prophylactic antibiotics or IVIg. Monthly treatment is usually 
adequate (dose 200-400 mg/kg).
Chronic myeloid leukaemia (CML) and myelodysplastic syndromes 
Immunological features
• Chromosomal abnormalities occur in almost all cases o f CML and myelodysplastic syndromes. 
The Philadelphia chromosome (t(9;22)) is the most common, but others have been described, 
including the Sq-syndrome, monosomy 7, trisomy 8,19, or 20, and deletions on other chromo­
somes (12 and 20). The deletions o f chromosome 5 are o f interest because they map to the region 
containing the genes for IL-3, -4, -5, G-CSF, and GM-CSF.
• There is a high incidence o f progression to acute myeloid leukaemia
• Abnormal neutrophil function is well described: neutropenia is common in myelodysplasia 
Even if  the neutrophil count is normal, function is often not, with abnormalities o f adhesion, 
chemotaxis, phagocytosis, and bacterial killing being well documented. This occurs particularly 
with monosomy 7 in childhood.
• Infections are common.
Acute leukaemias 
Overview
• Acute leukaemia is a common malignancy of childhood, and accounts for about 30-40% of 
paediatric malignancy. 80% of cases are due to acute lymphoblastic leukaemia (ALL).
• Certain primary immunodeficiencies are risk factors for ALL (Bloom's syndrome, ataxia te­
langiectasia, Schwachmann's syndrome, xeroderma pigmentosa). Most ALLs are В cell in origin.
• T-ALL is associated strongly with HTLV-1 infection in areas where this virus is endemic. A 
number o f chromosomal translocations have been described, including the Philadelphia translo­
cation (t(9;22)), which is common in adult ALL. T-ALL is often associated with translocations 
involving the T-cell receptor genes.
• ALL is classified according to the FAB classification, on the basis o f cytological appearance, 
into L I, L2, and L3 types. Immunophenotyping allows the distinction o f  B-, T-, and null (rare) 
ALLs.
• Acute myeloid leukaemia has also been classified by the FAB group into M0-M7, depending 
on the predominant cell type identified by morphology and cytochemistry. Cases o f AML may 
be secondary to Wiskott-Aldrich syndrome, Chediak-Higashi syndrome, and Fanconi anaemia, 
as well as to the use o f cytotoxic drags such as cyclophosphamide.
• Occasionally, biphcnotypic leukaemias may be detected, defined as the presence o f at least two 
markers from each lineage (e.g. lymphoid and myeloid). They account for 5-10% o f acute leu­
kaemia and tend to have a poor prognosis. Often they present as AML, but have evidence o f 
clonal rearrangements o f immunoglobulin and Ter genes.
Immunological features
• In ALL the immune system is usually normal, although primary IgM responses to some anti­
gens (viruses), may be poor. Secondary responses are usually normal. Non-neoplastic cells are 
normally present in normal numbers. The leukaemic clones rarely have functional activity, al­
though there have been reports o f  cytokine production. Rare cases may be hypogammaglobu- 
linaemic at presentation
• Chemotherapy is profoundly immunosuppressive, affecting both T- and В-cell function and 
rendering patients neutropenic. Careful attention to prevention o f  infection (isolation, irradiation 
o f  food, gut decontamination) is essential.
Immunological diagnosis
• Diagnosis o f  leukaemia is usually made on the basis o f suspicious blood films, supplemented 
by immunophenotyping o f  both peripheral blood and bone marrow, to identify the characteristics
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o f the leukaemic clone. This is supplemented by genetic analysis to identify any translocations: 
probes to the sites o f recombination for these translocations give a very sensitive tool for detect­
ing minimal residual disease in bone marrow after treatment.
• Leukaemia phenotyping is best undertaken by haematologists who will have access to suppor­
tive evidence from blood films, bone marrow smears and trephines, as well as cytochemical en­
zymatic studies. They will also undertake the therapy.
• Monitoring o f humoral and cellular function post-treatment, and especially after BMT, is es­
sential.
Immunotherapy
• The management o f ALL involves intensive chemotherapy and radiotherapy to sanctuary sites 
such as the nervous system (often with intrathecal methotrexate). For relapse or high-risk pa­
tients bone marrow or stem cell transplantation is used, either matched unrelated donors or 
purged autologous if  an HLA-identical donor is not available. There is a high risk o f long-term 
development o f non-Hodgkin's lymphoma and acute myeloid leukaemia.
• AML is treated similarly with intensive chemotherapy, with the option for BMT/HSCT when 
remission is obtained. Acute promyelocytic leukaemia associated with the t(15;17) translocation 
may be treated with all-trans retinoic acid, which allows differentiation of the blocked cells to 
mature neutrophils, although BMT is still required.
■ Certain cytokines may have a role as adjunctive agents, allowing intensification o f chemother­
apy.
Bone marrow and stem cell transplantation
• Bone marrow (BMT) or stem cell (HSCT) transplantation is part of the treatment for a variety 
o f inherited diseases (SCID and SC1D variants, CGD, HIGM, Wiskott-Aldrich syndrome, os­
teopetrosis, Gaucher's disease) in addition to its role in the acute leukaemias and CML with blast 
transformation.
• BMT leads to an immediate severe immunodeficiency, due to the conditioning required to al­
low 'take'. All blood products must be irradiated to prevent viable lymphocytes engrafting and 
must be CMV'.
• There follows a period o f gradually improving immune function while the immune system re­
constitutes. This recapitulates immunological ontogeny.
• T-cell function reconstitutes early, but full В-cell function may take up to 2 years. IgG2 levels 
may remain depressed and there are frequently poor responses to polysaccharide antigens.
• Degree of reconstitution is affected by the degree o f mismatch and by graft-versus-host disease.
• Return of T-cell function in vitro (positive PHA) is usually taken to define the time when re­
lease from isolation is safe, but this is usually the last parameter to normalize. Anti-CD3 stimula­
tion responses usually return early.
• Appearance o f recent thymic emigrants may be detected by measurement o f TRECs (T-cell re­
ceptor excision circles) and by the use o f CD45RA and CD27 to define naive and effector CD4* 
T-cell re-appearance.
• While В-cell function is poor during the acute phase and for the first year thereafter, IVtg pro­
phylaxis is essential.
• Return o f В-cell function can be monitored by IgA/IgM levels and development o f isohaemag- 
glutinins. Reappearance of class-switch memory В cells is also valuable, especially in patients 
transplanted for hyper-IgM syndromes.
• Once off IVIg, a  full programme o f immunizations should be undertaken, starting with killed 
vaccines (killed polio, DPT, Hib, and Pneumovax*). The response to these can be assessed (pre- 
and post-levels are required, and remember that antibody from IVIg may persist for up to 6 
months or longer).
• Once there is a good response to killed/subunit vaccines, then live vaccines can be administered 
(MMR).
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* Immunological function in chronic GvHD is markedly abnormal, with a persisting risk of inva­
sive infections o f all types. The gastrointestinal involvement superimposes a severe nutritional 
defect, which further reduces immune function.
Extremes of age: prematurity
* At birth, infants are dependent for the first 6 months of life on maternally transferred immu­
noglobulin (IgG only).
* Immune function gradually develops, although there is usually a physiological trough in IgG 
levels at around 6 months: if  this is prolonged, then transient hypogammaglobulinaemia of in­
fancy results.
* Additional protection to the neonatal gut is provided by breastfeeding, particularly in the first 
few days when the IgA-rich colostrum is produced.
* Maternal antibody transfer is an active process in the placenta that begins at mound 14 weeks' 
gestation and accelerates markedly after 22 weeks. The process can take place against a  concen­
tration gradient and is selective for some IgG subclasses: lgG2 is transferred relatively less well.
* Antibody-deficient mothers will also be at risk o f producing hypogam-maglobulinaemic in­
fants, who will require IVIg for the first 6 months o f life. Good replacement therapy during 
pregnancy will obviate the need for this.
* Premature delivery interrupts the placental transfer and leaves the infant deficient in immu­
noglobulins and with a relatively less mature humoral and cellular immune system. Breastfeed­
ing is rarely possible, but oral administration o f colostrum is desirable to prevent necrotizing en­
terocolitis. Infections are often problematic, although other factors, such as ГШ nursing, venous 
and arterial lines, and lung immaturity, all contribute. Group В streptococcal infections are par­
ticularly troublesome.
Immunological features and diagnosis
* All immunoglobulins will be low, as will be IgG subclasses. However, the 'normal' ranges are 
calculated from full-term delivery. Provided that there are no major complications, the immune 
system rapidly catches up after delivery and there are rarely long-term sequelae.
* Responses to immunization schedules may be poor.
Immunotherapy
* The role o f IVIg replacement as routine for premature infants has been investigated exten­
sively, with conflicting results, and a consensus as to the value is difficult to obtain.
- Differences in products and batches may relate to highly variable 
levels of anti-group В streptococcal antibodies.
- Better products, enriched for specific antibodies to the problem pathogens, may be re­
quired.
- Oral, IgA-rich products have also been used to reduce the risk o f enterocolitis.
* Immunization of the premature causes problems in timing, as there may be very poor responses 
if routine immunizations are given at intervals calculated from date o f delivery uncorrected for 
gestational age.
Extremes of age: the elderly
Immunological changes in the elderly are multifactorial, relating to the decline in normal immu- 
noregulatory processes, the increased incidence o f  disease, and the increased use o f  drugs. There 
is no relationship to chronological age.
Immunological features
* There is no significant change in lymphocyte numbers or subsets in the healthy elderly, al­
though lymphoid organs show a reduction o f  germinal centres.
* Mucosal immunity seems to be reasonably intact, although the non-specific inflammatory re­
sponse is reduced.
* Aged lymphocytes have metabolic abnormalities such as reduced S'-nudeotidase activity (also 
associated with СУЮ), and there are changes in the expression o f  surface antigens.
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• Immunoglobulin levels change with age: IgG and IgA tend to rise while IgM and IgE fall. Pri­
mary humoral responses are reduced and secondary responses give lower peak litres and a more 
rapid fall with time. Antibody affinity may also be poorer. Some studies have shown that vaccine 
responses in the elderly may be as good as in younger people.
• CVID may present for the first time post-retirement, but this diagnosis should only be enter­
tained when other secondary causes have been eliminated.
• With increasing age there is an increasing incidence of small monoclonal bands on electropho­
resis (MGUS), such that 20% of 95-year-olds will have bands. These are present at low levels 
and are rarely o f great significance.
• There is a parallel increase in autoantibodies o f all types. These are usually oresent at low titres 
and are not associated with disease. Normal ranges for antibody titres should be adjusted to take 
account o f these changes.
• Cell-mediated immunity, as tested by mitogen responses and by DTH testing, are also reduced 
in the elderly. Thymic function is probably better than previously thought and new thymic emi­
grants can be detected in the elderly.
• Biologically, the healthy very elderly (> 85 years old) represent a special group. There may be 
combinations o f MHC genes that can be associated with survival (in Japan, a high frequency of 
DR1 and low frequency of DR9), but this might be due to selection out o f those individuals with 
less favourable MHC types associated with autoimmune disease.
• Coexisting disease imposes additional strains on the immune system, for example, chronic lung 
disease from smoking, cardiac failure with pulmonary oedema and malnutrition. These often tip 
the balance away from the immune system in favour o f invading pathogens.
• Diseases such as influenza have a disproportionate effect on the elderly through the risks of 
secondary bacterial infection and exacerbating pre-existing underlying diseases. Infections 
common in early childhood, such as meningitis, are also more common in the elderly 
Immunological diagnosis
• The investigation of the elderly for immunodeficiency should be symptom-driven. 
Immunotherapy
• Preventative vaccination of at-risk groups is thought to be helpful, for instance with influenza 
vaccine and Pneumovax®. Risk groups are those with underlying significant disease, particularly 
chronic lung disease. However, protection may be poor because o f the underlying decay o f im­
mune function.
• Consideration should also be given to ensuring that other vaccines such as tetanus are kept up 
to date (this tends to be forgotten in the elderly) as tetanus antibodies may fall below protective 
levels. Keen gardeners are at most risk.
• Immunoglobulin therapy may be required for those with significant symptomatic hypogam- 
maglobulinaemia. Occasional elderly patients may prefer the simplicity o f weekly IMIg at their 
GP's surgery rather than regular hospital trips.
Transfusion therapy
• In addition to immediate reactions to blood products due to transfused white cells, pre-formed 
antibodies (to HLA or IgA), etc., there is evidence for an immunosuppressive effect. This is most 
noticeable in the effect on renal allograft survival.
• I VIg has complex immunoregulatory properties when used in high doses.
• Crude factor VIII concentrates were immunosuppressive, although this may relate as much to 
chronic hepatitis due to hepatitis C. High-purity FV1II is much less immunosuppressive.
• Other infections transmissible by blood, such as HIV and CMV, can have major immunosup­
pressive effects.
• The use o f  unirradiated blood in the immunocompromised (with роог/absent cell-mediated 
immunity; CMI) may lead to engraftment o f viable lymphocytes and the development o f graft- 
versus-host disease.
• Lymphocytes may be viable for up to 2 weeks in bank blood.
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Chronic renal disease (nephrotic syndrome and uraemia)
Nephrotic syndrome
• Renal protein loss should always be considered when investigating hypogammaglobulinaemia.
• Investigation o f  humoral f unction is essential i f  there is significant proteinuria.
• In the nephrotic syndrome there is an increased susceptibility to Pneumococcus and other strep­
tococci.
• Typical pattern is loss o f  immunoglobulins in order o f ascending molecular weight, depending 
on die selectivity o f  the proteinuria, with preferential loss o f IgG, then IgA, and preservation of 
IgM until gross nephrosis ensues.
• The IgG synthetic rate is normal or increased and the IgM catabolic rate is normal.
• Responses to Pneumovax® arc poor but responses to influenza are normal.
• Poor neutrophil chemotaxis and opsonization are also described.
• Loss o f  complement proteins such as C3 and factor В may also contribute to poor bacterial 
handling through decreased opsonization.
Uraemia
• Chronic uraemia is immunosuppressive with poor humoral and cellular immune responses. The 
molecules responsible for this are uncertain.
• Lymphopenia is common, affecting CD4* and CIJ8+ T-cells; DTH and mitogen responses are 
reduced.
• Immunoglobulins and specific antibody responses to pneumococcal and hepatitis В vaccines 
may be low. Double doses o f  HBV vaccines (40 pg) are advised.
• Lymph nodes show a loss o f  secondary follicles.
• Neutrophil function shows defective chemotaxis and phagocytosis, with impaired oxidative 
metabolism, leading to poor bacterial killing.
■ Certain types o f dialysis membrane (cellophane, now no longer used) activated the alternate 
pathway of complement, with release o f anaphylotoxins and neutrophil activation leading to se­
vere circulatory and respiratory problems.
• Dialysis patients often have a CD4+ T-cell lymphopenia; increased expression o f CD1 lh/CD18 
is seen on neutrophils. Increased T-cell apoptosis may occur.
Renal transplantation
Renal transplant recipients will be on long-term immunosuppressive therapy. They have an in­
creased risk of papillomavirus-induced skin tumours, EBV-induced lymphomas and 
B-lymphoproliferative disease, and poor humoral and cellular immune function. Monitoring is 
required, especially if  lymphocytotoxic agents such as azathioprine are used.
Protein-losing enteropathy and liver disease (cirrhosis)
Protein-losing enteropathy
Causes Secondary hypogammaglobulinaemia may be due to protein-losing enteropathy, for 
which there are many causes:
• Menetrier's disease (giant rugal hypertrophy)
• Coeliac disease and other types o f sprue
• Inflammatory bowel disease (Crohn's disease)
• Infections-hookworm, ТВ
• Fistulae post-gastrectomy syndrome
• Neoplasms
• Allergic gut disease (eosinophilic gastropathy)
• Secondary to constrictive pericarditis and gross right heart failure
• Whipple's disease
• Chylous effusions
• Intestinal lymphangiectasia (dilated lymphatics).
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Immunological features
• Immunoglobulins are low, with a short half-life, but the synthetic rate I * may be increased.
• Specific antibody responses may be normal, although they may decline rapidly.
• Lymphopenia is associated with dilated or blocked lymphatics (intestinal lymphangiectasia, 
constrictive pericarditis, right heart failure). This may lead to poor mitogen responses and DTH 
reactions.
Diagnosis
• Proof that the bowel is the source of immunoglobulin and cellular loss is difficult as most labo­
ratories are singularly unkeen on trying to measure faecal immunoglobulin excretion! Whole 
bowel perfusion studies may make this more tolerable.
• Radiolabeled albumin excretion in the faeces will quantitate the loss.
• Full studies of humoral and cellular function are required, together with investigation for the 
underlying cause (radiology, endoscopy, and biopsy).
Liver disease (cirrhosis)
■ Increased infections are seen (especially with alcohol which directly impairs macrophage func­
tion) with bacteria and mycobacteria.
• Complement components are reduced (decreased synthesis).
• Neutrophil phagocytosis and chemotaxis occur.
• T-cell function is poor.
Metabolic disorders
A number of metabolic diseases are associated with concomitant immunological impair­
ment.
• Glycogenosis type lb: neutropenia and neutrophil migration defect Recurrent infections a prob­
lem: septicaemia, wound infections, osteomyelitis, and sinusitis.
• Mannosidosis: recurrent severe infections; impaired neutrophil chemo-taxis. Pom T-cell re­
sponses to PHA and concanavalin A (ConA).
• Galactosaemia: increased risk o f  Gram-negative septicaemia due to abnormalities o f neutrophil 
motility and phagocytosis.
• Myotonic dystrophy: hypercatabolism o f IgG but not albumin, IgA, or IgM may occur, al­
though infections are not usually a major problem.
• Sickle-cell disease: increased susceptibility to meningitis and septicaemia There is an acquired 
splenic dysfunction, due to infarction. Tissue hypoxia also contributes to bacterial infection. Se­
rum immunoglobulins and vaccine responses are usually normal, even to polysaccharide anti­
gens. It is recommended that all patients should be treated as other asplenic or hyposplenic pa­
tients and should receive Pneumovax and Hib vaccines, and be considered for prophylactic an­
tibiotics.
• Coeliac disease: this may be accompanied by splenic atrophy and these patients should be in­
vestigated and treated as other asplenic patients.
• Prolidase deficiency: rare autosomal disorder with rashes, skin ulceration, dysmorphic features, 
splenomegaly, and recurrent infections It also appears to be associated with a risk o f developing 
SLE. It is diagnosed by the presence o f iminopeptiduria.
Diabetes mellitus 
Immunological mechanisms
• There is an underlying genetic susceptibility to type I diabetes (the HI.A type is shared with 
CV1D) and consequent immune dysregula-tion. As a result o f die association with the A l, B8, 
DR3, C4Q0 haplo-type, there is an increased incidence o f C4 deficiency in diabetes.
• In established disease, the raised glucose itself interferes with both innate and specific immune 
functions. Most o f the research has been done on chemically induced or genetic diabetes in mice; 
much less work has been done on human diabetes.
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• Humoral function is impaired: IgG levels may be reduced, while IgA may be increased. Spe­
cific antibody responses may show poor primary immune responses and the non-enzymatic gly- 
cation o f immunoglobulin may interfere with function. Both T-dependent and T-independent an­
tigens are affected.
• Lymphoid organs are essentially normal but peripheral blood lymphocytes may show variable 
abnormalities. CMI may be depressed with poor DTH responses and abnormal mitogen re­
sponses and poor cytokine production (IL-2).
• Macrophage and neutrophil function is also reduced.
• Type I diabetes is strongly associated with coeliac disease: hyposplenia may occur.
• Infections with Candida and other fungi, ТВ, and pneumococci are more common in diabetes. 
Staphylococcal colonization of the skin is higher in diabetics than in normal individuals.
- Abnormalities o f immune function are more marked in type I diabetes but correlate poorly with 
blood glucose levels. It is possible that immune dysfunction relates to glycation of surface anti­
gens on immunologically important cells.
Diagnosis and treatm ent
• Recurrent infections in diabetics should be investigated in the normal way and not merely ac­
cepted, particularly if  diabetic control is not bad. This should include humoral and neutrophil 
function.
• Regular pneumococcal vaccination is recommended.
Iron deficiency and nutritional status 
Iron deficiency
• Induced sideropenia due to sequestration is part o f the body's response to chronic infection, as 
iron is essential to bacteria. However, it is also essential to host defences.
• Iron deficiency due to loss or inadequate intake impairs neutrophil bactericidal activity, as it is 
essential for the activity of myeloperoxidase. There is often a T lymphopenia Immunoglobulins 
are usually normal but specific antibody production is reduced. All the changes are reversible 
with iron.
Nutritional status
• The immunodeficiency of malnutrition is difficult to disentangle because it is usually accom­
panied by multiple other health problems, which make identification o f cause and effect impos­
sible.
• Marasmus is total nutritional deficiency, while kwashiorkor is protein deficiency in a high- 
calorie diet.
• Both are usually accompanied by vitamin deficiency.
• Increased susceptibility to infection seems to be the rule.
• Non-specific barriers are impaired (especially in vitamin A deficiency).
• There may be variable abnormalities o f neutrophil bactericidal activity, but these may well be 
secondary to infection.
• Immunoglobulins are often normal or high, even if the albumin is low. IgE levels may be ele­
vated, even in the absence of significant parasitic infections, suggesting dysregulation of the 
Thl:Th2 axis.
• Mitogen responsiveness is reduced in kwashiorkor. Lymph nodes show germinal centre deple­
tion and there is thymic atrophy, although the latter is also a feature o f infection.
Asplenia
• Acquired asplenia (surgery, trauma) or hyposplenia (sickle-cell disease, coeliac disease) is as­
sociated with an increased susceptibility to overwhelming infection with capsulated organisms, 
Capnocytophaga canimorsus (dog bites), and problems in handling malaria Babesia
and Bartonella (all intra-erythrocytic organisms).
• Risk appears to be lifelong, and is not limited to the first 2-3 years after splenectomy, as was 
previously thought.
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■ Degree of compromise also depends on the reason for splenectomy. For example, individuals 
splenectomized for lymphomas often have a more severe defect than those splenectomized for 
trauma.
• Ideally, all patients undergoing elective splenectomy should be immunized with Pneumovax 
and Hib vaccine and probably with the meningococcal A and C or meningococcal conjugate 
vaccine preopera-tively. If  this is not possible, then immunization prior to discharge may be ade­
quate, although responses immediately post-surgery will be reduced.
• All asplenic patients should be on prophylactic antibiotics (penicillin V, 500 mg twice a day, 
for choice) and should have their antibodies to Pneumovax* and Hib measured. Those with 
suboptimal levels should be (re)-immunized. Those with poor responses to Pneumovax should 
receive the conjugated pneumococcal vaccine Prevenar*. Annual influenza immunization is es­
sential to reduce risks o f secondary bacterial sepsis
• Asplenic patients may also not maintain adequate levels following vaccination for more than 3- 
5 years and regular checks should be carried out to ensure that protection is adequate. Note that 
the licence for Pneumovax does not indicate that it can be given this frequently. However, pro­
vided steps are taken to avoid immunizing patients with high antibody levels, the risk of adverse 
events appears to be low.
• Dog bites are dangerous and patients must seek immediate assistance: antibiotic prophylaxis is 
essential.
• Specific advice is required for foreign travel to malarial areas.
Drugs and toxins 
Drugs
The major drugs is immunosuppression, other drugs have also been reported to cause immunode­
ficiency. In many cases the evidence is poor, because pre-existent immunodeficiency has not 
been excluded. However, anticonvulsants, especially phenytoin and caibamazepine, both have 
strong associations with humoral immune deficiency, which may or may not resolve on with­
drawal of the drugs. Newer anticonvulsants may also be associated with humoral immunodefi­
ciency.
Toxins
• Smoking suppresses mucosal immune responses, improving some allergic diseases such aller­
gic alveolitis.
• Illegal drugs have considerable immunosuppressive potential, in part due to contaminants. 
Cannabis is particularly dangerous to severely immunocompromised patients as it may contain 
fungal spores.
• Alcohol in excess suppresses macrophage function, and as result increases the risk o f tubercu­
losis.
Burns
• Bums cause a highly significant acquired T- and В-cell immunodeficiency.
• Disruption o f the integrity o f  the normal cutaneous barriers and associated non-specific de­
fences is a serious problem. Complement levels will be reduced by loss.
• in severe bums neutrophil function is impaired and there is a  lymphopenia, with depletion o f 
lymphoid organs.
• Mitogen, and allogeneic responses are reduced.
• These changes may be stress-related, due to excessive endogenous steroid production (Curl­
ing's ulcer is also associated) or to the release at the burned site o f bacterial products.
• Immunoglobulin levels fall, often dramatically, due to reduced synthesis and increased loss 
through exudation. However, there is no benefit from IVIg replacement therapy.
• The best treatment is good intensive care and rapid grafting to re-establish normal barrier func­
tion.
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Thoracic duct drainage
• This used to be used as an immunosuppressive technique for die treatment o f rheumatoid ar­
thritis.
• It usually occurs now as an unintended consequence o f radical oesophageal surgery; chylotho- 
rax results, usually draining through the surgical drains.
• Loss o f the circulating lymphocyte pool occurs within 48-72 hours and leads to severe pro­
longed lymphopenia, followed by severe panhypo-gammaglobulinaemia.
• Opportunist infections (PCP, Candida) occur.
• Chylothorax should be drained to the abdominal cavity if  possible to allow conservation of 
lymphocytes. IVIg will be required, together with prophylactic co-trimoxazole, antivirals, and 
antifungals.
• Reconstitution o f the immune system is dependent on thymic function and may take up to 2 
years. Once normal lymphocyte numbers are achieved, a  programme o f re-immunization is re­
quired, commencing with killed or subunit vaccines.
Physical and environmental factors 
Radiotherapy and ionizing radiation
• Specific immune responses are affected (T- and В-cells); neutrophil and macrophage function 
is usually spared unless there is radiation damage to bone marrow.
• T-cell proliferative responses to mitogens and antigens remain depressed after irradiation for 
years.
• Lymphopenia, particularly o f CD4* T-cells, is common; humoral immune function is reduced. 
Ultraviolet light
Photoimmunosupprression occurs even with low levels o f  UV light exposure; apoptosis may be 
increased. NFkB in T-cells is activated by UV light.
Chronic hypoxia (attitude)
• Increased infections are noted at high altitude.
• Hypoxic therapy has been used as an adjunct to sports conditioning: this is associated with 
measurable alterations in circulating lymphocyte profiles, although the patterns are not consis­
tent.
T raum a and surgery
* Systemic inflammatory response syndrome (SIRS) is recognized in trauma and major surgery 
It is caused by cytokine release (TNF-сф, IL-ip, IL-6) and may lead to multi-organ failure.
* A Thl to Th2 switch and reduced T-cell proliferation have been noted but this is in part medi­
ated by prostaglandin release from macrophages.
* Antibody production is inhibited by P-endorphin (reversible by naloxone).
* Prolonged administration of anaesthetic agents in ITU may contribute to worse immune func­
tion.
* Preventing tissue hypoxia is crucial (supplemental oxygen).
Proteus syndrome
Proteus syndrome is a hamartomatous condition with partial gigantism of hands and feet, with 
pigmentary lesions, bony abnormalities, multiple benign tumours (lipoma, haemangioma), and 
developmental delay. Hypo-gammaglobulinaemia has been reported.
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Immunotherapy
Introduction
The aim o f this chapter is to giver an overview o f  the very complex but exciting area o f immuno­
therapy. Despite great advances in the basic science, the results o f clinical immunotherapy have 
not been as good as had been hoped. Nonetheless, die advances in basic immunology continue to 
provide new avenues to explore.
M ajor mechanisms of immunomodulation
* Immunization:
- active;
- passive.
* Replacement therapy:
- immunoglobulin (IM, SC, IV);
- Cl-esterase inhibitor;
- ai-antitrypsin;
* Immune stimulants:
-drugs;
- cytokines.
* Immune suppressants:
-drugs;
- monoclonal antibodies;
- cytokines and antagonists;
- IVIg;
- antibody removal (plasmapheresis).
* Desensitization:
- domestic allergens;
- pollen allergens;
- bees and wasps;
- other allergens.
* Anti-inflammatory agents:
-NSAIDs;
- anti-cytokines (anti-TNF); IL-1 ra;
- anti-complement mAbs;
- anti-endotoxin mAb;
- anti-T-cell/anti-B-cell mAbs.
* Adoptive immunotherapy:
- bone marrow transplantation;
- stem-cell transplantation;
- thymic transplants.
Passive immunization
Protection is provided by transfer of specific, high-titre antibody from donor to recipient. The 
effect is transient (maximum protection 6 months). Protection is immediate (unlike active immu­
nization).
Problems
* Risk o f  transmission o f  viruses.
* Serum sickness (including demyelination); acute reactions.
* Development o f  antibodies against infused antibodies reduces effectiveness.
* Identification o f  suitable donors (Lassa fever, rabies).
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Types
■ Pooled specific human immunoglobulin.
• Animal sera (antitoxins, antivenins).
• Monoclonal antibodies (anti-endotoxin).
Uses
• Hepatitis A prophylaxis (but new vaccine provides active immunization and longer prophy­
laxis).
• Hepatitis В (for needlestick injuries), tetanus, rabies, Lassa fever.
• Botulism, VZV (especially during pregnancy and in the immunocompromised), diphtheria, 
snake bites (post-exposure).
• Rhesus incompatibility (post-delivery anti-D).
Active immunization
The purposes o f  active immunization are to:
• stimulate the production of protective antibody (opsonization, complement fixation, enhanced 
phagocytosis, blocking uptake (virus neutralization));
• stimulate antigen-specific T-cells: whether these are Thl or Th2 cells depends on the type of 
pathogen and the optimal protective response;
• produce long-lasting immunological memory (T- and B-cells):
- mediated by the retention o f antigen on follicular dendritic cells in lymph nodes, leading 
to a long-term depot:
- hence antibody levels often persist years after the primary course o f immunizations have 
been completed, rather than decaying to zero;
« produce herd immunity': the generation o f a  sufficiently large pool o f immune individuals re­
duces the opportunity for wild-type disease to spread, increasing the effectiveness o f the immu­
nization programme;
- over 75% immunization rates are required to achieve this.
Active immunization can use:
• purified component, e.g. toxin (inactivated “  toxoid);
• subcomponent;
• live attenuated pathogen (e.g. BCG, polio).
Active immunizationcan be combined with passive immunization (although wis may reduce the 
development of long-term immunological memory).
•This approach is used for tetanus and rabies as a strategy for treatment, post-exposure. 
Toxoid/subcomponent vaccines
• Immune response frequently requires augmentation with adjuvants.
• May be side-effects from adjuvants.
• No risk that disease will be produced.
• Inactivation may damage key epitopes and reduce protection.
• Safe to use in the immunocompromised but responses (and protection) unpredictable.
Attenuated vaccines
• Usually more immunogenic and do not require adjuvants.
• Risk o f reversion to wild type (e.g. polio).
• Side-effects from culture contaminants (demyelination from duck embryo rabies).
• May produce mild form of disease (measles, mumps).
• Contraindicated in immunosuppressed (paralytic polio in antibody deficiency).
• Unexpected viral contaminants (SV40 and polio; hepatitis В and yellow fever).
G eneral problems of active immunization
Active immunization has a number o f  problems, including die following:
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• Allergy to any component (e.g. residual egg protein, often in viral vaccines from the growth 
media).
• Reduced or absent responses in immunocompromised (including splenectomy).
• Delay in achieving protection (primary and secondary immune responses require multiple in­
jection schedules).
• Preferred route of administration (site o f IM; SC, Ш):
- route o f administration may determine the type of immune response;
- route to be relevant for the route o f  infection o f the pathogen (e.g. need for mucosal 
immunity to enteric organisms).
• Storage: most live vaccines require refrigerated storage to maintain potency; this may be a 
problem, especially in tropical countries.
• Age at which a vaccine is administered may alter the response, e.g. responses to polysaccharide 
antigens are poor in:
- children under the age o f 24 months;
- the elderly.
• Maternal antibody, passive immunization, concomitant medical illness, and associated drug 
therapy may reduce the response.
• Ideally, responses should be checked serologically in patients where there may be a poor re­
sponse.
• Serological unresponsiveness does not preclude good T-cell immunity (hepatitis B).
• Anti-self immune response to immunization (e.g. autoimmunity after meningococcus group В 
polysaccharide administration).
• Multiple immunogenic strains o f target organism (e.g. Meningococcus, Pneumococcus). 
Additional stimulation of the immune system
Poorly immunogenic antigens may be used if  combined with agents that non-specifically in­
crease immune responses Cadjuvants').
• Adjuvants:
- 'depot' o f antigen (alum-precipitated; oil);
- non-specific stimulation (Freund's; MDP); Freund's adjuvant is too potent to be used in 
humans. It has however been safely used in microlitre quantities;
- polymerization (liposomes; ISCOMS—Quil A);
- expression in vectors (e.g. use o f vaccinia; chimeric viruses; BCG, Salmonella).
• Use o f immunogenic carrier proteins conjugated to primary antigen:
- tetanus toxoid;
-diphtheria toxoid.
Modern approaches to vaccine development
Development o f more potent but safer vaccines is always the goal.
• Molecular techniques have been used to modify pathogens through site-specific mutation, re­
ducing pathogenicity, or by inserting the gene into a carrier (vaccinia, Salmonella).
• Development o f the host response to the carrier organisms means that it can only be used once.
• Molecular techniques allow the safe synthesis o f bulk quantities o f antigen (e.g. hepatitis В sur­
face antigen).
• Recombinant technique needs to be selected carefully to ensure appropriate post-translational 
glycosylation o f the antigen.
• Recombinant organisms may also be used to target antigens to particular cells, for example:
- Salmonella are rapidly taken up by macrophages;
- inserted gene products will also be directed straight to antigen-presenting cells.
• Conjugation o f  poorly immunogenic antigens (such as polysaccharides) to immunogenic pro­
teins (tetanus, diphtheria toxoids).
• Humoral immune response to the polysaccharide switches from lgG2 to IgGi and IgGj.
• Specific peptides are being used experimentally to try to stimulate specific T-cell responses.
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• Epitope mapping o f antigens to determine the T- and В-cell epitopes is required.
• Direct injection into muscle o f  nucleic acid (RNA, DNA) coding for specific genes, coupled to 
gold microsphere carriers or in plasmids, generates an immune response.
• Nucleic acid is not degraded but is taken up into myocytes and specific protein production can 
be detected for several months thereafter, leading to an excellent depot preparation.
• Concern over risk o f bystander attack by the immune system on myocytes containing the in­
jected DNA.
Generation of effective response
To generate an effective immune response, both host and pathogen factors need to be taken into 
account Factors encouraging the development o f an effective vaccine involve both infectious 
agent factors and host factors.
• Infectious agent factors:
- one or a small number of serotypes; little or no antigenic drift;
• pathogen is only moderately or poorly infectious;
- antigens for B- and T-cell epitopes are readily available;
- the immune response can be induced readily at the site o f natural infection;
- wild-type infection is known to produce protective immunity;
- availability of animal models to test vaccine strategies.
• Host factors:
• humoral and cellular immunity is readily induced;
• HLA background of population is favourable to a high response;
- proposed antigens induce appropriate Thl or Th2 response.
Factors in the infectious agent that mitigate against an appropriate immunization response and 
therefore prevent the development o f good vaccines include the following.
• Marked antigenic variation/drift; many serotypes causing disease: this limits the ability to gen­
erate an effective vaccine (e.g. pneumococcal disease).
• Potential for change in host range o f the pathogen (e.g. change in cell tropism o f  viruses such 
as HIV).
• Infection may be transmitted by infected cells that are not recognized by the immune system 
even after immunization.
• Integration o f  viral DNA into the host genome (latency).
• Natural infection does not induce protective immunity.
• Pathogen uses 'escape' mechanisms:
- resistant external coats, e .g  mycobacteria;
- poorly immunogenic capsular polysaccharides;
- antigenic variation in response to host immune recognition, e g. influenza virus, ma­
laria;
- camouflage with host proteins, e .g  CMV and fc-microglobulin;
- production o f  proteins similar to host proteins, e.g. enterobacteria; may give rise to auto­
immunity;
- extracellular enzyme production to interfere with host defence (staphylococcal protein
A);
- production o f  molecules that disrupt immune responses, e .g  superantigens.
• Pathogen-induced immunosuppression (HIV).
• Failure to form appropriate response (e.g complement-fixing antibodies).
• No suitable animal model.
Host factors that mitigate against an appropriate immunization response and therefore prevent 
the development o f  good vaccines include the following.
• Immune response is inappropriate, e .g  antibody when cellular response is required (e.g 
leishmaniasis).
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* Immune response enhances infection, e g. antibody formation may enhance infection through 
increased uptake into macrophages (yellow fever, HIV).
* Cells o f immune system are target o f infection.
* 'Wrong' HLA background predisposes to a low response or autoimmunity.
The ultimate goal o f any immunization programme is the eradication o f die disease. This re­
quires that:
• the infection is limited only to humans;
- there is no animal or environmental reservoir,
- absence o f  any subclinical or carrier state in humans;
• a high level o f  herd immunity can be established to prevent peison-to-person spread:
• this requires considerable infrastructural support to ensure that all at-risk popula­
tions are targeted for immunization;
• this has only been achieved for smallpox;
• however, herd immunity for smallpox has waned as the immunization pro­
gramme have stopped; bioterrorism with smallpox is a significant threaL
Replacement therapy
This is used for treatment o f primary and some secondary immune deficiencies.
Replacement therapies for some primary and secondary immune deficiencies
Type of deficiency Replacement therapy
Antibody deficiency Immunoglobulin (IV, SC)
a<-antitrypsin deficiency di-antitrypsin
Complement deficiency Cl-esterase inhibitor
Fresh-frozen plasma (vitally inactivated)
Cellular immune deficiency Bone marrow transplantation (stem cell
transplant)
Cord blood transplant 
Thymic transplant
Combined immune deficiency
(SCID)
Bone marrow transplantation (stem cell 
transplant)
Cord blood transplant 
Thymic transplant 
Gene therapy (ADA)
Red cells (ADA)
PEGyiated-ADA 
Immunoglobulin (IV, SC)
Cytokines (IL-2, y-IFN)
Phagocytic defects Bone marrow transplantation (stem cell 
transplant)
Cord blood transplant 
Granulocyte transfusions 
Cytokines (G-CSF, GM-CSF, 1L-3)
Intravenous immunoglobulin (IVIg) for replacement therapy 1 
Manufacture and specification
* IVIg is a blood product, prepared by cold ethanol precipitation of pooled plasma.
* Donors are screened for transmissible infections (HIV, HCV, HBV).
* Plasma is not used currently (risk of prion disease); no test currently available to identify prion 
disease in donors.
* Donated plasma is usually quarantined until donor next donates (avoids undetected infection at 
time o f first donation).
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• Donor pool usually >1000 donors, to ensure broad spectrum of 
antibody specificities.
Subsequent purification steps vary between different manufacturers 
but all are based on the original Cohn fractionation process.
• The IgA content is variable.
Significant levels o f  IgA may be important when treating IgA-deficient patients, who may rec­
ognize the infused IgA as foreign and respond to it, leading to anaphylactoid responses on sub­
sequent exposure.
Uncertain how much o f a problem this, and there is no standardized method for detecting clini­
cally significant anti-IgA antibodies.
All current products have lowAmdetectable IgA, except for lyophilized Sandoglobulin®.
• Product must have low levels o f pre-kallikrein activator, Ig fragments, and aggregates as these 
three can cause adverse events on infusion.
• Variations of IgG subclasses do not seem to make significant differences to the effectiveness as 
replacement therapy.
• Comparing the presence o f functional antibodies in individual products I is difficult as there 
are no internationally standardized assays, but IVlg
must have intact opsonic and complement-fixing function.
• All licensed products must have at least two validated antiviral steps:
- cold ethanol precipitation;
- pH4/pepsin;
- solvent/detergent treatment;
- pasteurization;
- nanofiltration.
• No product should be viewed as virally 'safe'.
Full counselling about risks and benefits must be given to patient, with written information, and 
this must be recorded in the medical notes.
Written consent must be obtained prior to therapy and retained in the medical notes.
• Liquid preparations are now preferred for ease o f administration.
Uses
• IVlg (or SCIg) is mandatory for:
- replacement in the major antibody deficiencies (XLA, СУЮ);
- m combined immunodeficiencies (pre- and immediately post-BMT).
• IVlg is also recommended in patients with secondary hypogammaglobulinaemia, such as CLL 
and myeloma, post-chemotherapy.
• The role o f IVlg in IgG subclass and specific antibody deficiency is less secure, and regular 
prophylactic antibiotics might be tried first, with IVlg reserved for continuing infection despite 
therapy (assess risk-benefit).
• Where there is doubt, a 1-year trial is reasonable, with monitoring o f clinical effectiveness 
through the use o f symptom diaries.
• To ensure a realistic trial, adequate dosing and frequency o f infusions must be undertaken to 
ensure that benefit will be obvious.
Dose regime
• Treatment should provide 0.2-0.6 g/kg/month given every 2-3 weeks for primary antibody de­
ficiency, or as an adjunct in combined immunodeficiency.
• Older patients with CLL may manage on monthly infusions.
• Most patients on monthly schedules become non-specifically unwell or develop breakthrough 
infections after 2-3 weeks.
Under these circumstances the interval should be shortened.
• Rare hypercatabolic patients, or those with urinary or gastrointestinal loss, may require weekly 
infusions o f large doses to maintain levels.
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• Adjust dose according to the trough IgG level, aiming to achieve a trough IgG level within the 
normal range (6-16 g/1).
• Aim for higher trough in patients with established bronchiectasis or chronic sinusitis (target 
trough 9 g/1), as this will reduce lung damage.
• Breakthrough infections are an indication to re-assess interval and target trough level.
IVTg for replacement therapy 2: adverse reactions and risks of infection 
Adverse reactions
• Most adverse reactions are determined by the speed of infusion and the presence of underlying 
infection.
• Untreated patients receiving their first infusions are most at risk.
• Reactions are typical immune complex reactions:
- headache;
- myalgia;
- arthralgia;
- fever;
- bronchospasm;
- hypotension;
- collapse;
- chest pain.
• Pre-treatment o f the patient with antibiotics for 1 week prior to the first infusion reduces anti­
genic load and reaction risk.
• Hydrocortisone (100-200 mg IV) and an oral antihistamine (cetirizine, fexofenadine) given be­
fore the infusion are also o f benefit.
• The first infusion should be given at no more than two-thirds o f the manufacturer's recom­
mended rate.
• Start slowly and increase rate in steps every IS minutes.
• Similar precautions may be required before the second infusion.
• Reactions may occur in established recipients if:
- there is intercurrent infection;
- there is a  batch or product change.
• Other adverse events include 
-urticaria;
- eczematous reactions;
- delayed headache and fatigue (responds to antihistamines!);
-  medical problems from transferred antibodies (e.g. ANCA-uveitis).
• Products should only be changed for clinical not financial reasons.
- Severe anaphylactoid reactions have been reported after switching products.
- IVIg products are not interchangeable.
Risks o f infection
• Infection remains a major concern.
-  Hepatitis В is no longer an issue.
- There have been a significant number o f outbreaks o f hepatitis C.
- Other hepatitis viruses (HGV) may cause problems.
- No risk o f  HIV transmission, as die process rapidly destroys the virus.
- Safety in respect o f  prion disease is not known but risk will be cumulative with continuing ex­
posure.
- Antiviral steps reduce but do not eliminate risk.
• Batch exposure needs to be kept to a  minimum.
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IVIg for replacement therapy 3: monitoring and home therapy 
Monitoring
• Check HCV PCR and baseline LFTs pre-treatment
• Store pre-treatment serum long-term.
• Monitor trough IgG levels on all patients regularly (alternate infusions).
• Monitor liver function (alternate infusions, minimum every 3-4 months)—transmissible hepati­
tis.
• Repeat HCV PCR if  any unexplained change in LFTs.
• Monitor CRP-evidence o f  infection control.
Record batch numbers o f all IVIg administered.
• Use symptom diaries in appropriate patients to monitor infective symptoms, antibiotic use, and 
time off work/school.
• In the event o f a significant adverse reaction:
- immediate blood sampling for evidence o f  elevated mast-cell tryptase, complement ac­
tivation (СЗ, C4, C3d);
- send sample for anti-IgA antibodies (if IgA deficient);
- screen for infection (CRP, cultures);
- rare antibody-deficient patients seem to react persistently to IVIgs: changing to a differ­
ent product may sometimes assist. Occasionally continued prophylactic antihistamines, 
paracetamol, or even steroids may be required before each infusion to ensure compliance with 
therapy.
Home therapy
• For patients with primary immunodeficiencies, home treatment is a well-established alternative 
to hospital therapy.
• Criteria for entry to home therapy programmes are laid down in approved guidelines.
• Patients should not be sent home on IVIg without formal training and certification by an ap­
proved centre.
• The centres will also arrange for long-term support, with trained home therapy nurses and sup­
port from community pharmacy suppliers.
• Home therapy is not available in all countries for legal and/or financial reasons.
Criteria for home therapy
C riteria for home therapy ____________
4-6 months hospital therapy 
Must have good venous access (IVIg)
Patient must have a  trainable long-term partner
Comments______________________
Must be reaction-free
Consider SCIg if  venous access poor
Infusions must never be given alone
Patient must have access to telephone at site 
where infusions wilt be given 
GP must be supportive
Patient must accept regular follow-up at Train­
ing Centre
Patient must agree to keep infusion logs with 
batch records
Patient and partner must complete training pro­
gramme, with written assessment
To call for assistance if  problems
Rare for GP to be called 
Annual supervised infusions are advis­
able
Essential for dealing with batch recalls,
look-back exercises
Training manual must be provided
Intramuscular and subcutaneous immunoglobulins for replacement therapy 
Intramuscular immunoglobulin (IMIg)
There is no role for IMIg in replacement therapy. Administered doses are too low to be effective 
in preventing infection. However, occasional older patients prefer the convenience o f  a weekly
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injection at their GP’s surgery to hospital-based infusions. IMIg has been associated with an ad­
verse reaction rate o f 20%.
Subcutaneous immunoglobulin (SClg)
For those with poor venous access, high-dose SClg replacement is at least equivalent to IVIg in 
tom s o f maintaining adequate trough IgG levels and preventing infection.
• 16% solution of immunoglobulin is used.
• Specific licensed SClg preparations are now available from several manufacturers.
• It is administered in a weekly dose of 100 mg/kg via a syringe driver, in multiple sites.
• Two infusion pumps (Graseby battery-powered drivers for 10 ml syringes) may be used simul­
taneously.
• Rate is usually set to 99 ml/h (maximum).
• 10 ml per site is the usual maximum tolerated dose per site.
• Tolerability is reasonable, with local irritation being the only significant side-effect.
• Regular trips to hospital will be required for trough IgG and LFT monitoring.
• Trough levels tend to run approximately 1 g/1 higher than the same dose given as IVIg on a  2-3 
weekly cycle.
• Syringe drivers must be checked at least annually by a qualified medical electronics technician.
Cl-esterase inhibitor for replacement therapy
Deficiency of Cl-esterase inhibitor causes episodic angioedema, which may be fatal if involving 
the upper airway.
• Purified Cl inhibitor is available on a named-patient basis as Berinet-P.
• These are blood-derived products and carry the same risks as IVIg in respect o f  tranmissible 
infections.
• Products undergo viral inactivation steps (steam-treatment).
• A recombinant product is undergoing clinical trials.
• Patients should have samples checked for LFTs and HCV status prior to each course o f treat­
ment.
• Appropriate consent should be obtained if possible.
• Batch numbers must be recorded.
• Indications for treatment include:
• attacks above the shoulders;
- surgical prophylaxis (including major dental work).
• It is less effective against bowel oedema, but if  pain is severe one dose should be given.
• Attacks involving the bowel should be treated with fluids, analgesics, and NSAIDs.
• Surgery should be avoided unless there is good evidence for pathology unrelated to HAE.
• Dose is 500-1000 U (1-2 ampoules) administered as a slow bolus IV.
• Levels o f Cl-esterase inhibitor level in the serum should rise to above 50% for several days.
• Same dose is used for prophylaxis.
• When used as treatment, it will prevent attacks progressing, but does not lead to a dramatic 
resolution of symptoms; accordingly laryngeal oedema may require other measures, such as tra­
cheostomy, as urgent procedures.
• Plasma can be used if  the purified concentrate is unavailable, but is less effective and may even 
increase the oedema by providing fresh substrate for the complement and kinin cascades.
• Pooled virally inactivated FFP is now available, and may carry a reduced risk of infection, al­
though this is debated.
• Experimental treatments with kinin inhibitors are undergoing trials.
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di-Antitrypsin (di-AT) fo r replacement therapy
ot|-AT deficiency leads to progressive emphysema and to liver disease. Purified a I-AT is now 
available on a named-patient basis. Trials have not been that encouraging, but this is because 
late-stage patients with established disease have been involved. No good prophylactic trials have 
been undertaken in asymptomatic patients, so it is not yet known how effective the drug is in 
preventing complications. Supplementation may also be useful during acute infections when 
high local levels o f  trypsin are released by activated neutrophils. Infusions need to be given at 
least weekly to maintain enzyme activity.
Immune stimulation
Specific immunostimulation
Specific immune stimulation =  immunization.
Non-specific immunostimulation
• A number o f agents are now available that act as non-specific immune stimulators and have 
significant clinical benefit.
• Specialist literature should be consulted for current dose regimes.
BCG
• Direct stimulant o f  immune system; activates macrophages 
- Only found to be o f value in bladder cancer.
• As it is a live agent, it should not be administered to those with concomitant immunosuppres­
sion (lymphoid malignancy, drug-induced).
• Derivative o f cell wall muramyl dipeptide (MDP) licensed in Japan to enhance bone marrow 
recovery after chemotherapy.
• Other bacterial products are under investigation (extracts o f Corynebacterhun) as immu-
nostimulants.
Cimetidlne
• Known to have immunoregulatory properties, not related to anti-H2 activity, as actions do not 
appear to be shared with other anti-H2 drugs such as ranitidine.
• Thought to reduce T suppressor activity.
• Has been used with success in the hyper-lgE syndrome to reduce IgE and in СУШ to increase 
IgG production.
Glatiramer (Copaxone)
• An immunostimulatory drug, comprising synthetic peptides, administered by injection.
• Used in the treatment o f relapsing and remitting multiple sclerosis.
• Side effects include chest pain, allergic reactions, and lymphadenopathy.
G-CSF/GM-CSF
• Act on bone marrow precursors to increase production of mature neutrophils.
• Used as adjuncts to chemotherapy to prevent or reduce neutropenic sepsis.
• Used to mobilize stem cells for apheresis.
• Used to treat congenital neutrophil disorders: Kostman's syndrome, cyclic neutropenia, idio­
pathic neutropenia.
• PEGylated form of G-CSF available to increase duration of action.
• May increase the risk of myeloid malignancy.
• Do not use in Kostman's syndrome where there are cytogenetic abnormalities, as risk of malig­
nant transformation is increased.
• Bone pain may be a side-effect.
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Interleukin -2 (Aldesleukin)
• Licensed for use in metastatic renal cell carcinoma.
• Can produce tumour shrinkage, but no increase in survival.
• Intravenous administration is associated with a  severe capillary leak syndrome.
• Rarely used.
a-interferon
• Main use now is in treatment o f  hepatitis C, in combination with ribavirin.
• PEGylated interferon is available, to increase duration o f action.
• Also valuable in carcinoid tumours, hairy cell leukaemia and lymphomas, myeloma, mela­
noma, and hepatitis B.
• Side-effects can be severe and include severe flu-like symptoms and 3 severe depressive state 
(suicide may be provoked): patients with a history o f depression should not receive a-IFN.
• Dose is determined by the condition treated.
p-interferon
• Used in the treatment o f relapsing and remitting multiple sclerosis.
• Side-effects similar to those of a-interferon but may also cause humoral immune abnormalities, 
and monitoring o f serum immunoglobulins pie- and post-treatment is recommended.
y-lnterferon (immukin*)
• y-IFN-lb is used as adjunctive therapy in patients with chronic granulomatous disease for pre­
vention and treatment o f infections.
• It can also be used to increase response rate to HBV vaccination in poor responders.
• Side-effects include severe flu-like symptoms.
• Dose is usually 50-100 pg/m2 three times a week.
Levamisole
• Originally introduced as an anti-parasitic drug.
• Found to increase circulating T cells, activate macrophages, and enhance DTH reactions.
• Used in RhA and as adjuvant in colonic cancer (FDA approved).
• May cause agranulocytosis (in HLA B27+ patients).
Immunosuppressive/ immunomodulatory drugs: corticosteroids 
These drugs are based on endogenous products o f die adrenal cortex and form the mainstay o f 
immunosuppressive therapy; synthetic compounds are more potent Natural steroids are highly 
plasma bound (cor-ticosteroid-binding globulin; albumin). Actions o f corticosteroids are mani­
fold.
Actions
• Transiently increased neutrophils (decreased margination and release o f mature neutrophils 
from marrow).
• Decreased phagocytosis and release of enzymes (lysosomal stabilization).
• Marked monocytopenia and reduced monokine (IL-1) production.
• Alteration of cellular gene expression (high-affinity cytoplasmic receptor translocated to nu­
cleus) via NFkB inhibition through increased cytoplasmic concentrations of 1кВа.
• Release of lipomodulin (inhibits phospholipase A2 with reduction o f arachidonic acid metabo­
lites).
• Lymphopenia due to sequestration in lymphoid tissue and interference with recirculation (CD4+ 
T-cells > CD8+ T-cells > В-cells) and lymphocytotoxic effects (high doses).
• Decreased T-cell proliferative responses (inhibit entry into G1 phase).
• Reduced serum IgG and IgA.
• No effect on NK. or antibody-dependent cell-mediated cytotoxicity (ADCC) activity.
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Side-effects
• Carbohydrate metabolism: poor cellular glucose uptake; increased hepatic gluconeogenesis; 
and glycogen deposition.
• Increased lipolysis and free fatty acid (FFA); increased selective fat deposition.
• Inhibit protein synthesis and enhance protein catabolism., Increase glomerular filtration rate 
(GFR) and sodium retention; decrease calcium absorption, inhibit osteoblasts.
• Clinical side-effects are multitudinous:
- diabetes;
-  hyperlipidaemia;
- obesity;
- poor wound healing;
- growth arrest (children);
- myopathy;
- hypertension;
- purpura and skin thinning;
- cataracts;
- glaucoma;
- peptic ulcer;
- allergy (synthetic steroids);
- avascular necrosis;
- psychiatric complications;
- thrush.
• Patients on medium- to long-term treatment require regular checks o l blood pressure, blood 
sugar, and bone mineral density.
• Prophylactic therapy against bone loss is highly desirable, especially in females and all older 
patients. Optimal therapy is yet to be determined but includes hormone replacement therapy 
(HRT; if not contraindicated by underlying disease), vitamin D and calcium, or oral bisphospho-
nate.
• Doses o f over 20 mg/day for long periods may also increase the risk о opportunist infection 
with Pneumocystis carinii; consideration should therefore be given to the use of low-dose co- 
trimoxazole.
Uses
• Autoimmune diseases, e.g. SLE, vasculitis, rheumatoid arthritis.
• Polymyalgia rheumatica, giant-cell arthritis.
• Allergic diseases (asthma, hay fever).
• Inflammatory diseases (Crohn's disease).
• Malignant disease (lymphoma).
■ Allograft rejection.
• Other immunological diseases (ITP, glomerulonephritis).
Dosage regimes
• Prednisolone is the stock drug. Other steroids have little advantage but the BNF has equiva­
lency tables.
• Enteric-coated tablets are kinder to patients, but may lead to erratic absorption.
• If  plain steroids are used, gastroprotection with either an H2-antagonist or proton-pump inhibi­
tor is most effective in preventing ulceration.
• Low-dose steroids for RhA (prednisolone 7.S mg/day) have been used: most patients are now 
on methotrexate or anti-TNF agents.
• For SLE higher doses (up to 30 mg/day) are required (larger doses for cerebral lupus).
• Life-threatening immunological disease requires much higher doses, 1-2 mg/kg, orally or IV.
• Various pulsed regimes using IV methylprednisolone have been advocated, especially in acute 
vasculitis. The evidence is split over their effectiveness: 10 mg/kg is advocated, pulsed at vary­
ing intervals, often in combination with IV cytotoxics.
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• Topical steroids with limited absorption are invaluable in controlling local allergic symptoms 
(asthma, hay fever).
• Where patients who have been on long-term steroids are being tailed o ff they will remain 
adrenally suppressed for up to 6 months after cessation of therapy and should therefore have 
steroid cover for illnesses, operations, etc. Patients should carry warning cards.
Immunosuppressive/ immunomodulatory cytotoxic drugs: azathioprine
Azathioprine is converted in vivo to 6-mercaptopurine and acts to inhibit the synthesis o f inosinic
acid (precursor o f purines) thus inhibiting DNA synthesis and reducing cell replication.
Actions
• Preferentially inhibits T-cell activation rather than В-cell activation.
• Reduces the circulation of large 'activated' lymphocytes, but has little effect on small resting 
lymphocytes.
• Long-term use causes significant lymphopenia (T- and B-cells).
• Hypogammaglobulinaemia, due to inhibition o f В-cell proliferation (less or no effect on T-cell 
proliferation).
• Suppression of monokine production.
Side-effects
• Causes profound bone marrow suppression: this is related to deficiency alleles of the enzyme 
thiopurine methyltransferase (TPMT) involved in its metabolism.
• Screening for enzyme levels is widely available.
• Toxic hepatitis (related to TPMT deficiency).
• Opportunist infections (including HSV, papillomaviruses).
• Gastric upset (probably unrelated to TPMT deficiency).
• Teratogenicity.
• Malignancy (lymphoma).
• PUO syndrome (hypersensitivity).
Uses
• Autoimmune diseases (SLE, rheumatoid arthritis, vasculitis, liver disease, myasthenia, inflam­
matory bowel disease).
• As a 'steroid-sparing' agent.
Dosage
• In view of the potential for severe/fatal side-effects, azathioprine must be introduced carefully.
• Initial dose should not exceed 1 mg/kg and the patient should receive weekly full blood counts 
with a differential white count for the first month o f therapy.
• If there is any drop in platelets or white cells, it is unsafe to continue with therapy.
• Deficiency alleles for TPMT are present in 1 in 300 o f the population: pre-treatment screening 
is helpful.
• If  it is tolerated, then the dose can be increased to 2.5 mg/kg (or in special circumstances to 4 
mg/kg).
• The need for continuing therapy needs to be reviewed regularly.
• Hypogammaglobulinaemia may be severe and require replacement therapy, although recovery 
may eventually occur over several years.
• Liver function tests must also be monitored.
• Allopurinol is contraindicated with azathioprine as it interferes with elimination and raises 
blood levels.
Immunosuppressive/ immunomodulatory cytotoxic drugs: cyclophosphamide and 
chlorambucil (alkylating agents)
These drugs bind to and cross-link DNA and possibly also RNA, thus 'interfering with DNA rep­
lication and transcription. Effects are dependent on the phase of the cell cycle during exposure 
and the competence o f the DNA repair mechanisms.
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Actions
• Dose-dependent lymphopenia (T (CD8+ > CD4+) and В cells).
• Reduced В-cell proliferation and antibody synthesis (reduced IgG and IgM).
• Lesser effect on T-cells (CD8+ > CD4+, which may actually enhance T-cell responsiveness un­
der certain circumstances).
Side-effects
• Bone marrow depression.
• Alopecia.
• Haemorrhagic cystitis (caused by acrolein)—ensure good hydration and use mesna for doses 
above 200 mg/kg. May be less risk with pulsed IV therapy.
• Sterility (males and females-offer males sperm banking and warn all patients o f reproductive 
age and record in notes).
• Secondary lymphoid neoplasms ((11-fold increase), bladder tumours (10% long-term), skin 
tumours (fivefold increase), and acute myeloblasts leukaemia).
• Opportunist infections (use co-trimoxazole and antifungal prophylaxis).
• Nausea and vomiting (high dose).
M ajor uses
• Vasculitis, especially Wegener's granulomatosis, PAN, MPA, CSS.
• SLE and RhA.
• Glomerulonephritis (including Goodpasture's).
Dosage
• There is considerable debate over the optimal regimes for use o f cyclophosphamide.
- Continuous low-dose oral cyclophosphamide (2-4 mg/kg/day).
- Intravenous pulse therapy (10 mg/kg/pulse or 0.75-1 g/m2 body surface area; intervals deter­
mined by protocol and blood counts).
• Long-term side-effects may be higher with continuous oral therapy, but this may reflect the 
higher total dose, and lower doses may be effective.
• In life-threatening conditions, high-dose IV pulses, with IV steroids, will have a  faster effect 
(remember mesna cover and IV fluids).
• Chlorambucil is used orally in doses o f 0.03-0.06 mg/kg/day and is less toxic to the bladder 
than cyclophosphamide, but probably equally toxic to the marrow in therapeutic doses.
• Dosages o f both drugs will require adjustment in renal impairment Regular blood counts are 
required, according to current local protocols.
Immunosuppressive/ immunomodulatory cytotoxic drugs: methotrexate (MTX) 
Methotrexate is a competitive inhibitor o f  the enzyme dihydrofolate reductase and impairs syn­
thesis o f tetrahydrofolate from folic acid (required as cofactor for thymidine synthesis). It there­
fore interferes with DNA synthesis. It is also thought to interfere with other intracellular en­
zymes. As an immunosuppressive agent it is used in low weekly doses | (much lower than the 
doses used as an antineoplastic agent). Low-dose MTX probable inhibits the enzyme 5-amino- 
imidazole-4-caiboxamide ribonucleotide (AICAR) transformylase, leading to the accumulation 
o f ICAR and increased adenosine.
Actions
• Variable effects on lymphocyte numbers in peripheral blood.
• Possible inhibition o f monokine production.
• Inhibition o f lipo-oxygenase pathway.
• Reduction in antibody synthesis.
• Converted to methotrexate polyglutamates, which persist long-tom intracellularly and are po­
tent inhibitors o f  AICAR tranformylase and dihydrofolate reductase.
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Side-effects
• Mucositis, nausea, and vomiting.
• Bone marrow suppression (megaloblastic-may be reversed by folinic acid rescue): may be 
worse if  other anti-folate drugs are со-administered, e.g. sulphasalazine, co-trimoxazole.
• Hepatic fibrosis (dose-related).
• Pneumonitis (5% of patients), a hypersensitivity reaction.
• Sterility.
Uses
• RhA; psoriatic arthropathy.
• Polymyositis/dermatomyositis.
• GvHD in BMT.
• Adjunctive therapy with infliximab.
Dosage
• The drug is given weekly either orally or IM.
• Initial dose is 7.5 mg (adult), increased stepwise depending upon side-effects and clinical bene­
fit to a maximum of 20-30 mg/week.
• Dose may need reducing in renal impairment.
• Care needs to be taken with co-administration o f  other drugs.
• Folinic acid may reduce risk of bone marrow toxicity and mucositis (given 24-36 hours later). 
Folic acid will not be effective as MTX inhibits its conversion to the active form.
The most frequent cause o f side-effects, including death, is the inadvertent daily administration 
o f  the drug-always check carefully. Do not rely on pharmacy systems to spot errors.
■ Baseline tests should include FBC, LFTs, chest radiograph, and lung function.
• Monitor weekly (initially) pre-dose full blood counts and regular liver function tests.
• If  abnormal LFTs are noted, the drug dose should be reduced or the drug stopped.
»It is thought that the risks of monitoring for liver disease by biopsy outweigh any benefit
• Development o f pneumonitis is an absolute indication for withdrawing the drug; high-dose 
steroids may be required.
Immunosuppressive/ immunomodulatory cytotoxic drugs: 2-chlorodeoxyadenosine (2CDA, 
cladribine) and fludarabine
• Mode of action is by inhibition o f adenosine deaminase, i.e. effectively producing ADA- 
defleient severe combined immunodeficiency.
• Primary use is in the treatment o f haematological malignancy (В-cell tumours), but they have 
the potential, with careful use, to be potent immunosuppressive agents.
• Both produce a profound and long-lasting В-cell and CD4+ T-cell lymphopenia.
• Prophylactic antibiotics (co-trimoxazole) and antifungals are advisable.
• Long-term monitoring o f lymphocyte surface markers and serum immunoglobulins is advisable 
after treatment.
Immunosuppressive/ immunomodulatory drugs: cidosporin (CyA)/tacrolimus 
(FK506)/siro!imus (rapamycin)
These three agents are macrolide antibiotics derived from fungi. They act specifically on T- 
helper cells, but leave other cell types unaffected. Target cells are inhibited but not killed (there­
fore effects are fully reversible on cessation of treatment).
Modes of action
• Cidosporin (CyA) interacts with cyclophilin, a 17 kDa protein (peptidyl-prolyi cis-trans isom- 
erase) and tacrolimus interacts with FK-BP12, a 12 kDa protein, similar to cyclophilin.
• Complex prevents calcineurin, a calcium- and calmodulin-dependent protein, from dephos- 
phorylating the nuclear factor of activated T cells (NF-AT), reducing transcription o f the IL-2 
gene.
• Immunosuppressive activity is not directly related to this activity.
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• CyA and tacrolimus inhibit IL-2 and IL-2Ra gene expression and prevent T-celt activation 
(cells arrested at G0/G1).
• Sirolimus has no effect on IL-2 production; it binds FK-BP, but the complex does not inhibit 
calcineurin; it appears to block calcium-independent signalling (via CD28) and inhibits mTOR.
• May interfere with macrophage function (lymphokine release and receptor synthesis).
• CyA interferes with В-cell proliferation and antibody production.
Side-effects
• Hypertension.
• Hirsutism.
• Nephrotoxicity.
• Hepatotoxicity.
• Lymphomas (NHL-85% EBV*).
• Opportunist infections (CMV, papillomaviruses, HHV-8).
• Neurotoxicity.
• Multiple drug interactions (CyA and tacrolimus induce cytochrome P450(IIEI)).
• Diabetes (inhibition of insulin release).
• Headache.
Uses
• Combination therapy for allografts.
• RhA, SLE.
• Autoimmune diseases (uveitis, Behcet's, inflammatory bowel disease).
Dosage
• CyA and tacrolimus are available orally and intravenously.
• Dosage for CyA depends on the circumstances, but 10-15 mg/kg/day may be required for al­
lograft rejection, while 5 mg/kg may suffice for autoimmune disease.
• Iacrolimus dosage is 0.1 -0.3 mg/kg/day for allograft rejection; experience o f  this drug is less in 
autoimmune disease, but doses up to 0.1 mg/kg/day in divided doses appear to be effective.
■ Monitoring of drug levels is desirable for both drugs; this can prevent toxicity and monitor
compliance.
• Sirolimus dosage is 6 mg as a stat. dose followed by 2 mg daily, with drug monitoring and ap­
propriate dosage changes, in allografts. Dosages for use in autoimmune disease are not defined.
• Because it operates on different activation pathways it may make a useful combination treat­
ment.
• Creatinine and electrolytes, liver function, and blood pressure should be monitored regularly.
Immunosuppressive/ immunomodulatory drugs: mycophenolate mofetil (MMF) and bre- 
quinar
Mycophenolate mofetil (MMF)
This drug is a prodrug o f mycophenolic acid. In its actions it is similar to azathioprine.
Actions
• Blocks inosine monophosphate dehydrogenase and blocks synthesis о guanine, but has no ef­
fect on salvage pathway.
• It acts predominantly on lymphocytes, to prevent proliferation, but ha; little effect on non­
lymphoid cells.
Side-effects
• Lymphopenia
- Opportunist infections (CMV, HSV)
• Lymphoma
• Hepatotoxicity.
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Uses
• Prophylaxis o f allograft rejection
• Autoimmune disease: SLE nephritis; uveitis.
Dosage
• Dosage is 1 g twice a day, increased to maximum of 1.5 g twice daily.
• FBC and LFTs should be monitored regularly.
Brequinar
Brequinar is an experimental drug that inhibits pyrimidine synthesis. It has the greatest effects on 
В-cells and antibody production, especially IgE. It is effective in animal models o f allograft re­
jection.
Immunosuppressive/ immunomodulatory drugs: leflunomide
• After oral administration is converted to an active metabolite that inhibits dihydro-orotate de­
hydrogenase (involved in pyrimidine synthesis and required by T cells).
•T cell proliferation is blocked.
• Used in RhA: as effective as methotrexate.
• Onset of action is slow (4-6 weeks).
• Side effects include severe hepatotoxicity and Stevens-Johnson syndrome.
Drug can be 'washed-out' with cholestyramine or activated charcoal (binds it in the gut).
• It is teratogenic: effective contraception is required.
• Dose is 100 mg daily for 3 days; then 10-20 mg daily.
• Monitoring with regular FBC and LFTS mandatory.
Immunosuppressive/ immunomodulatory drugs: D-penicillamine and gold 
D-Penicillamine This enigmatic drug comes and goes in terms o f its utility as an immunomodu-
tator.
• Precise immunological actions are not known.
• It decreases antibody production.
• It inhibits T-cell proliferation, possibly through enhanced hydrogen peroxide production or 
through sulphydrylation o f the surface receptors o f the lymphocytes.
• Neutrophil chemotaxis and oxidative function are impaired.
• Macrophage antigen-presenting function and monokine production are reduced.
• Also believed to inhibit collagen synthesis; hence its use in scleroderma.
• Very slow in its onset o f  action.
• Main side-effects include a  range o f autoimmune diseases, including myasthenia gravis, renal 
disease (nephrotic), SLE, polymyositis, and Goodpasture's syndrome.
• Mainly used in RhA and scleroderma, but has fallen out o f favour due to side-effects.
• Dosage is 250 mg daily increased to 1 g daily.
• Regular monitoring (every 1-2 weeks initially) o f renal function, urinalysis, and FBC required.
• Penicillin-allergic patients may be at increased ride o f reacting to penicillamine.
Gold
• Gold may be given either as 1M injections or orally: evidence suggests that parenteral therapy 
is more effective.
• Concentrated selectively in macrophages, and reduces monokine production (IL-1); hence also 
reducing T- and В-cell responses.
• Impairs endothelial expression o f adhesion molecules and hence reduces cellular traffic to sites 
o f inflammation.
• Profile o f side-effects is similar to that o f penicillamine, and the onset o f action is also slow.
• It is used only in RhA: now mainly replaced by anti-TNF agents and methotrexate.
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• Dosage is dependent on the route and expert advice on current regimes should be sought from a 
clinician experienced in its use.
Immunosuppressive/ immunomodulatory drugs: hydroxychloroquine/mepacrine
• Antimalarials have a particular role to play in trie management o f joint and skin complaints in 
connective tissue, diseases.
• Effective in relieving the fatigue experienced in association with connective tissue diseases 
such as SLE and Sjogren's syndrome.
• Mode o f action is uncertain, but there is evidence that they interfere with the production o f  cy­
tokines and reduction o f production o f  granulocyte lysosomal enzymes.
• Anti-platelet action demonstrated: may be valuable in anti-phospholipid syndrome.
• Onset o f action is slow.
• Well-tolerated with few side-effects.
• Haemolysis may occur in G6PD-deficient patients.
• Retinal toxicity is possibly a  problem with hydroxychloroquine, and definitely a problem with 
chloroquine (not used in rheumatic disease now).
• Evidence that there is a  significant risk o f  ocular toxicity ftom hydroxychloroquine is minimal.
• Loss o f colour discrimination may be an early sign.
• Hydroxychloroquine may cause nausea and vomiting which can be severe and usually occurs 
during the initiation phase.
• Mepacrine stains the skin yellow.
• Preferred antimalarial is hydroxychloroquine.
• Starting dose for hydroxychloroquine is 400 mg/day (adult), reducing to maintenance o f  200 
mg/day. Alternatively the maximum daily dose is calculated as 6.S mg/kg lean body mass.
• Mepacrine is an unlicensed drug in the context o f autoimmune disease, and die dose is 50-100
mg per day.
Immunosuppressive/ immunomodulatory drugs: thalidomide/oxypeatifylliuc
• Thalidomide is an interesting drug that reduces the severity of conversion reactions due to 
treatment o f lepromatous leprosy.
• It is a potent inhibitor of TNF-a production by monocytes, due to interference with gene tran­
scription.
■ It decreases the expression of adhesion molecules.
• Circulating CD4+ T cells are reduced.
• It inhibits -y-interferon production by T cells, due to preferential stimulation of Th2 cells.
• Side-effects include its well-documented teratogenicity, neuropathy, 
and drowsiness (which may limit dose).
• It is used in the management o f ulceration in Behcet's syndrome and in reducing the severity of 
GvHD.
• Dosage is 100 mg/day, reducing to 50 mg on alternate days.
• Nerve conduction studies should be carried out as a baseline pre-treatment, and at intervals on 
treatment.
• Women o f child-bearing age must be formally counselled over the risks and agree to take ap­
propriate contraceptive measures. This must be recorded in the notes.
■ Oxypentifylline is a drug originally introduced for peripheral vascular disease. It has similar 
but weaker actions to thalidomide in inhibiting TNF-a production.
Immunosuppressive/ immunomodulatory drugs: sulphasalazine and colchicine
Sulphasalazine
• Sulphasalazine was originally introduced as an antibiotic.
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• It comprises sulphapyridine coupled to 5-aminosalicylic acid via a  diazo bond that can be split 
by enteric bacteria.
• The precise mode o f  action as an immunomodulatory agent is uncertain.
• It has minor immunosuppressive activities, mainly localized to die gut, but little effect on pe­
ripheral blood lymphocyte numbers or function.
• It is used predominantly in inflammatoiy bowel disease, rheumatoid arthritis, and seronegative 
arthritides, in doses o f 500-2000 mg/day in divided doses.
• It has a significant array o f side-effects including male infertility, macrocytic anaemia, rash, 
Stevens-Johnson syndrome, and secondary hypogammaglobulinaemia.
• Regular monitoring o f FBC is required.
Colchicine
• Colchicine is a  useful anti-inflammatory.
• Precise immunological role is uncertain, but it inhibits microtubule assembly and therefore in­
hibits mitosis.
• Concentrated in neutrophils and inhibits chemotactic activity, thus reducing the accumulation 
o f non-specific inflammatory cells.
• Valuable in Behcet's syndrome and familial Mediterranean fever.
• Value is limited by side-effects at therapeutic doses (diarrhoea and gastrointestinal discomfort).
• Usual dose is up to 0.5 mg four times daily, if  tolerated.
Immunosuppressive/ immunomodulatory drugs: dapsone
• Used to treat dermatitis herpetiformis.
• Inhibits fi-integrin-mediated neutrophil adherence to endothelium by binding to intracellular G-
protein.
• Main side-effect is haemolysis, which is marked in G6PD-deficient patients.
• Always check G6PD status prior to use and monitor FBC for signs o f  haemolysis (reduced hap­
toglobins are a sensitive indicator of haemolysis).
• Dose is usually 1-2 mg/kg/day.
Immunosuppressive/ immunomodulatory biological*: high-dose IVIg
High-dose IVIg is widely used as an immunomodulatory agent in autoimmune diseases. The
precise mechanisms of action clinically are uncertain, although many mechanisms have been
postulated.
Actions
• Fc-receptor blockade on phagocytic cells.
• Inhibition o f cytokine production.
• Inactivation o f  pathogenic autoantibodies (anti-idiotypes).
• Inhibition of autoantibody production by B-cells.
• Decreased T-cell proliferation.
• Actions o f soluble cytokines, cytokine receptors, and antagonists present in IVIg.
• Inhibitory actions o f  stabilizing sugars.
Side-effects
• Aseptic meningitis (elevated lymphocytes and protein in CSF) secondary to sugars.
• Renal failure (secondary to osmotic load from sugars).
• Massive intravascular haemolysis (secondary to IgG isoagglutinins).
• Hyperviscosity (CVAs, Ml).
• Immune complex reactions in patients with high-titre rheumatoid factors, cryoglobulins (types 
II and III), or other immune complex disease, e.g. SLE.
• Anaphylactoid reactions (IgA deficiency; infected).
Main uses
• Replacement therapy for primary and secondary immunodeficiencies.
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• Autoimmune cytopenias (ITP, AIHA).
• Vasculitis: Kawasaki syndrome; Wegener's granulomatosis.
■ Neurological diseases (acute Guillain-Bane, СЮР, pure motor neuropathy, myasthenia gravis, 
LEMS, MS).
• Factor VIII and factor IX inhibitors.
• Anti-phospholipid antibodies in pregnancy.
• Autoimmune skin disease (pemphigus, pemphigoid, epidermolysis bullosa acquisita).
•Eczema.
• Polymyositis, dermatomyositis.
Dosage
• Dosage regimes range from 0.4 g/kg/day for 5 days, through I g/day for 2 days to 2 g/kg/day as 
a single dose.
• Minimal evidence is available to distinguish between the schedules.
• Fewer doses may be required for ITP.
• My own practice is to start all high-dose regimes on the 5-day schedule to assess tolerability 
and then increase to 1 g/kg/day for 2 days subsequently.
• In adults and children, risks of renal impairment and aseptic meningitis are highest with the ul­
trarapid infusion schedule o f 2 g/kg/day, and
I avoid this if  possible.
• Rapid infusions should be avoided in all elderly patients because of the risks o f hyperviscosity.
• Pre-treatment IgA deficiency and high-titre rheumatoid factors should be excluded, and renal 
function assessed.
• Pre-treatment FBC, LFTs, and hepatitis serology (HBV, HCV) should also be measured.
• IgA-deficient patients require special care, and should be on products low in IgA (Octagam®, 
Flebogamma®, Gammagard-SD , Vigam-5®, Sandoglobulin-NF®).
• If there is renal impairment to start with, daily creatinines should be measured and, i f  there is a 
rise o f 10% or more, then therapy should be discontinued.
• FBC should be repeated during the course to ensure that haemolysis does not take place (hap­
toglobin is a sensitive indicator o f intravascular haemolysis).
• Infusion rates should follow manufacturers' guidelines.
• There must be no switching o f products.
Immunosuppressive/ immunomodulatory biologicals: polyclonal antibodies, high-dose anti- 
D immunoglobulin, and blood transfusion effect
Polyclonal antibodies
• Xenogeneic antisera raised by the immunization o f  animals with purified human T cells or 
thymocytes (rabbit anti-thymocyte globulin (ATG) and rabbit anti-lymphocyte globulin (ALG)) 
are potent immunosuppressive agents.
• They cause a profound lymphopenia.
• They are difficult to standardize and have significant batch-to-balch variation.
• They also contain cross-reactive antibodies that react with other cells types, including platelets.
• Utility is limited by the development o f a host-anti-rabbit response, which both neutralizes the 
xeno-anti serum and also gives rise to a serum sickness reaction
Actions
• Complement-mediated lymphocyte destruction.
• Cause marked but variable lymphopenia.
• Reduced T-cell function.
Uses
• Acute graft rejection or GvHD.
• Diamond-Blackfan syndrome.
Dosage
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• Dosage depends on batch but is usually within the range o f 5-30 mg/kg/day.
• Effect can be monitored by absolute lymphocyte counts or flow cytometric analysis o f periph­
eral blood lymphocytes.
High-dose anti-D immunoglobulin
• High dose anti-D immunoglobulin can be used to control autoimmune haemolytic anaemia in 
Rhesus D* patients.
• Mechanism o f  action is unclear.
Blood transfusion effect
• In renal allografts it has been well-documented that both donor and random blood transfusions 
reduce the risks o f graft rejection.
• Immunological mechanism is uncertain.
Immunosuppressive/ immunomodulatory biologicab: monoclonal antibodies I
Since the first edition o f  this book there has been an explosion of monoclonal antibodies, now 
mainly chimeric or humanized molecules, and these are replacing murine monoclonal antibodies, 
which have a high rate o f induction o f anti-mouse antibodies, which abolish the effectiveness.
Infliximab (Remicade®)
• Chimeric monoclonal antibody to TNF-a.
• Licensed for use in Crohn's disease, rheumatoid arthritis, ankylosing spondylitis.
■ Major hazard of use is significant increase in tuberculosis.
• Screening for ТВ prior to administration is advised.
• Use of Quantiferon Gold may be valuable in establishing previous tuberculous infection.
• Development of PUO, cough, weight loss should trigger search for ТВ.
• Induces development o f anti-nuclear antibodies.
• Must be used in combination with MTX to prevent the development o f anti-chimera antibodies.
• Dose 3 mg/kg as IV infusion, repeated at 2 ,6, and then 8 week intervals.
• Cessation of therapy in Crohn's disease may lead to loss of effect when re-introduced.
Adalimumab (Humira®)
• Another monoclonal antibody to TNFa.
• Side-effects, dosing, and indications are similar to those for infliximab.
• Co-therapy with MTX is recommended.
• Dose is 40 mg on alternate weeks subcutaneously.
Alemtuzumab (MabCampath®)
• Humanized anti-CD52 monoclonal (Campath®).
• Lytic antibody: targets predominantly В cells.
• Used in В-cell lymphomas and B-lymphoproliferative disease (EBV*) in the immunosup-
pressed.
• Causes tumour lysis and cytokine release syndrome (capillary leak), as for rituximab. 
Rituximab (MabThera®)
• A humanized anti-CD20 monoclonal antibody, expressed on normal cells, censed for use in 
non-Hodgkin's В-cell lymphomas.
• Licensed for use in non-Hodgkin's В-cell lymphomas.
• Can cause massive tumour lysis syndrome, with cytokme release (antibod/-complement medi­
ated lysis) and capillary leak syndrome 1-2 hours after infusion.
• Fever and chills, nausea and vomiting, and hypersensitivity reactions are common.
• Analgesic and antihistamine should be administered before treatment.
• Full resuscitation facilities should be available.
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• Synergistic with chemotherapy.
• Likely to be valuable ip the treatment o f autoimmune diseases where autoantibody plays a sig­
nificant role (autoimmune haemolytic anaemia, ITP).
• Also shoeing promise as adjunctive therapy in SLE.
• Side-effects include severe and prolonged hypogammaglobulinaemia due to destruction o f nor­
mal B-cells.
O m a liz u m a b  (Xolair®)
• A humanized monoclonal antibody against IgE Fc region that prevents binding to the high- 
affinity IgE receptor.
• Trials in asthma have been disappointing but it will probably be more valuable in allergic rhi- 
noconjunctivitis, where'IgE is more definitively involved.
B asilixim ab (Simulect®)
• A humanized monoclonal antibody that binds to the а -chain of the IL-2 receptor and prevents 
T-cell proliferation.
• Used in the prophylaxis o f acute organ rejection in renal allografts, in combinations with cyc­
losporin and со rti со steroids.
• Main side-effect is severe hypersensitivity.
• Dose is 20 mg 2 hours before transplant and 20 mg 4 days after surgery.
Immunosuppressive/ immunomodulatory biologkats: monoclonal antibodies 2 
D aclizum ab (Zenapax®)
• A humanized monoclonal antibody that binds to the -у-chain o f the EL-2 receptor and prevents 
T-cell proliferation.
• Used in the prophylaxis of acute organ rejection in renal allografts, in combinations with cyc­
losporin and corticosteraids.
• Main side-effect is severe hypersensitivity.
• Dose is 1 mg/kg by IV infusion in the 14 hours pre-transplant, then continued daily for 14 days. 
Gemtuzumab (Mylotarg®)
■ A monoclonal antibody against the CD33 antigen expressed on myeloid leukaemic blasts and 
normal myeloid cells.
• Used to treat AML in first relapse.
Anti-CD154
• Anti-CD 154 (gp39, CD40 ligand} blocks the binding of CD1S4 on activated but not testing 
T-cells with CD40 on В-cells and APCs.
•It will induce a slate o f immunodeficiency similar to HIGM.
• Experimental models have shown benefit in allograft rejection and autoimmunity.
Trastuzumab
•A  humanized antibody against the epidermal growth factor receptor Her-2.
•Blocks and downregulates the receptor.
• Valuable in the treatment o f metastatic breast cancer where the tumour overexpresses Her-2.
• Her-2 is also expressed on other tumours.
Abciximab (ReoPro®)
• Monoclonal antibody binding to platelet glycoprotem llb/llla receptors.
• Used once only as an adjunct to heparin and aspirin in high-risk patients undergoing percuta­
neous transluminal coronary artery interventions to prevent thrombotic complications.
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О К Т З (m urom onab-C D 3® )
• Murine antibody against T-cell CD3 e-chain.
• Used to treat allograft rejection.
• Associated with high incidence of the development o f HAMA (human anti-mouse antibodies) 
that reduce its effect and cause a serum sickness reaction.
• Now used less, as humanized alternatives are available. .
Digoxin-specific antibody (Dlgibind®)
• Fab' fragments o f antibody against digoxin.
• Used to treat digoxin poisoning by tending to the drug.
Other immunosuppressive/immunomodulatory biologic» Is 
Other biologicals include cytokine antagonists and fusion proteins.
E tanercept (Enbrel®)
I Etanereept is a soluble fusion protein of the ligand binding portion of the type 2 TNF receptor 
(p75) coupled to the Fc portion of human IgGi.
• It binds both TNF-a and TNF-p.
• It is synergistic with MIX.
• It is licensed for use in RhA, psoriatic arthritis, and juvenile arthritis.
• It may be o f value m Behcet's disease and uveitis.
• Demyelination has been reported; risk of immunosuppression is significant.
• Dose is 23-50 mg twice a week by subcutaneous injection for 12 weeks, reducing to 2S mg 
twice a week with a maximum duration o f therapy of 24 weeks.
• If there is no response by 12 weeks, then it should be discontinued.
Anaklnra (Klneret®)
• A recombmant version of the naturally occurring IL-1 receptor antagonist.
• Blocks the action o f  IL-I.
• Has been used in RhA, but evidence o f benefit is not compelling.
• Causes neutropenia and headache.
• Dose is 100 mg daily subcutaneously.
CTLA4Ig
• This is a  fusion protein o f CTLA4, a T-cell surface molecule, and human lgG|.
• CTLA4 binds to B7 on APC and blocks the binding o f B7 to T-cell CD28, preventing the co­
stimulatory stimulus required for T-cell activation and inducing anergy.
• Currently undergoing trials in psoriasis and lupus (not promising!).
O ther experim ental biological agents
Many other biological agents are in clinical trials. Not all will prove clinically valuable. Some 
are shown in the table: many others are being tested.
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Some immunosupiiresswe/immunomodulatory biological agents in clinical trials
Agent Target
Pegsunercept Pegytated soluble TNF receptor type I (RhA)
Atlrzumab Humanized anti-IL-6 monoclonal antibody (RhA)
Natalfeumab Humanized antibody against cefl adhesion molecules 4-1 and 4-7; tri­
als in MS. RJA may lead to progressive multifocal leucoencephalopa- 
thv(PML)
Alefocept CD2 antagonist
HuMAX-IL-15 Anti-IL-15 monoclonal antibody
Pexelumab and 
eculizumab
Complement C5 Inhibitors, in trial for paroxysmal nocturnal haer- 
noglobinuria
Total lymphoid irradiation  (TLI)
• TLI is experimental as an immunosuppressive therapy, having been used previously for the 
treatment o f lymphoid malignancies.
• Produces profound impairment o f T-cell numbers and function, although there is a small popu­
lation of radio resistant small lymphocytes.
• A more modem variant is to use UV sensitizing agents (psoralens) and then irradiate leucocytes in 
an extracorporeal circulation (photopheresis).
• TLI may be o f benefit in intractable rheumatoid arthritis, multiple sclerosis, and severe SLE. 
Side-effects
• Severe leucopenia
• Thrombocytopenia.
• Opportunist infections.
• Lymphoma (NHL).
Thoracic duct drainage
• Has been used in the past for treatment of severe RhA.
• Causes a severe and long-lasting immunosuppression
• Similar effects are seen from accidental thoracic duct damage in oesophageal arid cardiac 
surgery, where a chylous effusion is allowed to dram unchecked.
• A profound and persistent lymphopenia o f  both T-and В-cells is caused/
• Recovery o f immune function may occur over a long period.
• Prophylaxis against Pneumocysns carinii pneumonia and fungal infections will be required if  
the drainage is accidental.
Plasmapheresis
• Plasmapheresis is the removal o f  plasma constituents using automated cell separators. The 
plasma components are removed by either centrifugation or membrane filtration.
• Erythrocytes and other cellular components are re-in fused and the removed plasma replaced 
with either FFP or FFP + IVIg to maintain circulating volume.
• About 50% o f  the plasma is removed each time.
■ A therapeutic course is usually 3-5 daily treatments.
• The amount o f  antibody removed depends on volume o f  distribution. 90% oflgM  but only 
20% o f IgG is removed each time as only 40% o f  die IgG is within the vascular space.
• Plasmapheresis also has the advantage o f  the removal o f  immune complexes and small me­
diators (toxins, anaphylotoxins, cytokines), in addition to the antibodies.
• Plasmapheresis is only suitable for urgent therapy, as antibody levels return rapidly and fre­
quently overshoot to higher levels after plasm apheresis is discontinued. It is important to 
commence conventional immunosuppression at the same time.
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Side-effects
* Leakage/air embolism
* Anticoagulation (citrate toxicity )/thrombocytopenia.
* Reactions to replacement fluids.
Uses
* Hyperviscosity (Waldenstrom's macroglobulinaemia, IgA myeloma).
■ Goodpasture's syndrome/Wegener's granulomatosis.
* Cryoglobulinaemia.
* Myasthenia gravis.
* Guillain-Barre syndrome (but IVIg is as good).
* It has been tried in other autoimmune diseases (RhA, FVUI antibodies, MS, lupus nephritis) with 
variable anecdotal success.
* A limiting factor in its use is access to appropriate equipment 
Immunoadsorption
* Selective removal o f  autoantibodies has been attempted using an extracorporeal circuit includ­
ing a column o f inert beads coated with protein A or protein G for specific adsorption o f  lgG.
* This treatment is experimental and it is not widely used in clinical practice.
Allergy interventions: drugs
Treatment for allergic disease is divided into three major target areas mast cells, released me­
diators, and the specific immune response. Treatment can be topical or systemic: topical is pre­
ferred if  this is effective. The underlying chronic inflammatory component especially o f 
asthma, needs always to be addressed rather than just using symptomatic agents. Corticosteroids 
and antihistamines are more effective as prophylactic agents, taken before allergen exposure.
Mast-cell active drugs
* Corticosteroids (interfere with synthesis of leukotrienes).
* Mast-cell stabilization: cromoglycate'nedocromil/ketotifen (prevent allergen-triggered calcium 
flux and hence prevent degranillation).
Released mediators
* P-Agonists (smooth muscle relaxation, some anti-inflammatory effect (salmeterol)).
* Antihistamines: use long-acting high-potency non-sedating drugs without cardiotoxicity 
(loratidme, desloratidine, levocetirizine, cetinzine. fexofenadme].
* Corticosteroids.
* Anti-PAF drugs (clinical results disappointing).
* Leukotriene (LTD4) antagonists, monteleukast, zafirleukasl (useful adjunctive treatment in 
asthma).
* 5-lipoxygenase inhibitor, zileuton (asthma).
* Kinin antagonists: icatibant (anti-bradykinin B2 receptor antagonist), WIN64338, FR173657 
(orally active B2 antagonist).
Specific IgE
* Desensitiiation
* Peptide therapy (experimental)
* Anti-FcRe therapy (experimental)
* Omalizumab, anti-lgE.
Allergy interventions: desensitization (immunotherapy)
Mechanism of benefit
- Mechanism o f desensitization is uncertain: specific IgE may rise in early stages of treatment then
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fall.
• The role of'blocking antibodies' (lgG4) is unknown.
• One hypothesis suggests that sequential exposure gradually switches the CD4* T-cell response 
from Th2 to T hl, reducing IgE production and the levels o f  the pro-allergic cytokmes IL-4 and 
IL-5.
Indications
Desensitization should be considered for patients with:
- anaphylaxis to insect venoms;
- rhinoconjunctivitis not controlled with maximal medical therapy, used correctly, and 
including repeated courses o f oral steroids.
Asthma may be amenable to treatment but carries high risks.
Exclusions
Current guidelines suggest that desensitization is inapropriate for those with:
- multiple allergies;
- severe asthma (FEV i < 75% predicted): seasonal wheeze only induced by pollen is not 
a contraindication to desensitization out o f the pollen season;
- heart disease;
- hypertension requiring (5-blockade (difficult to resuscitate in emergencies);
- use of angiotensm converting enzyme (ACE) inhibitors] in creased risk of angioedema, 
local and systemic);
- during pregnancy;
- excess alcohol consumption (increased risk o f side-effects).
• Age > 50 years is associated with poor responses (exception is venom immunotherapy). 
Schedules
• Traditional desensitization is done with weekly injections o f increasing doses o f aqueous aller­
gen until maintenance doses are reached at 14-IS weeks.
• Once on maintenance doses, intervals between injections are spaced out to 4-6 weeks for 3 
years.
Short course (4 or 6 injections over the winter) o f adsorbed allergens (Pollmex® and Pollinex 
Quattro®) are as effective for pollen allergies: course is repeated annually for 3 years.
• Allergens available include:
• venoms: bee, wasp, bumblebee (for market gardeners who use bumblebees for pollina­
tion);
- pollens: grass, birch pollen;
- animals: cat (potent allergen associated with high incidence o f  side-effects), horse, dog 
(but this is not as effective as the others);
- house dust mite.
• Highly purified allergens should always be used: whole insect extracts or multiple allergens 
combinations are not recommended.
• All except Pollinex® are unlicensed at present and are therefore administered on a  named- 
patient basis. Formal written consent is required.
• Precise protocol and total duration of therapy varies depending or ths allergen.
• All require long-term commitment from patients.
■ Schedules are onerous and the leeway for changes to accommodate holidays are minimal.
• Patients must not undertake vigorous exercise after injections (increased risk o f side-effects).
• Injections cannot be given if patient is unwell.
• Pre-treatment with antihistamines reduces risk o f local reactions.
• Peak flow should be monitored pre- and 30 minutes post-injection.
■ All patients must stay for at least 1 hour post-injection (no exceptions).
• Rush and ultra-rush schedules have been devised, but are rarely re quired in practice and signifi­
cantly increase the risks o f reactions.
• Desensrtotion must be carried out in hospital and staff must be conversant with emergency
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management o f anaphylaxis and cardiac arrest procedures.
Side-effects
* Main-side effects are pain and swelling at site o f injections (pre-treat with antihistamine and 
supply oral steroid).
* Systemic reactions may occur (cough is often the first sign): treat as for any acute allergic reac­
tion.
* Risk of reactions is increased:
- during the up-dosing period (aqueous allergens);
- in patients treated with cat allergen;
- if  patient has mtercurrent infection (defer injection);
- if  patient is extremely anxious (use sedation if  necessary);
- if  patient is exposed to allergen naturally during the up-dosing period;
- if  patient is drinking excess alcohol;
- if  patient is started on ACE inhibitor 
Sublingual therapy
« Sublingual desensitiialion is widely practised in Europe.
* Allergen drops or tablets are placed under the tongue on a daily basis.
* Local tingling and minor swelling may occur.
* Experience from Europe suggests that this is safe and effective and can be administered at 
home.
Adoptive immunotherapy 
Interleukin-2 and LAK therapy
• LAK therapy (lymphokine-activated killer cells) has been proposed as a treatment for ma­
lignant disease.
• Peripheral blood lymphocytes are harvested and tha t stimulated in vitro with high-dose IL- 
2 and re-infused into the patient with additional 1L.-2.
• Side-effects are severe and tumoricidal activity limited.
• A better approach may be to expand tumour-invading lymphocytes (TIL).
• The therapy is moderately toxic in therapeutic doses (fluid retention; capillary leak syn­
drome).
• There is some evidence of benefit in melanoma and renal cell carcinoma (salvage 
therapy).
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Questions and answers
1. Wfeb cytokines regulate neutrofil production?
GM-CSF, G-CSF
2. What is the proportion of each immunoglobulin class in the circulation?
IgG 
IgA 
IgM (males) 
IgM (females) 
IgG subclasses 
IgGi 
IgGi 
IgG}
IgG,
IgA subclasses 
IgA i 
lgA2
Total IgE 
IgD
6.8-15.4 g/l 
0.84-2.97 g/l 
0.54-1.90 g/l 
0.81-2.30 g/l
4.2-10.8 g/l 
1.5-6.0 g/l 
0.5-1.9 g/l 
0.2-1.4g/l
0.7-2.4 g/l 
0.2-0.9g/l
<100 kU/l or <100 IU/ml 
0.01-0.04 g/l
3. What are the clinical features of immunodeficiency?
Recurrent infections.
There is no universally accepted definition of what constitutes ‘recurrent infection' and there­
fore it is difficult to be categorical about who should be investigated for immunodeficiency. 
The following should be used as guidance.
• Two major or one major and recurrent minor in I year.
• Unusual organisms (Aspergillus, Pneumocystis).
• Unusual sites (liver abscess, osteomyelitis).
• Chronic infections (sinusitis).
• Structural damage (bronchiectasis).
4. What is treatment of X-linked agammaglobulinaemia?
• I intravenous IgG should be started at the earliest opportunity; dose of200-600mg/kg/month 
given at intervals of 2-3 weeks. Longer intervals do not give satisfactory replacement.
• Subcutaneous immunoglobulin given weekly (same total dose) is an alternative.
• Trough IgG levels should be monitored regularly, with the aim of maintaining a level well 
within the normal range (6-9 g/l). Early institution of IVIg and adequate trough levels pre­
clude the development of bronchiectasis.
• Prompt antibiotic therapy (course of 10-14 days) for upper and lower respiratory tract infec­
tions together with physiotherapy and postural drainage if lung damage has already occurred 
Ciprofloxacin is a valuable antibiotic (though not licensed for small children). Use cystic fi­
brosis approach of zero tolerance to cough.
• As children get older and can comply, perform regular lung function testing, including 
transfer factor.
• High resolution CT scanning (HR-CT) is useful for identifying subclinical bronchiectasis, 
but imposes a significant radiation burden and should not be overused.
• Do not give oral polio vaccine as patients often fail to clear it, which increases the risk of 
reversion to wild type, with consequent paralytic disease.
• Genetic counselling of the patient and family once genetic basis confirmed. Identify and 
counsel carriers.
• Long-term immunological follow-up (plus additional specialist input as required).
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5. What is immunology selective IgA deficiency?
• The IgA will be undetectable (< 0.05 g/I), but total IgG and IgM will be normal. IgG sub­
classes may be reduced (G2 and G4). Secreted IgA will be absent (secretory piece deficiency 
is vanishingly rare), but testing for this is of little clinical value.
• T-cell function is normal (PHA and antigens).
• Autoantibodies may be present (anti-IgA antibodies). There will be an increased IgE in the 
presence of atopic disease.
« In the absence of IgA, IgM and IgG appear on mucosal surfaces.
6. How do diagnosis of chronic mucocutaneous candidiasis syndromes?
There is no unequivocal diagnostic test.
• In vivo and in vitro T-cell responses to Candida antigens are poor or absent but anti-candida 
IgG antibodies are high.
• Acquired immunodeficiency and other risk factors for Candida (diabetes, steroid inhalers, 
Sjogren's syndrome, proton-pump inhibitor use) should be excluded.
• Presence of superficial candidiasis with an endocrinopathy, either overt or cryptic (autoan­
tibody positive without symptoms), is highly suspicious: AIRE gene should be checked.
7. What is treatment of chronic mucocutaneous candidiasis syndromes?
• Treatment is difficult: Candida will respond well to antifungals (fluconazole or itracona­
zole) but inevitably relapses when the antifungal is withdrawn. Resistance to these antifim- 
gals may occur. Prolonged therapy is undesirable and increases the chances o f hepatotoxicy. 
Newer antifungals are voriconazole and caspafungin - these should be used sparingly.
• Avoid the use of proton-pump inhibitors as these increase the risk of oesophageal candidi­
asis.
• IVlg should be considered for patients with recurrent bacterial infections. Continuous anti­
biotics tend to exacerbate the candidiasis.
• y-lFN may have some beneficial effect..
• BMT/HSCT should be considered for severe forms but the procedure is difficult in heavily 
infected patients.
• Maintain regular surveillance for significant endocrine disease, in particular adrenal insuffi­
ciency, which may be insidious in its onset. Treat endocrine disease normally.
8. What is treatment of chronic granulomatous disease?
• Long-term antibiotics (co-trimoxazole and itraconazole) are the mainstay o f treatment. Use 
the liquid formulation o f itraconazole (better absorption) and monitor trough levels, adjusting 
dose accordingly.
• Low-dose prophylactic y-IFN tends to be used instead.
• Acute infections should be treated promptly with intravenous antibiotics, supplemented 
with high-dose y-IFN.
• Drainage of large abscesses may be required.
• Inflammatory bowel disease may be significantly helped by high-dose steroids, particularly 
where there are obstructive lesions due to granulomata. This increases infection risk.
• BMT/HSCT is the treatment o f choice and should be carried out early before infective 
complications become a threat to life. Results from transplantation in adults me now good.
• Kell-negative XL-CGD patients are a transfusion hazard, and need to be transfused with 
Kell-negative blood.
9. What arc immunological features human immunodeficiency virus 1 and 2
• Virus enters the cells via a cognate interaction of the gpl20 env with CD4+ and a 
chemokine receptor, either CxCR4 or CCRS.
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• It also infects other CD4+ cells (macrophages, dendritic cells) and other cells expressing 
CD4-like surface proteins (neuronal cells).
• Macrophage tropic viruses use CCR5, and infect T-cells poorly; T-cell tropic viruses use 
CXCR4 for entry and form syncytia.
• Resistance to viral infection is associated with polymorphism in the chemokine receptors.
• A viral isolate entering T-cells via CD8+ has been described.
• Uptake of virus into phagocytic cells may be augmented by antibody, and complement.
HIV activates complement.
• High levels of viral replication may take place in lymph nodes.
• Initial viraemia after infection is controlled by CD8+ cytotoxic T-cells (increased cell num­
bers). The asymptomatic phase is characterized by strong cytotoxic responses, but viral repli­
cation still detectable intermittently, HIV is not a true latent virus.
• The antibody response to major viral proteins appears after a lag phase of up to 3 months 
and persists through the asymptomatic phase but declines in late-stage disease.
• Marked В-cell dysfunction with polyclonal increase in immunoglobulins and the appear­
ance of multiple autoantibodies.
• In the seroconversion illness there is a dramatic fall in CD4+ T-cells and rise of CD8+ T- 
cells. The levels of CD4+ T cells may drop to a level at which opportunist infections may oc­
cur at this early stage (poor prognostic indicator). Levels then usually recover to within the 
low normal range. There is then a slow decline of absolute CD4+ T-cell count over time 
(years) following infection.
• Passage to the symptomatic phase is characterized by a rapid drop in CD4+ T-cells, loss of 
cytotoxic activity, and switch of virus type from slow-growing, non-syncytial-forming strains 
to rapidly growing, syncytial-forming strains (quasi-species evolving through lack of replica­
tive fidelity and under immunological selection pressure). This is accompanied by the occur­
rence of opportunist infections.
• Activation of T-cells enhances viral replication and hence CD4* T-cell destruction. There­
fore, opportunist infections enhance the self-destruction of the immune system. Long-term 
non-progressors and patients responding to highly active antiretroviral therapy (HAART) 
show good proliferative responses to gag proteins Progression has been associated with a 
switch from Thl to Th2 responses.
• HIV preferentially infects CD45RO* cells but the depletion of T-cells affects principally 
CD45RA+CD62L+ naive T-cells.
• T-cell depletion is caused by increased apoptosis, impaired production (HIV effects on 
thymus), and destruction of both infected and uninfected cells.
• HIV replication is suppressed by natural CCRS chemokine ligands, RANTES, MIP-lo, and 
MIP-1 p, which are secreted by CD8* T-cells SDF-la is the natural ligand forCXCR4. High 
levels of chemokine production have been associated with resistance to infection.
10. What is Basiliximab (Simulect®)?
• A humanized monoclonal antibody that binds to the а-chain of the IL-2 receptor and pre­
vents T-cell proliferation.
• Used in the prophylaxis of acute organ rejection in renal allografts, in combinations with 
cyclosporin and со rti со steroids.
• Main side-effect is severe hypersensitivity.
• Dose is 20 mg 2 hours before transplant and 20 mg 4 days after surgery.
Websites
Clinical Immunology Society www.climmmsoc.org 
European Society for Immunodeficiencies www.esid.org
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